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State-of-the-art methodologies to study biochemical networks are often invasive and enable to 
quantify biochemical events only on cell populations or at a single point in time for a single cell, 
and therefore, cannot adequately quantify the fast, asynchronous and heterogeneous 
responses. In order to address these limitations, we have developed a unique sensing platform 
based on fluorescence lifetime imaging microscopy (FLIM) capable to multiplex at least three 
biosensors by utilizing Förster Resonance Energy Transfer (FRET) efficiently.  
After an overall introduction in Chapter 1, I describe the rational design and characterization 
of novel FRET pairs aiming to utilize the visible spectrum efficiently in combination with FLIM 
in Chapter 2. We combined blue, green and red donor fluorescent proteins that are excited at 
the same wavelength (840 nm for two-photon excitation) with genetically encoded quenchers, 
i.e. non-fluorescent chromoproteins as acceptors. This sensing platform enables the 
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of three key enzymes in DNA damage-induced cell death, caspase-2, -3, and -9. We confirm 
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network - formerly impossible - permitted us to design perturbations of cell fate choices utilizing 
clinically relevant inhibitors. These perturbations resulted in changes in cell fate in response to 
Cisplatin, a clinically desirable outcome that suggests new avenues for combinatorial drugging 
and a new strategy to reveal cancer vulnerabilities that may be otherwise confounded by typical 
genetic and non-genetic heterogeneity. 
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Summary 
Genetically identical cells show a heterogeneous response to a multitude of signals such as 
growth factors and DNA damage. While this heterogeneity has been shown to be a major 
determinant of treatment success in several diseases including cancer, little is known about 
how differences in biochemical signalling networks underlie such heterogeneity.  
State-of-the-art methodologies to study biochemical networks are often invasive and enable to 
quantify biochemical events only on cell populations or at a single point in time for a single cell, 
and therefore, cannot adequately quantify the fast, asynchronous and heterogeneous 
responses. In order to address these limitations, we have developed a unique sensing platform 
based on fluorescence lifetime imaging microscopy (FLIM) capable to multiplex at least three 
biosensors by utilizing Förster Resonance Energy Transfer (FRET) efficiently.  
After an overall introduction in Chapter 1, I describe the rational design and characterization 
of novel FRET pairs aiming to utilize the visible spectrum efficiently in combination with FLIM 
in Chapter 2. We combined blue, green and red donor fluorescent proteins that are excited at 
the same wavelength (840 nm for two-photon excitation) with genetically encoded quenchers, 
i.e. non-fluorescent chromoproteins as acceptors. This sensing platform enables the 
simultaneous detection of three biochemical reactions within single living cells providing new 
opportunities to characterize and understand non-genetic heterogeneity. 
In Chapter 3, I will demonstrate the first application of this novel platform by studying the activity 
of three key enzymes in DNA damage-induced cell death, caspase-2, -3, and -9. We confirm 
the heterogeneous nature of Cisplatin-induced cell death in genetically identical cells but reveal 
the existence of at least three subpopulations of cells characterized by distinct caspase 
dynamics. By combining biochemical and morphological information we infer the existence of 
different biochemical network topologies that are associated with alternative death phenotypes 
each cell adopts, such as apoptosis and programmed necrosis.  
Finally, deconvolution of cellular populations and direct measurement of a three-node caspase 
network - formerly impossible - permitted us to design perturbations of cell fate choices utilizing 
clinically relevant inhibitors. These perturbations resulted in changes in cell fate in response to 
Cisplatin, a clinically desirable outcome that suggests new avenues for combinatorial drugging 
and a new strategy to reveal cancer vulnerabilities that may be otherwise confounded by typical 
genetic and non-genetic heterogeneity. 
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Chapter 1 Overall introduction | Studying 
biochemistry in single living cells 
1.1 Dynamic signalling networks determine cell fate at the 
single-cell level 
Biochemical networks determine the fate of a cell by regulating cellular responses to internal 
and external signals. Most networks process more than one signal that encodes for different 
cellular outputs. Different signals may be distinguished by various, non-mutually exclusive 
mechanisms, such as a change in the abundance of network components, their activity, post-
translational modifications and subcellular location. Importantly, those mechanisms are rarely 
static but change dynamically over time (Kholodenko et al., 2010; Purvis and Lahav, 2013) 
Experimental investigation of network dynamics suffers, however, from significantly 
underappreciated issues. Methods such as genomics, transcriptomics, proteomics or 
metabolomics allow the simultaneous characterization of tens of thousands of biomolecules 
enabling the enumeration of most of the network components; however, these methods are 
intrinsically invasive requiring cell fixation or extraction. Although single-cell ‘omics’ 
approaches are becoming feasible, it is very unlikely that such methodologies will be ever 
expanded to single-cell live measurements. Therefore, causality between phenotypic cell fate 
changes and biochemical networks over time can be only inferred from time snapshots of 
networks measured on single cells at best, but more routinely on ensemble measurements. 
Population-based studies have provided and will still provide invaluable insights into network 
topology (how individual genes or gene products interact with each other) and dynamics. For 
example, by demonstrating how differences in the dynamics of the same network lead to 
different cell fates (Santos et al., 2007). Santos et al. used a combination of quantitative 
Western Blot and siRNA-mediated perturbation of the RAF/MEK(MAPKK1)/ERK(MAPK1)- 
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signalling network to show that transient activation of ERK induced by Epidermal Growth 
Factor (EGF) leads to proliferation, while sustained activation induced by Neuronal Growth 
Factor (NGF) leads to differentiation (Santos et al., 2007; Fig. 1.1A). Using a computational 
approach called Modular Response Analysis (MRA), Santos and colleagues were able to 
determine the direction and strength of signalling in the MAPK (Mitogen Activated Protein 
Kinase) signalling three-nodes (RAF, MEK and ERK) network and use the topological 
information so obtained to engineer cell fate with the use of small molecule inhibitors. In fact, 
using a Protein Kinase C inhibitor that does not target MAPK signalling directly, but interferes 
with one of the feedback loops within the MAPK pathway, Santos and colleagues could 
rationally convert the transient EGF-induced MAPK response to a sustained NGF-like 
response and convert the pro-proliferative EGF effect into EGF-induced differentiation. This 
demonstrates how the knowledge of network dynamics can help design perturbations to 
change cell fates.  However, this otherwise powerful approach was unable to assess the cell-
to-cell heterogeneity of a response, which may mask asynchronous and subtle signalling 
events.  
The effect of such heterogeneity on the study of network dynamics is best exemplified with the 
p53 dynamics in response to DNA damage (Lahav et al., 2004). Using fluorescence imaging 
 
  
Figure 1.1 – Signalling dynamics determine cell fate at a single-cell level.  
A, B, C: Dynamics of ERK, p53 and NFκB determine cell fate. D: Heterogeneity in single-cell responses results 
in misinterpretation of real kinetics if studied on a population average. Adapted from Purvis et. al, 2013. 
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Lahav et. al. observed that the p53 levels oscillate after γ-irradiation and that the pulse 
frequency determines cell fate (Fig. 1.1B). In each single cell, the pulses have a fixed height 
and duration and are undampened over time. In contrast, measuring p53 levels by Western 
Blot led Bar-Or et al. to the conclusion that such pulses a dampened, because on a single-cell 
level later pulses were increasingly out of phase, leading to a decrease of the signal in average 
(Lev Bar-Or et al., 2000; Fig. 1.1D, top). Similarly, time-lapse imaging revealed that caspase-
3 is activated in a fast, switch-like fashion, and not gradually as judged by Western Blot on an 
asynchronous population (Tyas et al., 2000; Fig. 1.1D, bottom). Using fluorescence 
microscopy, other processes have been found to exhibit heterogeneous network dynamics 
including the immune-signalling of NFkB (Nuclear Factor κB); Tay et al., 2010; Fig. 1.1C) as 
well as the EGF receptor signalling (Shankaran et al., 2009).  
Finally, Ryu et al. have directly addressed the single-cell heterogeneity that Santos et al. were 
unable to address in their seminal work discussed above (Ryu et al., 2015; Santos et al., 2007). 
Using the same system as Santos et al. in which EGF- and NGF-dependent dynamics 
determine cell fate, but measuring ERK dynamics at single-cell level using a FRET biosensor, 
they showed that the ERK response to EGF/NGF is highly heterogeneous between cells, 
undetectable by Santos’ method. Furthermore, refinement of Santos’ original model using 
single-cell data allowed to accurately predict that the delivery of multiple EGF pulses should 
lead to a change in cell fate to differentiation, in the absence of any genetic of chemical 
perturbation, showing that frequency of growth factor stimulation, and not only the identity can 
remodel pathways. While this crucial finding could have wide implications for the study of 
network dynamics, it was only enabled with the prior knowledge of the existence of differential 
feedback loops described by Santos (Santos et al., 2007), because only one network 
component, ERK, could be measured with this approach. The inability to combine single-cell 
measurements with the read-out of several network nodes is a central impediment to fully 
grasp the complexity of cellular networks, from which all studies discussed above have 
suffered so far.   
Importantly, non-genetic as well as genetic heterogeneity in cellular signalling has pronounced 
consequences in human disease, where it, for example, determines resistance to 
chemotherapeutic drugs in cancer treatment affecting patient survival (Caiado et al., 2016; for 
a more detailed introduction to heterogeneity in cancer also see Chapter 2). Moreover, it has 
been suggested  that the failure to sufficiently incorporate not only network topology but also 
dynamics at the single-cell level into the models to predict targets for development of new 
drugs has made them unsuccessful (Huang, 2013; Jørgensen and Linding, 2010; Pawson and 
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Linding, 2008). Thus, Pawson and Linding coin the term “Network Medicine” to describe a 
novel approach to treating diseases, i.e. by targeting network dynamics, for example by using 
a larger number of small perturbations in contrast to targeting one of few central network 
nodes. However, the degree of quantitative, single-cell information required for these 
predictions, can not be obtained using current single-cell techniques, as they are often limited 
to monitor one or two biochemical reactions at a time.  
To overcome this limitation, we set out to redesign quantitative imaging assays from their 
foundations with the long-term aim to convert a power technique such MRA described by 
Santos et. al., i.e. measurement of multiple events and targeted perturbation to quantify their 
dynamics, into a single-cell assay capable to resolve the heterogeneity in network topologies 
and cell fate choices, or in other words, to perform what we call “Single-Cell Biochemistry”.  
1.2 Single-Cell Biochemistry allows the study of 
heterogeneity in dynamic networks  
The Single-Cell Biochemistry platform combines targeted perturbation of signalling nodes with 
the simultaneous sensing of at least three network nodes in single living cells using multiplexed 
FRET sensors that are read-out by a fast and highly efficient spectrally-resolved fluorescence-
lifetime imaging (FLIM) setup and in-house developed analysis software (Fig. 1.2).  
In Chapter 2 of this dissertation, I describe the rational design of the FRET pairs for three-
colour imaging by testing and optimizing a large number of fluorescent protein pairs.  
In Chapter 3, I show how those novel FRET pairs can be used to monitor the activity of three 
key caspases (caspase-2, 3, and -9) in the cell death network of the human cervical cancer 
HeLa cell line in response to the DNA damaging agent Cisplatin.  
Importantly, the novel FLIM hardware and software developed within the group permitted us 
to minimize acquisition times and increase dynamic range. These capabilities were exploited 
to measure hundreds of cells in live-cell imaging for 16 hours over 13 different fields of view at 
the comparatively high temporal resolution of 15 min. Utilizing a very efficient optical design 
and detection system, we were able to minimize phototoxicity.  
I will show that this approach allows us to study the order of caspase activation and their true, 
single-cell kinetics, establishing an so far undescribed role of caspase-9 activity downstream  
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of caspase-2 and -3 activation. I will further show that the presence or absence of caspase-9 
activation characterizes two distinct cell populations, with the absence of caspase-9 resulting 
in a delay in cell death. Furthermore, Cisplatin-treated cells not only die from apoptosis but 
also a necrotic form of cell death, adding another level of non-genetic heterogeneity. The death 
phenotype is correlated with the time of cell death, suggesting a link between biochemical as 
well as phenotypic observations. Using inhibitors to directly perturb caspase activity, this link 
is further investigated, showing that perturbation of any caspase prevents the efficient 
execution of apoptosis, delays cell death and shifts the cell fate towards necrosis. Finally, using 
treatments that sensitize caspases, cell death was found accelerated and no shift towards 
necrosis was observed, supporting a model where a delay in cell death due to the lack of 
caspase-9 in a subpopulation of cells or disruption of the caspase network results in a shift 
from apoptotic to necrotic cell death. 
In summary, Single-Cell Biochemistry combines key requirements for investigating signalling 
dynamics. First, it allows the simultaneous time-lapse imaging of at least three biochemical 
reactions in single living cells, which, second, permits the direct validation of biochemical 
models, using single-cell rather than population kinetics, and third, can deconvolve cell-to-cell 
heterogeneity with a high temporal resolution. Crucially, this biochemical information can be 
directly connected to microscopic cell fate such as changes in cell death.  
Finally, Single-Cell Biochemistry allows reverse engineering and testing targeted network 
perturbations to alter cell fate choices and thereby expose vulnerabilities of diseases such as 
cancer at a single-cell level, such as the requirement for caspase-9 for fast apoptosis, that 
previously went unnoticed due to a high degree of genetic and non-genetic heterogeneity.
Figure 1.2 – Concept of Single-Cell Biochemistry 
A chosen biological network consisting of multiple network nodes is probed using an array of FRET-based 
biosensors that are read-out using a novel fast and high-efficient fluorescence-lifetime imaging platform and in-
house developed data analysis and modelling. To achieve fully controllable and single-cell specific perturbation, 
light-controlled optogenetics tools are being developed. Adapted from A. Esposito. 
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Chapter 2 Rational design of FRET-based 
biosensors for Single-Cell Biochemistry 
2.1 Introduction 
 Fluorescence microscopy as a tool to correlate biochemical 
events with cell fate in single cells 
To study biochemical signalling in single cells and to correlate it with cell fate, the ideal 
biological tool needs to meet three requirements: First, a high spatial resolution to monitor and 
distinguish not only single cells but also subcellular signalling as well as any microscopic 
changes correlated with cell fate. Second, a high temporal resolution that allows quantitative 
monitoring of asynchronous biochemical events over time. And, third, high biochemical 
resolution, i.e. it needs to permit detection of biochemical events and separate multiple events 
that occur simultaneously. Only fluorescence microscopy is suited to meet all these 
requirements as it preserves both the integrity and the identity of individual cells. For instance, 
flow cytometry is often used to monitor a multitude of markers in single cells, but it cannot 
monitor changes over time on individual cells nor provide a subcellular resolution (Grecco et 
al., 2016). Single-cell genomics, epigenomics, transcriptomics, proteomics and metabolomics, 
all suffer from the same limitation (Kandpal et al., 2009), even though providing single-cell 
information, they only provide a snapshot in time. 
The power of fluorescence microscopy is its low-invasive non-destructive nature that allows 
monitoring the same cell over days and weeks combined with an ever-expanding toolbox of 
genetically encodable tools to monitor (i.e., fluorescence-based reporters) and probe (i.e., 
optogenetics) cell biochemistry. Fluorescent reporters can be broadly distinguished into those 
that are genetically encoded and reporters of chemical synthesis (Terai and Nagano, 2013; 
Xia et al., 2013). Synthetic probes benefit from high brightness and their simplicity but are 
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difficult to tune and adapt to new applications. Furthermore, their use in living cells is often 
hindered by non-existing delivery methodologies and limited stability over a long time. 
Genetically encoded fluorescent sensors 
In contrast, genetically encoded sensors have received particular attention because of their 
versatility for a multitude of applications including live cells, their modularity that allows fast 
adaptation to new requirements and their tunability using genetic engineering (Sanford and 
Palmer, 2017). Genetically encoded sensors have been used to sense a wide-range of 
physiological quantities and processes, including pH, redox, metals, ions, metabolites, physical 
force, crowding, voltage and signalling (Newman et al., 2011; Sample et al., 2014; Sanford 
and Palmer, 2017). A common characteristic of genetically encoded fluorescent sensors are 
fluorescent proteins, which, since the first steps of using the Green Fluorescent Protein (GFP) 
from the jellyfish Aequorea victoria two decades ago were made (Tsien, 1998), have rapidly 
expanded to span the whole visible spectrum and become an invaluable tool for cell biology 
and beyond (Rodriguez et al., 2017).  
It is possible to distinguish five classes of genetically encoded fluorescent sensors based on 
their mode of action (Sanford and Palmer, 2017): 
First, translocation sensors are based on the signal-dependent change in their subcellular 
localization, mostly between the cytoplasm to the nucleus or plasma membrane. This change 
is elicited by the modification of a targeting motif such as a nuclear localization signal by the 
signal/enzyme of interest. For example, imaging fluorescently-tagged ERK shuttling between 
nucleus and cytoplasm has provided key insights into growth-factor signalling dynamics (Ryu 
et al., 2015; Shankaran et al., 2009). While their modularity and relative ease of multiplexing 
are major advantages, their low dynamic range and signal-to-noise ratio makes accurate 
quantification challenging and the specific requirements for processes that can be sensed 
limits the number of applications. Also, for accurate quantification, a marker for the target 
location is required, limiting the number of processes that can be studied simultaneously.  
Second, sensors based on complementation consist of two or more non-fluorescent split 
fragments that when complemented in response to a signal mature and become fluorescent. 
For example, a split GFP has been rationally designed to become fluorescent upon protease 
cleavage of a linker peptide (To et al., 2016). While this class has low basal fluorescence, a 
high dynamic range and a good potential for multiplexing because it comprises a single 
fluorophore, maturation of chromophores takes several minutes and is irreversible, therefore 
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lacking temporal resolution for fast and reversible processes. Also, as an intensiometric 
sensor, i.e. based on the change in fluorescence intensity, other processes that result in local 
concentration changes such as cell shrinkage cannot be distinguished from a true signal. 
Third, environmentally-sensitive fluorophores that change spectroscopic properties when the 
chromophore, usually protected in the β-barrel of the fluorescent protein, is exposed to 
environmental changes. For instance, the β-barrel can be designed to allow ions to access the 
chromophore leading to quenching or changes in emission or excitation spectra allowing for 
sensing of ions and pH (Llopis et al., 1998; Miyawaki et al., 1997). Such sensors are well-
suited for multiplexing, but suffer from the same limitation as complementation sensors, 
because they rely on intensity changes. Furthermore, not all fluorescent proteins are suitable 
for this approach. 
Fourth, the novel class of dimerization sensors consists of two proteins, a fluorescent protein 
whose fluorescence is quenched when monomeric and a second protein that de-quenches the 
fluorescence upon heterodimerization. The dimerization is induced by the modification of a 
linker that brings the two proteins in close proximity (Alford et al., 2012a, 2012b). Such tools 
have been used to sense protease, ions and kinase activation, and recent improvements have 
also enabled ratiometric imaging, overcoming the limitations of an intensiometric readout (Ding 
et al., 2015). Together, these make this novel class a promising alternative to conventional 
reporters, however, multiplexing is currently limited as only a green, yellow and red version of 
this special protein pair have been found so far. 
FRET-based sensors 
Fifth and last, FRET biosensors constitute the largest and most diverse class of genetically-
encoded biosensors (Newman et al., 2011). FRET, or Förster resonance energy transfer, is 
the non-radiative transfer of energy from a donor to an acceptor fluorophore that occurs when 
they are in close proximity (typically < 10 nm) and if the emission spectrum of the donor 
overlaps sufficiently with the absorption spectrum of the acceptor (Bajar et al., 2016a; Förster, 
1948). FRET efficiency (E) describes the percent of the energy that is transferred from the 
donor to the acceptor and is a function of the distance between the donor and acceptor dipoles 
(r):  
 =
1
1 + (


)
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R0 is known as the Förster Radius or Förster Distance and describes the distance at which E 
is 50%. It depends on the photophysical parameters of donors and acceptors, including the 
inter-dipole orientation (or κ2, generally assuming the value of 2 3  in the approximation of freely 
rotating dipoles), the quantum yield of the donor, the extinction coefficient of the acceptor and 
the spectral overlap of donor emission and acceptor excitation spectrum. To be able to 
measure the distance between two β-barrel FPs with a diameter of around 4 nm each, an R0 
of at least 4 nm is required. Higher R0 – within limits – increases the change in FRET efficiency 
upon a given change in distance, i.e. the dynamic range of the pair (see Bajar et al., 2016 for 
an example). 
FRET-based biosensors can be grouped into two classes depending on whether donor and 
acceptor are covalently bound or not (Bajar et al., 2016a): In intermolecular FRET sensors, 
donor and acceptor are fused to different molecules and FRET efficiency can be used to 
measure their proximity (Stryer and Haugland, 1967). Considering the size of most globular 
proteins of a few nanometers, the typical limit of ~10 nm for FRET to occur enables to study 
direct protein-protein interaction with a spatial resolution that is hardly achievable with other 
fluorescent techniques including super-resolution microscopy.  
In comparison, in intramolecular FRET sensors, donor and acceptor are fused together with a 
linker that carries a sensor domain. When modification of the linker leads to a change in 
orientation or proximity of donor and acceptor, this can be measured by a change in FRET. 
Using various linkers, biosensors measuring pH, ion concentration, metabolites, 
phosphorylation, methylation, acetylation, ubiquitination, viscosity, mechanical stress, GTPase 
and protease activities have been developed with varying degrees of sensitivity, dynamic 
range and reversibility (for an extensive list see: Newman et al., 2011; Sample et al., 2014). 
This versatility is one of the major advantages of FRET biosensors. Due to their modular 
nature, linkers, as well as fluorophores, can be relatively easily modified using standard genetic 
tools allowing adaptation to new applications. Furthermore, changes in FRET are 
instantaneous and, except for protease sensors, reversible, allowing measurements of very 
fast processes such as Ca2+ signalling (Miyawaki et al., 1997).  
Measuring FRET 
A further advantage is that FRET can be measured with multiple methods, utilizing any 
characteristics of fluorescence, such as spectrum, lifetime and polarization, allowing to tailor 
the detection for each application (Bajar et al., 2016a).  
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In spectral imaging-based FRET (siFRET) FRET efficiency is derived from the spectra of donor 
and acceptor whose individual contribution to the overall spectrum is a surrogate for the FRET 
efficiency. Sensitized emission FRET (seFRET) is a popular method for FRET detection, 
because of its ease and speed. Most commonly, changes in FRET are measured by the ratio 
of donor and acceptor emission upon donor excitation, as FRET causes emission of the 
acceptor. Acceptor-photobleaching FRET (apFRET) is based on the de-quenching of donor 
emission through irreversible bleaching of the acceptor, but is not usable in live cells and does 
not allow measuring FRET changes over time. Polarization-resolved FRET (prFRET) monitors 
the polarization of the acceptor emission upon donor excitation which becomes partially 
depolarized if FRET occurs because the dipole orientation changes. Uniquely, prFRET permits 
measurement of HomoFRET between two spectrally identical fluorophores, and has a high 
dynamic range and very short acquisition times.  
Finally, in fluorescence lifetime imaging FRET (FLIM-FRET), the decay of the fluorescence 
emission of the donor is measured and the lifetime determined from the nanosecond decay 
pattern. Upon FRET, the fluorescence lifetime of the donor is reduced allowing a highly 
accurate and sensitive determination of the FRET efficiency. Two technologies are used to 
measure fluorescence lifetime: Frequency-domain FLIM measures the demodulation of 
frequency-modulated excitation light, a characteristic that is dependent on the fluorescent 
lifetime. In time-domain FLIM, the fluorescence lifetime is derived from the arrival times of 
single photons after an ultrashort (pico- to femtosecond) excitation pulse.  
For both methods, FRET efficiency (E) can be obtained from the lifetime of the donor in the 
presence () and absence () of the acceptor: 
 = 1 − (


) 
FLIM-FRET has several advantages compared to other, intensity-based detection methods, 
and is therefore sometimes considered the ‘gold-standard’ for FRET detection (Bajar et al., 
2016a). FLIM directly quantifies a molecular property of a donor fluorophore (i.e., the average 
time that the donor spends in its excited state) that is directly proportional to changes in FRET 
efficiencies (the surrogate measure of biochemical events). Therefore, FLIM-FRET is broadly 
insensitive to changes in fluorophore concentrations, variations in intensities caused by optics 
and spectral cross-talk. Typically, time-domain FLIM methods such as TCSPC (Time-
correlated single-photon counting) do not require calibrations, corrections and very efficiently 
use the limited photon-budgets available in biological experiments (Day and Davidson, 2012). 
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Two disadvantages are described frequently. First, long measurement times of up to several 
minutes are common to acquire sufficient photons for a good estimation of the fluorescence 
lifetime. However, recent technological advances such as integrated single-photon avalanche 
photodiodes (Li et al., 2010), fast and sensitive hybrid photomultiplier tube detectors (Becker 
et al., 2010) and modulated solid-state cameras (Esposito et al., 2005; Raspe et al., 2016; 
Zhao et al., 2012) allow to greatly reduce acquisition times to a few seconds while maintaining 
low excitation intensity suitable for live-cell imaging. Furthermore, the required know-how to 
operate and the costs of procuring FLIM instrumentation have decreased significantly and 
more commercial fully integrated systems are now available on the market and in core imaging 
facilities.   
In summary, fluorescence lifetime imaging and FRET-based biosensors provide quantitative 
and robust measurements on biochemical reactions in live cells. However, significant 
limitations in measuring several biochemical reactions in the living cell, in particular with FRET-
based biosensors, still persist. Therefore, one of the goals of this study was to redevelop 
FRET-based assays to enable quantitative and simultaneous measurements of at least small 
three-node biochemical networks in the living cell.  
 Key challenges in the design of FRET-based biosensors 
When designing FRET-based biosensors, two key challenges frequently arise, a low FRET 
efficiency and the formation of visible aggregates. 
Low FRET efficiency 
Maximizing the FRET efficiency, as well as the dynamic range of a sensor, are crucial for a 
sensitive, quantitative and reproducible measurement of biological events. As discussed in the 
previous section, FRET efficiency depends on the photophysical properties of donor and 
acceptor, their distance and relative orientation. Thus, approaches to maximize FRET 
efficiency have been focussed on these characteristics. 
Varying the donor-acceptor distance by changing the linker length is a frequently used strategy 
to improve FRET efficiency (Evers et al., 2006; Komatsu et al., 2011; Shimozono et al., 2006). 
In addition to changing the linker, the termini of donor and acceptor can be shortened to 
decrease the distance, which can increase FRET efficiency (van der Krogt et al., 2008), but is 
limited by the minimal structure required for fluorescence and the potential reduction of 
rotational freedom (Li et al., 1997). Furthermore, depending on the design of the FRET sensor, 
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short linkers that minimize the distance are not always possible, because short linkers can 
sterically hinder the function of the sensor. Thus, long flexible linkers are frequent in FRET 
sensor designs (Piston and Kremers, 2007). However, new approaches such as HiFRET which 
uses electrostatic ‘helper interactions’ to increase the affinity of donor and acceptor in the 
presence of a long linker can help to achieve high FRET efficiencies with long linkers 
(Grünberg et al., 2013). 
A change in the dipole orientation has primarily been achieved by swapping the position of 
donor and acceptor around the linker as well as the use of circular-permutated fluorescent 
proteins (cpFPs; Baird et al., 1999; Topell et al., 1999). In cpFPs, the amino- and carboxy- 
termini are either joined or inserted at different positions of the β-barrel resulting in an 
inclination of the cpFP relative to its fusion partner, which is well-suited to optimize FRET 
efficiency (van der Krogt et al., 2008; Nagai et al., 2004). 
Finally, improving the properties of the fluorescent proteins constituting the FRET pair are 
obviously crucial, including fast maturation, high photostability and sufficient spectral overlaps. 
For donors for FLIM-FRET a high quantum yield is favourable, while acceptors ideally have 
high extinction coefficient. The latter can be doubled by creating tandem-dimers (Campbell et 
al., 2002; Fradkov et al., 2002) which often results in a marked increase in FRET efficiency 
(van der Krogt et al., 2008). 
Aggregation 
The formation of visible aggregates (also termed ‘speckles’ in some publications) is a common 
feature of fluorescent proteins and their fusions across all spectra and can severely limit their 
usability.  
Different causes for the aggregation of fluorescent proteins have been reported. For instance, 
DsRed and its derivatives mRFP1 and dsRed2 can accumulate in lysosomes by an autophagy-
related mechanism (Katayama et al., 2008). Poor folding of a fluorescent protein can also 
cause aggregation regardless of their quaternary structure (Kremers et al., 2006). Last, 
oligomerization of the fluorescent proteins used in a FRET pair is a frequent cause for 
aggregation. The likely cause for such oligomerization is that in nature fluorescent proteins and 
chromoproteins often occur as dimers (e.g., GFP) or tetramers (e.g., dsRed); these oligomers 
show strong aggregation, in particular when fused to other proteins (Fradkov et al., 2002) 
and/or expressed at high levels (van der Krogt et al., 2008). Monomerization of FPs achieved 
by destabilization of dimer interfaces through mutagenesis and by cloning tandem-dimers often 
2.1 Introduction         13 
 
halts aggregation (Campbell et al., 2002; Fradkov et al., 2002; van der Krogt et al., 2008). 
Tandem-dimers are a fusion of two identical copies of a fluorescent protein and may promote 
intramolecular dimerization over inter-molecular dimerization, effectively generating a ‘pseudo-
monomer’ and inhibiting aggregation.  
Destabilization of dimerization interfaces (Bajar et al., 2016b; Merzlyak et al., 2007) and 
tandem-dimer fusions (Fradkov et al., 2002; Shaner et al., 2005) can be used either alone or 
in combination (Campbell et al., 2002; van der Krogt et al., 2008), depending on the specific 
fluorescent protein. Importantly, even when monomerization has been confirmed by 
biochemical means in cell-free systems (such as size-exclusion chromatography), fluorescent 
proteins might still oligomerize and aggregate in cells, as elegantly shown by using the natural 
tendency of endoplasmic reticulum to accumulate for testing FPs in cells (Costantini et al., 
2012; Cranfill et al., 2016). Also, even if original tetramers have been pseudo-monomerized as 
tandem-dimers, the tandem-dimers themselves can dimerize again to form a de facto tetramer 
showing reduced, but still visible, aggregation (Fradkov et al., 2002). 
This observation of oligomerization of supposed monomers supports a notion of van der Krogt 
et al. that FRET pairs in particular, even if they consist of monomers, are more prone to 
aggregation since the presence of two fluorescent protein moieties in close proximity increases 
the avidity (van der Krogt et al., 2008). In their example, the introduction of non-dimerizing 
mutations into CFP-YFP did not affect aggregation, while the tandem-dimerization of Venus 
(replacing YFP) abolished aggregation. This suggests that tandem-dimerization is not only 
useful for monomerization of FPs generally, but by tandem-dimerization of seemingly 
monomeric FPs as acceptors in FRET pairs the propensity to form aggregates can be reduced 
while gaining FRET efficiency through the doubling of the extinction coefficient.  
Apart from mutagenesis and tandem-dimerization further strategies have been suggested to 
reduce oligomerization. For instance, the concentration of FRET pairs inside cells strongly 
influences aggregation (van der Krogt et al., 2008). High expression can relatively easily be 
overcome by avoiding bright cells or by creating stable cell lines selected for moderate 
expression, but the drawback is that higher laser powers need to be used for imaging 
increasing phototoxicity. Moreover, in applications where FRET pairs are expressed in small 
spaces or the cellular volume decreases significantly, as during apoptosis in our work, an 
increase of local concentration can result in the creation of new aggregates (with increased 
FRET probably due to additional intra-molecular energy transfer in crowded environments) 
during the experiment, without the possibility to avoid such cells during the setup.  
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Importantly, aggregation is also dependent on the cells of choice, as noted by others (van der 
Krogt et al., 2008) and exemplified by a recent study showing mCherry, which never 
aggregated even at high levels in a large number of cancer cells strongly aggregated in 
neuronal cells (Laviv et al., 2016). This suggests that a change in cell line, if experimentally 
possible, can be an easy way to avoid aggregation.  
In summary, a growing number of solutions to overcome key challenges in the design of FRET-
based biosensor provide a toolbox for our endeavour to design a suite of FRET pairs suitable 
for multiplexing. In this Chapter, I will describe how we used a number of those to address an 
issue arising during the development of such pairs.  
 Multiplexing FRET pairs permits simultaneous readout of 
multiple biochemical events in single cells 
To achieve the goal of multiplexing FRET pairs several different approaches have been used, 
but all are limited to two simultaneously imaged FRET pairs. 
Multiplexing with two excitation lines 
Two spectrally-resolved FRET sensors are read out sequentially using two excitation 
wavelengths. This has first been achieved by using CFP and YFP as spectrally resolved 
donors that work with the same RFP acceptor. Using intramolecular FRET, the interaction of 
two Ras isoforms, labelled with CFP or YFP, and a binding domain labelled with tHcRed as 
acceptor was studied using FLIM measuring donor fluorescence lifetimes (Peyker et al., 2005). 
In an intramolecular FRET setup, CFP and YFP were each fused to dsRed with linker carrying 
a protease cleavage site and the increase in donor fluorescence upon loss of FRET measured 
(Kawai et al., 2005). Avoiding sharing of an acceptor which can have complex effects on FRET 
measurements (Bunt and Wouters, 2017), true spectrally distinct pairs have been first used to 
study RAS and Ca2+ signalling by FLIM (ECFP/mVenus, TagRFP-mPlum; Grant et al., 2008). 
Importantly, FLIM imaging of the donors proved essential for this combination, because of the 
low quantum yield of mPlum that was not sufficient to measure its sensitized emission. Using 
brighter, but less red-shifted acceptors, that are suitable for seFRET, several groups have 
reported dual-colour FRET imaging monitoring FRET pairs for a range of applications, 
including subcellular caspase-3 cleavage (mTFP-mCitrine, mAmetrine-tdTomato; Ai et al., 
2008), Src kinase and Matrix Metalloprotease activity (CFP/YFP, mOrange-mCherry; Ouyang 
et al., 2010), caspase-3 and Ca2+ imaging (mTFP-mCitrine, mAmetrine-tdTomato; Ding et al., 
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2011), PKA and cAMP activity (Cerulean-mCherry, mVenus-mCherry; Aye-Han et al., 2012) 
and Src kinase and Ca2+ signalling (mTagBFP-sfGFP, mVenus-mKOκ; Su et al., 2013). Using 
anisotropy FRET imaging, Warren et al. combined a standard CFP/YFP Ca2+ sensor with a 
homoFRET probe consisting of mCherry fused to the membrane-anchor of Akt kinase, which 
allows measuring Akt clustering by intermolecular FRET (Warren et al., 2015).  
While important insights have been gained using two excitation wavelengths, the delay 
between the acquisition of each pair which, depending on the detection setup, can be seconds 
to minutes, prevents the fully simultaneously imaging required for fast events. Furthermore, 
multiple exposures with different laser lines make phototoxicity more likely. 
Multiplexing with a single excitation line 
Using a single excitation wavelength for both donors has been made possible by the 
development of fluorescent proteins with a long Stokes shift (the difference between excitation 
and emission peak wavelengths; LSS). This permitted to study very fast processes such as 
cAMP and cGMP signalling by combining ECFP-EYFP sensors with LSS donor T-Sapphire 
linked to the RFP dimer2 that can be read out using ratiometric seFRET (Niino et al., 2009). 
Similarly, caspase-3 and fast Ca2+ imaging were studied using ECFP-mVenus and LSS-
mOrange-mKate sensors (Shcherbakova et al., 2012). To reduce spectral bleed-through of the 
first acceptor into the second pair that can lead to false-positive FRET efficacy changes, ‘dark’ 
acceptors (Ganesan et al., 2006) with a low quantum yield have been introduced in a number 
of studies. Niino et al. monitored cAMP and cGMP signalling with mTagBFP-sREACh and 
CFP/YFP using seFRET (Niino et al., 2010). However, because of the low quantum yield of 
sREACh, mTagBFP intensity was measured non-ratiometrically and therefore only providing 
relative FRET changes. Two recent studies used FLIM, which is ideal for dark acceptors since 
only the donor fluorescence lifetime is measured to obtain absolute changes in FRET 
efficiency, to monitor CaMKII and RhoA signalling with mEGFP-dimVenus and mCyRFP-
mMaroon pairs (Laviv et al., 2016) and PKA and ERK kinase activity with mTFP-ShadowG and 
LSS-mOrange-mKate2 (Demeautis et al., 2017). 
A different approach is based on the combination of three fluorophores that are either in a 
sequential, ‘two-step’ configuration in which the acceptor for donor 1 is also donor for 
acceptor 2 (Watrob et al., 2003), or in a ‘three-way’ configuration where one donor shares two 
acceptors that may also exhibit FRET between them (Galperin et al., 2004). So far, this 
approach has only been used to study three interactions in protein complexes, with the 
exception for two-step FRET which was used by Wu et al. to measure two different caspase 
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activities by creating a CFP-YFP-mRFP fusion with two protease linkers read out by seFRET 
using flow cytometry (Wu et al., 2006). 
Example for multiplexing three biochemical events using FRET 
Finally, one study has described simultaneously multiplexing of three FRET sensors for PKA, 
cAMP and Ca2+ consisting of only three different FPs (mTurquoise2-cpVenus, mTurquoise2-
mCherry, mCherry-cpVenus) that are imaged using three excitation wavelengths and a 
combination of ratiometric and spectral imaging FRET (Woehler, 2013). For unmixing, 
reference excitation and emission spectra are acquired for the individual pairs and then used 
to extract apparent FRET efficiencies from time-lapse data of the co-expressed sensors. While 
allowing very fast imaging and relative simple analysis, the use of three excitation wavelengths 
is undesirable for multiplexing, especially when extending to a higher number of fluorophores. 
Also, as discussed earlier, the use of intensiometric readouts makes this approach less 
quantitative as for example FLIM, and more prone to concentration artefacts resulting from, for 
example, a local increase in concentration due to cell shrinkage. Homogeneous and stable 
expression levels of all sensors in all cells are possible only in a few biological applications 
limiting the usefulness of this otherwise elegant approach.  
Design principles for three-colour single excitation FLIM-FRET suite 
In order to overcome the limitations in quantitative biochemical multiplexing of state-of-the-art 
techniques, we decided to rationalize the utilization of the visible spectrum and planned to 
combine (Fig. 2.1): 
i) Three donors with varying Stokes shifts that allow excitation with a single 
wavelength and simultaneous detection 
ii) Three ‘dark’ acceptors exhibiting high extinction coefficients and low quantum 
yields with spectral overlaps matched to their respective donor fluorophore, 
permitting us to minimize spectral cross-talk. 
iii) FLIM-based detection in order to obtain quantitative biochemical read-outs utilizing 
only fluorescence emitted by donor fluorophores. 
iv) Two-photon excitation to provide efficient separation between excitation and 
emission paths, z-sectioning and 3D imaging with non-descanned hybrid detectors 
which minimize optical losses. This strategy permits us to increase sensitivity and 
reduce acquisition times. Hybrid detectors could achieve photon count rates in 
excess of what common FLIM electronics were capable of at the beginning of this  
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v) project and, therefore, we customized read-out electronics achieving very fast 
(about one order of magnitude faster than standard electronics) and sensitive 
detection.  
vi) Finally, developing novel unmixing algorithms to achieve fast model-free and 
computational efficient data pipelines that permitted us to retrieve quantitative 
biochemical information from complex photophysical information. 
In this chapter, I will describe in detail the development and validation of these FRET pairs. In 
order to characterize them in a simple and biologically relevant context, we used short peptide 
linkers between donor and acceptor fluorescent proteins that carry well-characterized caspase 
(Cysteine-aspartic proteases) (Tyas et al., 2000) recognition sequences that are preferentially 
cleaved by three caspases that have been implicated in the DNA damage response: caspase-
2, -3 and -9. These sensors are experimentally simple to activate and known to provide a high 
dynamic range. Therefore, this strategy permitted us both to have a “molecular workbench” to 
test novel FRET pairs, microscopy and analysis tools, while addressing important questions 
related to dynamics and heterogeneity of caspase activation in response to DNA damage at 
the same time. 
 
  
Figure 2.1 – Efficient utilization of the visible spectrum for single-cell live biochemistry 
For multiplexing, we designed three FRET pairs that are excited at 840 nm two-photon excitation. The efficient 
utilization of visible spectrum permits us to increase the number of FRET pairs that can be imaged simultaneously 
and provides the opportunity for future integration with light-inducible enzymes that are currently under 
development in our laboratory. This scheme will permit to perturb and quantify small networks of biochemical 
reactions in living cells. The best three FRET pairs for multiplexing, developed as described in Chapter 2, are 
shown here. Adapted from A. Esposito. 
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2.2 Material and methods 
Detailed information for all reagents used in this study can be found in Table S4. 
 Molecular cloning 
All reagents were from New England Biolabs unless stated otherwise. Detailed information 
about the oligonucleotides and template sequences can be found in supplemental Tables S1 
and S2, respectively.  
To create the initial set of FRET sensors, the donors (mTagBFP, mAmetrine, and mKeima) 
and acceptors (sREACh, msCP576 and mNeptune; cloning performed by Bryn Hardwick and 
Meredith Roberts-Thomson (sREACh and msCP576) and Dr David Perera (mNeptune)) were 
amplified by PCR (Accuprime Pfx polymerase; Invitrogen) and purified using the QIAquick 
PCR Purification kit (Qiagen). The purified PCR products and the recipient vector pcDNA3.1(-) 
vector (Invitrogen) were digested with NheI and KpnI restriction enzymes for 1 hour at 37ºC, 
separated on a 0.8% Agarose (Biogene) gel and extracted using the QIAquick Gel Extraction 
(Qiagen) per manufacturer’s instructions. Ligation of vector and insert were performed using 
T4 ligase for 16 hours at 4ºC. After insertion of the donor, linker oligonucleotides were 
phosphorylated with Polynucleotide Kinase in T4 ligase buffer, annealed and ligated into NotI 
and KpnI sites using T4 DNA ligase for 2 hours at 16ºC, followed by the acceptors using KpnI 
and PmeI and as described for the donors. Linker sequences were (cleavage motif underlined): 
Uncleavable, LGGTGSGSGSASGG; caspase-2, LGGTGSGSGVDVADG and 
LGGTGSGSGVDTTDG; caspase-3: LGGTGSGSGDEVDG and LGGTGSGSGDEVDRG; 
caspase-7: LGGTGSGSGQKDVKDG; caspase-9 (short): LGGTGSGSGLEHDG; caspase-9 
(long): SPGSTLGGTGSGSGLEHDGPSGSA. 
Ligated plasmids were then transformed into in-house prepared competent DH5α bacteria 
using heat-shock. Plasmid DNA was prepared using the Plasmid Mini Kit (Qiagen) and 
screening performed by analytical digest and separation on an Agarose gel. Positive clones 
were confirmed by Sanger Sequencing (Source Bioscience), re-transformed into DH5α and 
plasmid DNA obtained using Plasmid Plus Maxi Kit (Qiagen) to reduce endotoxin 
contamination prior to transfection. 
2.2 Material and methods         19 
 
To change the linker in an existing construct, the construct was digested with KpnI and NotI, 
new linker oligos processed and ligated using T4 ligase as described above for the original 
linker. 
New donors and acceptors were inserted into the existing constructs by digesting the template 
and purified PCR-amplified insert with NheI/KpnI or NotI/PmeI, respectively, followed by gel-
extraction as above and ligation using Quick-Stick ligase (Bioline) for 30 min at room 
temperature. 
Codon optimization for expression of msCP576 in human cell lines was performed with the 
GeneArt gene synthesis online tool (Thermo Fisher Scientific). The optimized gene 
(msCP576h) was designed to integrate NotI/PmeI restriction sites utilized for subsequent 
subcloning into the corresponding sites in the mAmetrine-msCP576 containing plasmids by 
PCR-based restriction cloning as described above. ShadowG, bfloGFPc1, Ultramarine, 
hmKeima8.5 and mGarnet were codon-optimized as GeneArt Strings with suitable NheI/KpnI 
or NotI/PmeI sites. GeneArt Strings were used directly for restriction digest and ligated into 
both into FRET sensor backbones and an empty pcDNA3.1(-) as described for new donors 
and acceptors above. 
Tandem-dimer NirFP was created by co-worker Emma K. Richardson (who also created all 
constructs containing single copies of NirFP) using scar-less SapI-fusion cloning as described 
for tdTomato (Shaner et al., 2004). To link two copies of NirFP with a 14 amino-acid flexible 
linker (GHGTGSTGSGSSGT), NirFP was PCR-amplified from the pNirFP-C vector using two 
different set of primers, with the first adding a NheI restriction site to the N-terminus and the 
first seven linker residues followed by the SapI site to the C-terminus, and the second PCR 
adding the SapI N-terminally followed by the last seven linker residues and a NotI site. Purified 
and gel-extracted PCR products were digested with SapI followed by gel extraction. The 
digested products were then ligated for 16 hours at 16ºC overnight using T4 DNA ligase and 
the ligated products gel-extracted. To insert tdNirFP into the recipient vector, both insert and 
vector (pcDNA3-NirFP-mKeima) were digested with NheI and NotI, correct bands gel-
extracted and ligated for 16 hours at 16ºC overnight using T4 DNA ligase. The ligations were 
transformed into DH5α bacteria and plasmid DNA prepared and sequence confirmed as 
described above. 
Using a simplified and commercial scar-less fusion approach, Ultramarine and iRFP682 were 
tandem-dimerized with the same linker as used for tdNirFP above, but using the NEBuilder 
HiFi DNA Assembly kit. Two copies of either cDNA were amplified using two different sets of 
20 2.2 Material and methods 
 
overlapping primers designed using the NEBuilder online tool. The PCR products and 
pcDNA3-tdNirFP-mKeima backbone were digested using NheI and NotI restriction enzymes 
purified by gel extraction. Next, all three components (backbone and two PCR products) were 
ligated with their overlapping ends using the NEBuilder HiFi DNA Assembly Master Mix with a 
molar ratio of vector:insert of 1:2 while using 100 ng vector for 15 min at 50ºC. The products 
were transformed into DH5α bacteria and plasmid DNA prepared and sequence verified as 
described above. 
 Cell culture 
HeLa cells (CCL 2, ECACC #93021013) were obtained from the European Collection of Cell 
Cultures, maintained in DMEM (Gibco) supplemented with 10% fetal calf serum at 37ºC and 
5% CO2 in humified atmosphere and passaged by trypsinization (Trypsin-EDTA; Gibco).  
 Sample preparation for fluorescence lifetime imaging 
15,000 HeLa cells were seeded on 8-well LabTek II chambered coverglass (#1.5, Nunc cat. #  
155409). Transient transfection was performed 24 hours later with 125 ng of indicated plasmids 
using Effectene (Qiagen) (Fig. 2.3-4, 2.6, 2.9-11, 2.14A-F, 2.15A-H) or Jetprime (Polyplus) (all 
other figures) according to the manufacturer’s instructions. 24 hours (Effectene) or 6 hours 
(Jetprime) after transfection cells were washed with PBS (Phosphate Buffered Saline) and 
fresh medium added, which contained 40 uM Biliverdin (Sigma) for iRFP713 and iRFP682. 25 
µM of the irreversible and cell-permeable caspase inhibitors (see Tab. S4 for details) or DMSO 
(Dimethylsulfoxide) was added 2 hours before addition of 4 µM Staurosporine (Santa Cruz) or 
Ethyl Acetate (Sigma) as solvent control. Where indicated in pilot experiments, 10 µM 
Etoposide (Sigma) or DMSO was used for 16 hours instead of Staurosporine. At indicated time 
points, cells were fixed with 4% formaldehyde (Agar Scientific) for 10 min at room temperature 
(RT) and kept in PBS at 4ºC until use. 
 Spectral scans, fluorescence lifetime imaging and data analysis 
Imaging was performed with a Leica SP5 confocal laser scanning microscope (Leica 
Microsystems) equipped with a Ti:Sapphire two-photon laser (Coherent) tuned to 840 nm if not 
stated otherwise.  
2.2 Material and methods         21 
 
Emission spectra were acquired using the XYλ mode of the Leica SP5 with a 40x oil objective 
(Leica HCX PL APO CS 40.0x1.25 OIL UV), 256x256 pixel image size, 400 Hz scan speed, 
10 nm detection bandwidth and step size using the internal PMTs (photo-multiplier-tubes). The 
analysis was performed by exporting raw data for single cells from LAS Lite (Leica) to Microsoft 
Excel where the background was subtracted and normalized to the sum per cell or field of 
view. The average was calculated and normalized to the maximum. The relative contribution 
of acceptor fluorescence to donor emission was determined as the ratio of the area under the 
curve of donor-only and UCL control. 
Confocal images to visualize expression were acquired with a Leica SP5 with a 40x oil 
objective (Leica HCX PL APO CS 40.0x1.25 OIL UV), 1024x1024 pixel image size, 400 Hz 
scan speed, 16x line average, variable zoom and detection bandwidth optimized for maximum 
signal using the internal PMTs. If 1PE was used as indicated in the figure legend, the pin hole 
was closed to 1 airy units. Brightness, contrast and look-up table were adjusted using Fiji 
(ImageJ, NIH). 
For FLIM, the emission light was filtered according to the fluorophores used (mTagBFP: 
467-499 nm; mAmetrine: 506-545 nm; mKeima: 604-679 nm; all Semrock) and photons 
detected with a hybrid PMT operating in photon-counting mode connected to a module 
allowing time-correlated single-photon-counting (SPC-150; Becker & Hickl GmbH). Images 
were acquired with a 40x oil objective (Leica HCX PL APO CS 40.0x1.25 OIL UV), 256x256 
pixel image size and 400 Hz scan speed within 60 sec acquisition time. The fluorescence 
lifetime was calculated with SPCImage V4.9 (Becker & Hickl) fitting a monoexponential decay 
with adjusted threshold for background reduction and 1x binning. Intensity and lifetime images 
were exported from SPCImage. To generate lifetime distributions, the raw data was normalized 
to the sum of each FOV and multiple fields of view averaged in Microsoft Excel. Relative 
enzymatic activity (REA) and FRET efficiency (E) were calculated with average lifetimes 
obtained by summing the first moments of the lifetime distributions: 	 = 	

	
 and  =
1 −


. τ = average measured lifetime, τUCL = lifetime UCL-control, τD = lifetime donor-only 
control.  
 Western Blot 
For analysis of caspase sensor cleavage, 400,000 HeLa cells were seeded per 6 cm dish and 
24 hours later transfected with 500 ng (Donor-only control) or 100 ng (UCL-control, sensors 
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and empty-vector control) plasmid DNA using the JetPRIME reagent (Polyplus) according to 
the manufacturer’s instructions. The medium was changed 6 hours later. 24 hours after 
transfection, fresh medium was added containing 25 µM caspase-inhibitors followed by 4 µM 
Staurosporine (Santa Cruz) or Ethyl Acetate (Sigma) as solvent control two hours later, as 
detailed for imaging above. At indicated time points after treatment, the supernatant was 
removed, cells washed twice with PBS, detached with Trypsin-EDTA, collected in full medium 
and pooled with the supernatant. Cells were pelleted by centrifugation at 1000 rpm for 5 min 
at 4ºC, washed once in ice-cold PBS, resuspended in 100 µl PBS and transferred to a 
microcentrifuge tube followed by centrifugation at 13,000 rpm for 10 min at 4ºC. The pellet was 
stored at -80C until further processing.  
Lysis was performed by resuspending the pellet in 50 µl RIPA buffer (50 mM Tris pH 7.4, 
150 mM NaCl, 0.5% (w/v) Sodium deoxycholate, 0.1% SDS, 1% (v/v) IGEPAL) supplemented 
with 1 mM PMSF protease inhibitor (Sigma) and 1x Protease Inhibitor Complete (Roche) prior 
to use and incubated for 30 min on ice followed by centrifugation at 13,000 rpm for 10 min at 
4ºC. The protein concentration of the supernatant was determined by BCA assay (Pierce). 
10 µg of lysate was denatured with 1x sample loading buffer (Life Technologies) for 10 min at 
70ºC. Samples were separated on a 26-well 4-12% Bis-Tris SDS-PAGE gel (Life 
Technologies) and transferred onto a Hybond ECL (GE Healthcare) nitrocellulose membrane 
using wet transfer at 30 V for 120 min at 4ºC or 40 mA or 20 V for 16 hours at 4ºC. The 
membrane was stained with Ponceau-S solution (Sigma, cat. #7170) for 5 min to confirm 
efficient and even transfer. Blocking with 5% (w/v) milk in TBS-T (Tris Buffered Saline + 0.05% 
Tween-20) was followed by incubation with the primary antibody in blocking solution overnight 
at 4ºC (see Table S3 for details of all antibodies used). After washing 4x 5 min in TBS-T, the 
membrane was incubated with fluorescently-labeled secondary antibodies (IRDye; Licor) for 1 
h at room temperature, washed 4x 5 min with TBS-T and scanned using the Licor Odyssey 
scanner. Quantification of the bands was performed Image Studio version 5.25 (Licor) and 
ratios between cleaved and uncleaved sensor calculated in Microsoft Excel.  
 Data analysis and presentation 
If not stated otherwise, all analyses were performed in Microsoft Excel (Microsoft) and graphs 
prepared with GraphPad Prism version 5.0 (GraphPad Software). Foerster radii (r0) of donor-
acceptor pairs were estimated with an in-house developed Matlab script using published 
information on photophysical properties. 
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2.3 Results 
Each of the following sections describes the development of a blue, green and red light emitting 
FRET pair that was specifically designed for multiplexing, including discussions of FRET pairs 
that were deemed not good enough for subsequent experiments. Details of all tested 
fluorescent proteins and FRET pairs can be found in Tables 2.1 and 2.2 (located at the end of 
this chapter), respectively. 
To assess the suitability of FRET pairs, at least two constructs were created for each pair, one 
“UCL-control”, where donor and acceptor fluorophore are linked with a short 14 amino acid  
long peptide linker that is insensitive (“uncleavable”, UCL) to caspase cleavage, and a “Donor-
only” control, that consists of the donor FP with the UCL linker but lacks the acceptor (Figure 
2.2A). Constructs were transiently expressed in HeLa cells, fixed in formaldehyde, their 
emission spectra recorded and FRET efficiency determined using FLIM (Figure 2.2B, C).  
Those FRET pairs that showed sufficiently high FRET efficiency, consistent measurements, 
lack of secondary emission peaks, and did not exhibit significant aggregation were converted 
to caspase sensors introducing cleavage sites in the linkers in order to test their suitability to 
measure enzymatic activities (Figure 2.2B). Caspase-dependent cell death was induced by 
treatment with 4 µM Staurosporine (STS, a pan-kinase inhibitor) for 8 hours. Cells were also 
Figure 2.2 – Design principles of FRET pairs and experimental setup 
A: FRET pairs consist of a donor and acceptor fluorophore linked by a short peptide linker that is either 
proteolytically stable (uncleavable) or contains a specific substrate cleavage motif (in red) for the indicated 
caspase. 
B: Representation of the principles of FLIM data analysis for cleavage-based caspase sensors used for 
experiments in this chapter.  
C: General experimental protocol used for the validation of caspase FRET sensor in this chapter.  
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pre-treated with irreversible inhibitors for the respective caspases (Figure 2.2C) to assess the 
specificity and dynamic range of the sensors. 
 Development of a blue FRET pair for multiplexing 
As a donor for the blue FRET pair mTagBFP was chosen because it was the brightest blue 
fluorescent protein excitable at 840 nm two-photon excitation (2PE) at the time. We first tested 
sREACh as dark acceptor because it has been reported to work well for FRET with mTagBFP 
(Niino et al., 2010). sREACh is an optimized version of REACh2 that exhibits optimal spectral 
overlap with mTagBFP, but solves folding issues compared to REACh2. Compared to the 
parent YFP, sREACh was reported to exhibit a residual fluorescence of ~5% (Murakoshi et al., 
2008) that we considered sufficiently low for multiplexing with green FRET probes. However, 
spectral imaging of the mTagBFP-sREACh pair let us estimate that sREACh still contributed 
~12% to the total fluorescence (Fig. 2.3A), because of FRET and direct acceptor excitation. 
Although higher than expected under the chosen conditions, this residual fluorescence is still 
low enough to be properly unmixed by spectral or multicolour FLIM.  
We, therefore, introduced the canonical caspase-2 cleavage site VDVAD (Zhivotovsky and 
Orrenius, 2005) into the mTagBFP-sREACh linker and tested its suitability to sense caspase-2 
activity by FLIM. The sensor was well expressed in HeLa cells and exhibited 33% FRET (Fig. 
2.3B-D). Some aggregation of sREACh was visible in the green part of the spectrum in very 
bright cells, which did not affect fluorescence lifetime and can easily be avoided by choosing 
cells with moderate expression. STS treatment resulted in an increase in fluorescence lifetime 
relative to the untreated and UCL control (Fig. 2.3D-E). This change in fluorescence lifetime 
corresponded to an average of 65% relative enzyme activity (REA; Fig. 2.3F), indicating that 
65% of the sensor was cleaved. When the irreversible caspase-2 inhibitor Z-VDVAD was 
added, the fluorescence lifetime decreased only slightly, indicating limited specificity of this 
sensor. (Fig. 2.3E-F). As a note, several cells did not exhibit caspase-2 cleavage in one of 
three experiments performed resulting in the local maximum around 1500 ps (Fig. 2.3E) which 
in turn explains the large standard deviation in panel F.  
To increase the specificity for caspase-2, the substrate cleavage motif was changed from 
VDVAD to VDTTD. This change has been reported to increase the sensitivity by 4-fold and the 
specificity for caspase-2 over the caspase-3 substrate motif DEVD(G) by 2-fold (Fig. 2.4A; 
Kitevska et al. 2014). In our assay, the change to VDTTD indeed resulted in a higher sensitivity 
to caspase activation indicated by the increase in REA from 65% to 81% upon STS treatment.  
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The specificity as judged by the decrease of REA upon inhibitor treatment has also increased 
(65% to 64% (VDVAD); 84% to 60% (VDTTD)) (Fig. 2.4B-F).  
To complete the characterization of this sensor, expression and cleavage were analysed by 
Western Blot on whole cell lysates of HeLa cells that were prepared using the same protocol 
as for the FLIM experiments (Figure 2.4G). Both linker sequences were included for 
comparison. All constructs showed good expression at the expected molecular weights. We  
found that the lower molecular weight fragments that are present in all samples are due to 
fragmentation of the fluorescent proteins during denaturation in SDS-containing loading buffer, 
since lowering the temperature for denaturation reduced the amount of fragmentation (not 
shown). This has previously been observed for DsRed-like fluorophores (such as mTagBFP) 
with the breakpoint just before the chromophore resulting in the observed band pattern 
(Costantini et al., 2012).  
Upon STS treatment both linkers were efficiently cleaved, whereas the controls remained 
unchanged. Treatment with the caspase-2 inhibitor Z-VDVAD-FMK resulted in partial rescue 
of cleavage, in line with the partial rescue observed by FLIM. Quantification of the cleavage 
showed that as observed by FLIM, VDTTD was cleaved more efficiently than VDVAD (1.7-
fold) upon STS treatment and showed a slight increase in rescue upon inhibitor treatment (1.2-
fold, Figure 2.4H) 
 
 
Figure 2.3 – Characterization of a mTagBFP-sREACh as caspase-2 FRET biosensor for FLIM 
A: Fluorescence emission upon excitation with 840 nm two-photon excitation of donor-only controls (red) and 
uncleavable controls (blue).  
B: Representative intensity images (photon counts per pixel) of HeLa cells transiently transfected with indicated 
constructs after 8 hours STS or control treatment in the absence or presence of irreversible caspase-2 inhibitor 
Z-VDVAD-FMK.  
C: Fluorescence lifetime images of cells shown in B.  
D, E: Fluorescence lifetime distribution of control-treated cells (D) and cells treated with 4 µM STS (E) for 8 
hours in the absence (solid lines) or presence (dashed lines) of indicated inhibitors at 25 µM. Blue and red 
shaded curves show distributions of UCL and donor-only controls, respectively.  
F: Relative enzyme activity values computed from the respective lifetime distributions as shown in Fig. 2.2B. 
Bars show means and standard deviations.  
Data are from three independent experiments with at least 20 cells per experiment and condition. 
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Development of additional blue fluorescent FRET pairs for multiplexing 
Aiming to find truly non-fluorescent alternatives for sREACh that would be better suited for 
multiplexing, we screened literature for chromoproteins that may suitable acceptor for 
mTagBFP. We tested CRY2PHR, bfloGFPc1 and ShadowG (Figure 2.5, Tables 2.1-2.2),  
which all have been reported to be nonfluorescent (Bomati et al., 2014; Kennedy et al., 2010; 
Murakoshi et al., 2015).  
CRY2PHR showed no residual fluorescence and 11% FRET, but strongly aggregated in all 
cells (Fig. 2.5A-C). To reduce the aggregation, CY2PHR was systematically truncated to find 
the minimal domain that could be still mediate chromophore formation and exhibit FRET, but 
all fragments showed similar or increased aggregation and lower FRET efficiencies (Fig. 
2.5D-E).  
BfloGFPc1 was also completely dark and exhibited 16% FRET efficiency, which increased to 
21% after removal of a GFP-like N-terminal sequence (MVSKGEEDNMA) that we had added 
during synthesis to promote folding (Fig. 2.5F-G). Both bfloGFPc1 constructs showed 
aggregation in approximately a third of the cells (Fig. 2.5H).  
Next, we tested ShadowG, a chromoprotein derived from sREACh by others with the aim to 
reduce its residual quantum yield (Murakoshi et al., 2015). ShadowG showed a two-fold 
decrease of residual fluorescence compared to sREACh in our experimental conditions and  
Figure 2.4 – Improvement of caspase-2 sensing of mTagBFP-sREACh FRET pair 
A: Original and improved peptide linker sequences are shown with the caspase-2 cleavage site in red.  
B: Representative intensity images (photon counts per pixel) of HeLa cells transiently transfected with indicated 
constructs after 8 hours STS or control treatment in the absence or presence of irreversible caspase-2 inhibitor 
Z-VDVAD-FMK.  
C: Representative fluorescence lifetime images of cells in B. Scale bars are 50 µm.  
D, E: Fluorescence lifetime distribution of control-treated cells (D) and cells treated with 4 µM STS (E) for 8 hours 
in the absence (solid lines) or presence (dashed lines) of indicated inhibitors both at 25 µM. Blue and red shaded 
curves show distributions of UCL and donor-only controls, respectively.  
F: Relative enzyme activity values computed from the respective lifetime distributions. Bars show means and 
standard deviations. B-F: Data from three independent experiments with at least 20 cells per experiment and 
condition.  
G: Western Blot of HeLa cells transiently transfected with indicated constructs and treated as in B-F. mTagBFP 
expression was detected using a tRFP antibody and beta-actin is shown as loading control. Multiple bands 
correspond to FP cleavage during denaturation (see main text for details).  
H: Quantification of the Western Blot shown in G for the indicated lanes, and shown as the ratio of cleaved over 
the uncleaved sensor with fold changes indicated. G-H: Data from one experiment. 
 
2.3 Results         29 
 
  
Figure 2.5 – Alternative FRET pairs tested to replace mTagBFP-sREACh 
A-E: mTagBFP-CRY2PHR. A: Fluorescence emission spectra of transiently transfected HeLa cells upon 840 nm 
2PE for donor-only (red line) and UCL-control (blue line). B: Fluorescence lifetime distribution for cells in panel 
A showing 11% FRET. C: Representative intensity (photon counts per pixel) from FLIM measurements of HeLa 
cells expressing mTagBFP-UCL-CRY2PHR, coloured to show aggregation in bright yellow. D: Schematic of 
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exhibited ~30% FRET. Similarly to sREACh, moderate aggregation of ShadowG was observed 
in the green channel, but without affecting fluorescence lifetime measurements (Figure 2.5I-
K). Taken together, mTagBFP-ShadowG is a slightly better FRET pair compared to mTagBFP-
sREACh. However, as this FRET pair was cloned after a significant amount of experiments on 
caspase biology had already been performed and ShadowG still exhibited residual 
fluorescence emission, all following experiments were carried out with sREACh. 
In summary, we identified in mTagBFP-VDTTD-sREACh as a suitable caspase-2 FRET-
sensor for multiplexing. 
 Development of a green FRET pair for multiplexing 
As donor for the green fluorescent pair, mAmetrine was chosen due to it exceptional brightness 
and long Stokes shift that allows two-photon excitation at 840 nm (Table 2.1). Due to its 
putative high Förster radius, we selected a chromoprotein previously identified in the stony 
coral Montipora spongodes as acceptor, msCP576, originally reported simply as Keima clone 
number 20 (Kogure et al., 2006). msCP576 was used to evolve the long Stokes shifted red 
fluorescent protein mKeima and, at the best of our knowledge, it has not been used since for 
any application.  
In contrast to sREACh, no residual fluorescence of msCP576 was detected, making it an ideal 
dark acceptor (Figure 2.6A). Furthermore, mAmetrine-msCP576 exhibited 44% FRET 
efficiency as measured by FLIM, providing opportunities for higher dynamic ranges compared 
to mTagBFP-sREACh with 33% (Fig. 2.6 C-F).  
CRY2PHR domain structure with coverage of 12 cloned truncations constructs. E: FRET efficiency measured by 
FLIM for constructs shown in E.  
F-H: mTagBFP-bfloGFPc1. F: Fluorescence emission of transiently transfected HeLa cells upon 840 nm 2PE 
for donor-only (red line) and UCL-control (blue line). G: Fluorescence lifetime distribution for cells in F showing 
16% FRET efficiency for long version and 21% for short version (see main text). H: Confocal image of 
representative HeLa cells expressing mTagBFP-bfloGFPc1 coloured to show aggregation in white.  
I-K: mTagBFP-ShadowG I: Fluorescence emission of transiently transfected HeLa cells upon 840 nm 2PE for 
donor-only (red line) and UCL-control (blue line). J: Fluorescence lifetime distribution for cells in panel I showing 
29% FRET efficiency. H: Representative confocal images of HeLa cells expressing mTagBFP-UCL-ShadowG 
showing homogeneous expression without visible aggregation. 
A-B, E-G and I-J show averages of at least 10 cells per construct from one experiment. Scale bars are 30 µm. 
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Next, a linker was inserted containing DEVDG as canonical substrate cleavage motif for 
caspase-3 (Fig. 2.2; Tyas et al., 2000). Treatment with STS resulted in near complete cleavage  
of the linker as indicated by a relative enzymatic activity of ~90%. Caspase-3 inhibition partially 
prevented cleavage (Fig. 2.6 D-F) reducing REA to ~70%.  
However, we noticed that the expression of this sensor was low and barely sufficient for 
imaging and that in those rare cells with high expression, visible aggregates exhibiting low 
fluorescence lifetime occurred (Fig. 2.7A). Aggregation is a frequent issue with new fluorescent 
proteins and chromoproteins such as msCP576. For mAmetrine-msCP576, we hypothesized 
that incorrect expression of msCP576 was caused by the suboptimal mammalian codon usage 
of the original coral gene that, in turn, may cause also aggregation if msCP576 would be 
frequently mistranslated (Dobson, 2004). We, therefore, replaced msCP576 with a humanized 
version of the gene (msCP576h) obtained by gene synthesis introducing 147 silent point 
mutations (Fig. 2.7B-C). As shown in Figure 2.7A, the expression was markedly increased by 
the optimization while maintaining FRET. Aggregation in highly  
expressing cells still occurred, but only in very bright cells and, therefore, we decided to select 
mAmetrine-msCP576h as FRET pair amenable for multiplexing. Stable monoclonal cell lines 
selected for medium-expression level of the construct should harness the advantages of this 
FRET pair yet not exhibiting aggregation.  
Next, we aimed to increase the specificity of the sensor for caspase-3 because the limited 
rescue by Z-DEVD-FMK (Fig. 2.6F) upon STS treatment suggested a specificity lower than 
desirable. The canonical linker DEVDG (in general referred to as DEVD) has been shown to 
be cleaved efficiently by caspase-8 and caspase-7, and to a lesser degree by caspase-1 and  
Figure 2.6 – Characterization of mAmetrine-msCP576 as caspase-3 FRET biosensor for FLIM 
A: Fluorescence emission upon excitation with 840 nm two-photon excitation of donor-only controls (red line) 
and uncleavable controls (blue line). Ame, mAmetrine. 
B: Representative intensity images (photons per pixel) of HeLa cells transiently transfected with indicated 
constructs after 8 hours STS or control treatment in the absence or presence of irreversible caspase-3 inhibitor 
Z-DEVD-FMK.  
C: Representative fluorescence lifetime images of cells in B. Scale bars are 50 µm.  
D, E: Fluorescence lifetime distribution of control-treated cells (D) and cells treated with 4 µM STS (E) for 8 hours 
in the absence (solid lines) or presence (dashed lines) of indicated inhibitors at 25 µM. Blue and red shaded 
curves show distributions of UCL and donor-only controls, respectively.  
F: Relative enzyme activity values computed from the respective lifetime distributions. Bars show means and 
standard deviations.  
Data are from three independent experiments with at least 20 cells per experiment and condition. 
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Figure 2.7 – Optimization of mAmetrine-msCP576 by msCP576 codon optimization 
A: Representative confocal images for wild-type (left) and codon-optimized (right) mAmetrine-DEVD-msCP576 
FRET pair expressed in HeLa cells upon 840 nm 2PE excitation are shown. Scale bars are 30 µm. 
B: Human codon usage frequency for wild-type (left) and codon-optimized (right) msCP576 created during 
synthesis of the new gene. 
C: Sequence comparison of the wild-type and codon-optimized cDNA of msCP576, with consensus highlighted 
in blue. 
D, E: Fluorescence lifetime distribution of HeLa cells expressing the mAmetrine-msCP576h caspase-3 FRET 
sensor containing the codon-optimized msCP576h treated with solvent control (D) 4 µM STS (E) for 8 hours in 
the absence (solid lines) or presence (dashed lines) of indicated inhibitors at 25 µM. Blue and red shaded curves 
show distributions of UCL and donor-only controls, respectively.  
F: Relative enzyme activity values computed from the respective lifetime distributions.  
A, D-F: Data are from one experiment with at least 20 cells per condition. 
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caspase-6 in vitro (Stennicke et al., 2000). In contrast, the change to DEVDR was reported to 
result in a decrease of cleavage for all those caspases by 1-2 orders of magnitude (300-fold  
for caspase-8, 108-fold for caspase-1, 88-fold for caspase-7, 36-fold for caspase-6) while only 
decreasing processing by caspase-3 by 14-fold, and thereby resulting in the net increase in 
specificity for caspase-3 (ibid.). Furthermore, assessing the effect of the change to DEVDR in 
cells, Albeck et al. showed a 4-fold decrease of processing by caspase-8 upstream of 
mitochondrial outer membrane permeabilization compared to DEVD (MOMP; Albeck et al. 
2008). In our hands, the DEVDR-based caspase-3 sensor was indeed significantly more 
specific for caspase-3, resulting in a loss of REA of ~40% (from ~90% to 50%) instead of ~10% 
(80% to 70%) upon caspase-3 inhibitor treatment for the DEVDG linker (Fig. 2.8B-G). Thus, 
the efficiency of cleavage in response to STS was maintained, while increasing specificity 
(compare Fig. 2.6F and 2.8F). 
We completed the characterization of the sensor by monitoring sensor expression and 
cleavage by Western Blot,including both linker sequences (Fig. 2.8G-H). The FRET pairs are 
generally well expressed and exhibit the expected molecular weights albeit showing the 
degradation bands already discussed for mTagBFP-sREACh (Fig. 2.4G). Furthermore, 
specific high-molecular-weight bands between 200-250 kDa were present for all mAmetrine-
msCP576-containing constructs. These bands likely correspond to the aggregation we 
Figure 2.8 – Improvement of caspase-3 sensing of mAmetrine-msCP576h FRET pair 
A: Original and improved peptide linker sequences are shown with the caspase-3 cleavage site in red.  
B: Representative intensity images (photons per pixel) of HeLa cells transiently transfected with indicated 
constructs containing msCP576h after 8 hours 4 µM STS or control treatment in the absence or presence of 
irreversible caspase-3 inhibitor Z-DEVD-FMK at 25 µM. Ame, mAmetrine. 
C: Representative fluorescence lifetime images of cells in B. Scale bars are 50 µm.  
D, E: Fluorescence lifetime distribution of control-treated cells (D) and cells treated with 4 µM STS (E) for 8 hours 
in the absence (solid lines) or presence (dashed lines) of indicated inhibitors both at 25 µM. Blue and red shaded 
curves show distributions of UCL and donor-only controls, respectively.  
F: Relative enzyme activity values computed from the respective lifetime distributions. Bars show mean and 
standard deviation.  
B-F: Data from three independent experiments with at least 20 cells per experiment and condition.  
G: Western Blot of HeLa cell lysates transiently transfected with indicated constructs and treated as in B-F. 
mAmetrine expression was detected using a GFP (JL-8) antibody and b-actin is shown as loading control. 
Multiple bands correspond due FP cleavage during denaturation and higher molecular weight bands are 
functional, aggregated sensors (see main text).  
H: Quantification of Western Blot in panel G for the indicated lanes, and shown as the ratio of cleaved over the 
sum of uncleaved and aggregated sensor with fold changes indicated.  
G-H: Data from one experiment. 
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observed microscopically in highly expressing cells and seem to be resistant to denaturation, 
but are cleaved when treated with STS, indicating the presence of a functional sensor. We, 
therefore, summed the intensity of the putative aggregates as well as the monomeric 55 kDa  
band for the quantification of the Western Blot. As shown in Figure 2.8H, the change to DEVDR 
resulted in a 7.5-fold decrease in cleavage upon STS treatment, in line with the reported 
decrease in vitro (Stennicke et al., 2000). We noted that this decrease in sensitivity was not 
observed by FLIM (Compare Fig. 2.6F and Fig. 2.8F). Upon caspase-3 inhibitor treatment, 
DEVD showed a 6.8-fold decrease in cleavage compared to 1.9-fold for DEVDR indicating that 
at least on Western Blot, the increase in specificity observed by FLIM could not be observed.  
These discrepancies between Western Blot and FLIM measurements are currently 
investigated further by performing repeats of the Western Blot, but based on the FLIM results 
from three independent experiments with very little variation between the experiments, we 
decided to continue with the DEVDR linker for further FLIM-based studies.  
In summary, we found mAmetrine-DEVDR-msCP576h to be an excellent FRET pair for 
multiplexing and a suitable sensor for caspase-3 substrate cleavage by FLIM. 
Adaptation of mAmetrine-msCP576h as caspase-9 sensor 
Because of its excellent suitability for multiplexing and major challenges in constructing a red 
fluorescent caspase-9 sensor, we replaced the DEVDR linker with LEHD (Thornberry et al., 
1997) to be able to sense caspase-9 sensor cleavage and multiplex the blue caspase-2 sensor 
both with caspase-3 and caspase-9. This flexibility is also useful when the red part of the 
spectrum is used for other, non-FRET-based, detection. 
When treated with STS, FRET efficiency decreased by 20% corresponding to 50% REA (Fig. 
2.9A-E). Upon Z-LEHD-FMK inhibitor treatment, cleavage was almost completely lost, 
indicating a very high specificity of the linker for caspase-9. Those observations were 
confirmed by Western Blot (Fig. 2.9F-G). The incomplete cleavage of the caspase-9 sensor 
compared to near complete cleavage of the tested caspase-2 and caspase-3 sensor is likely 
reflecting differences in the enzymatic activity of these enzymes, with caspase-9 enzyme 
activity being low (Garcia-Calvo et al., 1999) and reported to be inactivated rapidly after 
activation (Malladi et al., 2009).  
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 Development of a red FRET pair for multiplexing 
The development of a red fluorescent FRET pair that is excitable at 840 nm together with the 
green and the blue fluorescent pairs described above has been a central challenge in the 
development of this multiplexing platform. 
First, we have tested all the long Stokes shift red fluorescent proteins (LSS-RFPs) available at 
the time: mKeima, LSS-mKate1, LSS-mKate2 and mBeRFP (see table Table 2.1 for details). 
As shown in Figure 2.10A, all LSS-RFPs show varying levels of green fluorescence at 840 nm 
two-photon excitation, which were generally found to be more pronounced than originally 
published, at least in our experimental conditions. Since for fast and efficient multiplexing 
minimal spectral overlap between the FRET pairs is crucial, mKeima was chosen as donor for 
the development of red FRET pairs, because it exhibited the least green fluorescence. 
Previously, mKeima had only been used as internal standard for spectral FRET imaging for 
CFP/YFP-like pairs, but not as FRET donor/acceptor itself (Kumagai et al., 2011). 
As acceptors, three proteins were identified that exhibited a sufficiently high extinction 
coefficient and spectral overlap with mKeima to provide a high Förster radius, thus being good 
candidates for acceptors when paired with mKeima (Tables 2.1 and 2.2.): cjBlue, iRFP713 and 
NirFP. 
Figure 2.9 – Adaptation of mAmetrine-msCP576 as caspase-9 biosensor 
A: Representative intensity images (photons per pixel) of HeLa cells transiently transfected with indicated 
constructs after 8 hours in 4 µM STS or control treatment in the absence of presence of irreversible caspase-9 
inhibitor Z-LEHD-FMK at 25 µM.  
B: Representative fluorescence lifetime images of cells in A. Scale bars are 50 µm.  
C, D: Fluorescence lifetime distribution of control-treated cells (C) and cells treated with 4 µM STS (D) for 8 
hours in the absence (solid lines) or presence (dashed lines) of Z-LEHD-FMK at 25 µM. Blue and red shaded 
curves show distributions of UCL and donor-only controls, respectively.  
E: Relative enzyme activity values computed from the respective lifetime distributions. Bars show mean and 
standard deviation.  
A-E: Data from three independent experiments with at least 20 cells per experiment and condition.  
F: Western Blot of HeLa cell lysates transiently transfected with indicated constructs and treated as in A-F. 
mAmetrine expression was detected using a GFP (JL-8) antibody and b-actin is shown as loading control. 
Multiple bands correspond due FP cleavage during denaturation and higher molecular weight bands are 
functional, aggregated sensors (see main text).  
G: Quantification of Western Blot in G for the indicated lanes, and shown as the ratio of cleaved over the sum 
of uncleaved and aggregated sensor with fold changes indicated. F-G: Data from one experiment. 
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First, the tetrameric non-fluorescent chromoprotein cjBlue was tested (Chan et al., 2006). We 
found that mKeima-cjBlue strongly aggregated in more than 90% of the cells rendering it 
unusable (Fig. 2.10B). When the emission at 840 nm 2PE was measured in few cells with less 
aggregation, no contribution to the overall fluorescence from cjBlue was observed, indicating 
that cjBlue is indeed non-fluorescent under our experimental conditions (Fig. 2.10C). In those 
cells, we could quantify a FRET efficiency of 16% for mKeima-cjBlue by FLIM (Fig. 2.10D). 
This demonstrates that mKeima-cjBlue could be a useful FRET pair if the aggregation issue  
 
  
Figure 2.10 – Donor and acceptor fluorophores for long Stokes shift red fluorescent FRET pairs 
A: Fluorescence emission spectra of HeLa cells transiently transfected with the indicated LSS-RFPs at 840 nm 
two-photon excitation. Lines are the average of at least 10 cells each and from one experiment. 
B: Representative confocal image of HeLa cells transiently expressing mKeima-UCL-cjBlue, coloured to show 
aggregates in hotter colours. All visible aggregates around the cell in the centre of the field of view are inside 
neighbouring cells. Scale bar is 30 µm. 
C: Fluorescence emission spectra of indicated constructs transiently expressed in HeLa cells at 840 nm 2PE. 
D: Fluorescence lifetime distribution of indicated constructs transiently expressed in HeLa resulting in a FRET 
efficiency of 16%.  
C-D: Data from one experiment with at least 5 cells per construct. Only cells with no or little visible aggregates 
were imaged. 
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was solved. To this end, co-workers performed mutagenesis on cjBlue to disrupt the 
tetramerization domain, based on the monomerizing mutations for related proteins Rmts5 and  
DsRed (not shown). However, our attempts in monomerizing mKeima-cjBlue were not 
successful and, therefore, cjBlue was not further utilized. 
Second, iRFP713 was used as an acceptor for mKeima. Dimeric iRFP713 belongs to a class 
of near-infrared fluorescent proteins that were evolved from bacterial phytochrome 
photoreceptors and that require the incorporation of the cofactor Biliverdin (BV) for maximal 
fluorescence (Filonov et al., 2011). Mammalian cells produce low levels of BV that is sufficient 
for 60% of maximal fluorescence, but the addition of exogenous BV is required for full 
fluorescence. Therefore, to test the mKeima-iRFP713 FRET pair, cells were incubated in a 
high, but nontoxic concentration of BV for 16 hours prior to the experiment. At 840 nm 2PE, 
iRFP713 did not seem to contribute to overall fluorescence at least in the spectral band we 
used to image mKeima (Fig. 2.11A). The use of short-pass filter at 700 nm that was required 
to separate the excitation and the emission optical paths for two-photon microscopy prevented 
us to detect possible fluorescence over 700 nm (ibid.).  
The FRET pair was well expressed in HeLa cells with fewer than 10% of cells showing small 
fluorescent aggregates (Fig. 2.11D, upper row). The construct was excluded from the nucleus, 
likely due to the larger size of iRFP713 compared to GFP-like proteins (~250 amino acids for 
GFP, ~300 for iRFP). However, strong aggregation was observed in all dead, shrunk cells, 
likely due to the increase of the local concentration of the construct in a smaller volume, which 
could promote aggregation (Fig. 2.11D, lower row). These aggregates also exhibited a lower 
fluorescence lifetime (illustrated by a broadening of the blue distribution in Fig. 2.11G) and 
therefore higher FRET efficiency, likely caused by inter-molecular FRET caused by molecular 
crowding (Fig. 2.11E-H). Whereas 15% FRET efficiency was measured in untreated cells, 
dead cells exhibited 25% for the uncleavable (UCL) control (Fig. 2.11H). FRET was dependent 
on the presence of exogenous added BV, as was the appearance of low-lifetime aggregates 
which were less pronounced in the absence of BV (Fig. 2.11 D-H).  
Despite this change in lifetime and aggregation in shrunk cells, we could still confirm sensor 
cleavage by FLIM (Fig. 2.11G-H) as well as Western Blot (Fig. 2.11B, C). Thus, mKeima-
iRFP713 promised to be a good FRET pair with two limitations. First, it is not well-suited for 
applications where the cell volume decreases strongly, such as the study of cell death, which 
results in aggregations with high apparent FRET that complicate the analysis. Second, 
exogenous addition of BV is required for FRET, at least in HeLa cells, which must be  
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incorporated into the experimental design. Intriguingly, mKeima-iRFP713 is a promising pair 
for in vivo FRET imaging since physiological levels of BV in animals are sufficient for full 
fluorescence, and therefore likely full FRET efficiency, as well as the advantage of using 2PE 
excitation at 840 nm which allows deeper tissue penetration.  
The third acceptor we investigated was NirFP (also known as eqFP670; Tables 2.1 and 2.2). 
Expression of mKeima-UCL-NirFP resulted in strong aggregation in more than 50% of all cells 
(Fig. 2.12A). When performing measurements on the cells with less or no aggregation, a 
contribution of NirFP to the overall emission could not be detected (Fig. 2.12B). FLIM 
measurements showed a FRET efficiency of 37% (Fig. 2.12C). Next, we swapped the position 
of donor and acceptor, which, in our hands, can affect both FRET efficiency as well as 
aggregation. We found an increase in the number of cells showing aggregation for NirFP-UCL-
mKeima, but with the aggregates appearing smaller (Fig. 2.12D). We, therefore, continued the 
development with NirFP-UCL-mKeima. The creation of tandem-dimers by fusing two copies of 
the same fluorescent protein with a short flexible linker has been used to reduce aggregation 
of dimeric FPs, such as tandem-dimer (td)Tomato (Shaner et al., 2004). As discussed in the 
introduction, it is suggested that the fusion promotes intramolecular dimerization between the 
Figure 2.11 – Characterization of mKeima-iRFP713 as caspase-9 FRET biosensor for FLIM 
A: Fluorescence emission of indicated constructs transiently expressed in HeLa cells at 840 nm 2PE. 40 µM 
Biliverdin was added 24 hours before formaldehyde fixation. Data from one experiment with 10 cells measured 
per sample. 
B: Western Blot of HeLa cells transiently transfected with indicated constructs and treated with 4 µM STS or 
solvent control for 8 hours. 40 µM Biliverdin was added 16 hours before addition of STS and was absent in the 
medium during the duration of treatment. mKeima expression was detected using the mKeima-Red antibody 
and β-actin is shown as loading control. Multiple bands correspond to FP cleavage during denaturation (see 
main text for details).  
C: Quantification of Western Blot in B for the indicated lanes, and shown as the ratio of the cleaved uncleaved 
sensor with fold changes indicated. B-C: Data from one experiment. 
D: Representative intensity images (photons per pixel) of HeLa cells transiently transfected with indicated 
constructs and treated as in B. No Biliverdin was added to cells in the last panel. 
E: Representative fluorescence lifetime images of cells in D. No Biliverdin was added to cells in the last panel. 
Scale bars are 50 µm. 
F, G: Fluorescence lifetime distribution of control-treated cells (F) and cells treated with 4 µM STS (G) for 8 hours 
after 16 hours incubation with (solid lines, mKeima-LEHD-iRFP713) or without (dashed lines, mKeima-UCL-
iRFP713) 40 µM Biliverdin. Blue and red shaded curves show distributions of UCL and donor-only controls, 
respectively. Data are from one experiment with at least 10 cells measured for each curve. 
H: FRET efficiency derived from indicated lifetime distributions in F-G. Bars show the mean and standard 
deviation of at least 10 cells of a single experiment for each condition and construct.  
I: Relative enzymatic activity for mKeima-LEHD-iRFP713 sensor constructs computed from the respective 
lifetime distributions shown in F-G. 
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two copies in the same molecule over inter-molecular dimerization with other molecules, thus 
resulting in effective monomerization of a tandem-dimer construct. We employed the same 
approach as described for tdTomato to create tandem-dimer NirFP (tdNirFP) linking two copies 
of dimeric NirFP with a short 14-residue linker (Fig. 2.12E). Indeed, aggregation was 
completely absent in the resulting tdNirFP-UCL-mKeima FRET pair (Fig. 2.12F). tdNirFP 
contributed 12% to the overall fluorescence compared to the donor only (Fig. 2.12G), which 
corresponds to the emission of tdNirFP at 650 nm that is slightly red-shifted compared to NirFP 
(Fig. 2.12H), due to direct excitation, sensitized emission or both.  
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TdNirFP-UCL-mKeima exhibits a FRET efficiency of 53% (Fig. 2.12I), making it to our 
knowledge the best red FRET pair yet reported, as well as the only red FRET pair that is 
excitable in the blue part of the visible spectrum, at 840 nm 2PE. However, when the standard 
14-residue long caspase-9 substrate cleavage linker was introduced and cells treated with 
STS, no change in fluorescence lifetime was observed (Fig. 2.12I-K), indicating that the linker 
is not cleaved. As the same linker in a different pair, mAmetrine-msCP576h, was efficiently 
cleaved upon STS treatment, the linker alone cannot be the reason for the loss of cleavage. 
We, therefore, hypothesized that the tandem-dimer could sterically prevent caspase-9 from 
processing the linker. Therefore, we extended the linker by 10 amino acids including prolines 
and glycines to provide a longer flexible linker (Fig. 2.13A). The new linker restored cleavage 
by STS as shown both by Western Blot (Fig. 2.13B-C) and FLIM (Fig. 2.13D-H). Similarly to 
the cleavage of the green mAmetrine-LEHD-msCP576h sensor, we observed only a ~50% 
maximal cleavage (Compare Fig. 2.9E and 2.13H). Treatment with the caspase-9 inhibitor 
Z-LEHD-FMK resulted in a two-fold decrease in cleavage, a specificity similar to those of the 
caspase-2 and caspase-3 sensors reported above (Fig. 2.13H). Notably, the decrease upon 
treatment with inhibitors was an order of magnitude smaller that determined by Western Blot 
(Fig. 2.13C). Along with similar discrepancies between FLIM and Western Blot observed for 
DEVD/DEVDR caspase-3 (Fig. 2.8H) and LEHD caspase-9 (Fig. 2.9H, 2.11C) linker, this  
Figure 2.12 – Development of tdNirFP-mKeima, a first-in-class long Stokes shift red fluorescent FRET 
pair 
A: Representative confocal image of HeLa cells transiently expressing mKeima-UCL-NirFP with 405 nm 1PE 
with aggregates shown in hotter colours. 
B: Fluorescence emission of the indicated constructs expressed in HeLa cells at 840 nm 2PE. Only cells with 
little to no aggregation were imaged. 
C: Fluorescence lifetime distribution cells in B, corresponding to 37% FRET efficiency. 
D: Representative confocal image of HeLa cells transiently expressing NirFP-UCL-mKeima with 405 nm 1PE 
with aggregates shown hotter colours. Note the different appearance of aggregates as compared to A.  
E: Schematic of the configuration of tandem-linker NirFP and the used linker sequence with N- and C-termini of 
adjacent NirFPs in red. 
F: Representative confocal image of HeLa cells transiently expressing tdNirFP-UCL-mKeima at 840 nm 2PE 
demonstrating the absence of any visible aggregation. 
G-H: Fluorescence emission of HeLa cells transiently transfected with indicated constructs at 840 nm 2PE (G) 
and 594 nm 1PE (H). 
I-J: Fluorescence lifetime distribution of control-treated cells (I) and cells treated with 4 µM STS (J) for 8 hours 
in the absence (solid lines) or presence (dashed lines) of caspase-9 inhibitor Z-LEHD-FMK at 25 µM. Blue and 
red shaded curves show distributions of UCL and donor-only controls, respectively 
K: FRET efficiency computed from I-J. Mean with standard deviations are shown. 
All data are from a single experiment and the average of at least 10 cells are shown per construct and condition 
in B-C, G-K. Scale bars are 30 µm. 
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suggests that observations about specificity and sensitivity made with those techniques are of 
limited use for a direct comparison. 
Compared to the shorter linker, FRET efficiency decreased by 18% to 35% (Fig. 2.13E), likely 
due to the larger distance between donor and acceptor or to changes in dipole-dipole 
orientation between donor and acceptor that may occur if donor and acceptors experience 
different steric hindrances in the two constructs. More importantly, we did not detect any of the 
issues experienced with other near-infrared acceptors (aggregation and unspecific FRET), 
making of tdNirFP-mKeima our best choice for the multiplexing platform.  
In summary, tdNirFP-mKeima is an excellent first-in-class FRET pair that is well suited for 
multiplexing with blue and green fluorescent FRET pairs with a single blue excitation 
wavelength and serves as a good caspase-9 substrate cleavage sensor. 
Alternative red-fluorescent long Stokes shift FRET pairs for multiplexing 
With new fluorescent proteins being published frequently, we continuously tested new 
combinations and benchmarked them against tdNirFP-mKeima. Table 2.2 reports results for 
all tested pairs, which will be described in the following section to guide further development 
and highlight common challenges in the development of this class of FRET pairs. 
Figure 2.13 – Characterization of tdNirFP-mKeima as FRET biosensor for caspase-9 substrate cleavage 
A: Schematic representation of the longer and more flexible caspase-9 linker used to overcome impaired 
cleavage by caspase-9. 
B: Western Blot of HeLa cell lysates transiently transfected with indicated constructs and treated with 4 µM STS 
or solvent control for 8 hours in the absence or presence of caspase-9 inhibitor Z-LEHD-FMK at 25 µM. mKeima 
expression was detected using the mKeima-Red antibody and b-actin is shown as loading control. Additional 
specific bands are due to FP fragmentation during denaturation. 
C: Quantification of Western Blot in B for the indicated lanes, and shown as the ratio of the cleaved uncleaved 
sensor with fold changes indicated. B-C: Data are from one experiment. 
D: Representative intensity images (photons per pixel) of HeLa cells transiently transfected with indicated 
constructs and treated as in B. Scale bar is 50 µm. 
E: Representative fluorescence lifetime images of cells in D.  
F, G: Fluorescence lifetime distribution of control-treated cells (F) and cells treated with 4 µM STS (G) for 8 hours 
in the presence (solid lines) or absence (dashed lines) of 25 µM Z-LEHD-FMK. Blue and red shaded curves 
show distributions of UCL and donor-only controls, respectively.  
H: Relative enzymatic activity for tdNirFP-LEHD-mKeima sensor computed from the respective lifetime 
distributions shown in F-G. Bars show mean and standard deviation. 
D-H: Data from three independent experiments with at least 20 cells per construct and condition. 
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mNeptune is a widely used bright monomeric RFP that with a Förster radius of 5 nm could be 
a good acceptor for mKeima (Lin et al., 2009). However, a strong, pH-sensitive green emission 
upon 840 nm 2PE excitation made it unsuitable for multiplexing with green fluorescent FRET  
pairs (Fig. 2.14A-B). Recently, new versions of mNeptune have been published that are 
optimized for higher pH stability and reduced green emission which could be more suitable for 
multiplexing and remain to be tested with mKeima (Chu et al., 2014). 
IFP4.1 belongs to the same class of bacterial phytochromes as iRFP713, but has a 57% lower 
extinction coefficient and is more strongly dependent on the addition of Biliverdin (Filonov et 
al., 2011; Shu et al., 2009). However, in contrast to the dimeric iRFP713, it has been described 
as a monomer which could reduce the tendency to aggregate. When pre-treated with high 
Figure 2.14 – Assessment of alternative FRET acceptors for mKeima 
A: Fluorescence emission of HeLa cells transiently expressing mKeima-UCL or mKeima-UCL-mNeptune at 
840 nm 2PE. 
B: Fluorescence emission of HeLa cells expressing mNeptune in PBS with varying pH at 840nm 2PE. 
C: Fluorescence emission of HeLa cells transiently expressing mKeima-UCL or mKeima-UCL-IFP4.1 at 840 nm 
2PE. 40 µM Biliverdin was added 24 hours prior to fixation. 
D, E: Fluorescence lifetime distribution of HeLa cells transiently expressing mKeima-LEHD-IFP4.1 (solid line) 
after 16 hours of treatment with 10 µM Etoposide (E) or solvent control (D). Blue and red shaded curves show 
distributions of UCL and donor-only controls, respectively. Cells were pre-treated with 40 µM Biliverdin 24 hours 
prior to addition of Etoposide. 
F: Fluorescence lifetime derived from distributions in D-E. Bars show the mean and standard deviation of at least 
10 cells in a single experiment. 
G, H: Representative confocal images of HeLa cells transiently expressing indicated constructs at 840nm 2PE 
with aggregates shown in hotter colours. 
I: Fluorescence emission of cells in G-H at 840 nm 2PE, with cells with little to no aggregation chosen for analysis. 
J: Fluorescence lifetime distribution of HeLa cells expressing indicated constructs with little to no aggregation. 
Both orientations exhibit 10% FRET efficiency. 
K, L: Representative confocal images of HeLa cells transiently expressing indicated constructs at 840 nm 2PE 
with aggregates shown in hotter colours. 
M: Fluorescence emission of HeLa cells transiently indicated constructs at 840 nm 2PE. No Biliverdin was added. 
N: Fluorescence lifetime distribution of HeLa cells expressing indicated constructs with little to no aggregation. 
As shown, tdiRFP682-UCL-mKeima was also treated with 40 µM Biliverdin 24 hours prior to fixation. BV 
treatment increased FRET from 5% to 40%. 
O, P: Representative confocal images of HeLa cells transiently expressing indicated constructs at 840 nm 2PE 
with aggregates in panel O shown in hotter colours, which are absent in P. 
Q: Fluorescence lifetime distribution HeLa cells expressing indicated constructs with little to no aggregation 
corresponding to 3% and 10% for mGarnet-UCL-mKeima and mKeima-UCL-mGarnet, respectively. 
R: Fluorescence emission of HeLa cells transiently expressing indicated constructs at 840 nm 2PE.  
All data are from a single experiment and the average of at least 10 cells are shown per construct and condition. 
Scale bars in all panels are 30 µm. 
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levels of BV for 16 h, analogous to iRFP713, no contribution to the overall fluorescence could 
be detected (Fig. 2.14C). Despite the addition of BV, only 3% FRET efficiency could be 
measured in untreated cells (Fig. 2.14D). In Etoposide-treated dead cells, which was used at 
that time as an alternative to STS, the fluorescence lifetime for the UCL control decreased and, 
surprisingly, increased for donor-only control and therefore FRET increased to 18% (Fig. 
2.14E-F). This is reminiscent to the decrease in fluorescence lifetime observed for mKeima-
iRFP713, suggesting that a similar mechanism, i.e. molecular crowding leading to 
intramolecular FRET, could be responsible. However, we observed no visible aggregation in 
dead cells, which could still be present, but too small to be detected microscopically. Still, as 
for iRFP713, a shift in fluorescence lifetime upon Etoposide treatment was observed, 
corresponding to around 50% REA (Fig. 2.14E-F). Overall, IFP4.1 is not a good replacement 
for iRFP713 nor for tdNirFP. 
Ultramarine is a non-fluorescent chromoprotein derived from the weakly fluorescent RFP 
Rtms5 and has been shown to work well as a dark acceptor for a range of cyan to green 
fluorescent proteins and could with a Förster radius of 4.6 nm be a suitable acceptor for 
mKeima (Pettikiriarachchi et al., 2012). Despite being reported as a pure monomer, mKeima-
Ultramarine showed strong aggregation in 40-50% of the cells, while Ultramarine-mKeima 
showed similar aggregation in 70-80% of the cells (Fig. 2.14G-H). When analysing cells without 
aggregation, Ultramarine did not contribute to the overall fluorescence and resulted in 10% 
FRET efficiency in both configurations (Fig. 2.14I-J). Notably, we created tandem-dimers for 
Ultramarine, but rather than abolishing aggregation, they caused strong aggregation in all the 
cells (not shown), indicating that tandem-dimerization is not a general solution for all  
instances of aggregation. In summary, Ultramarine, as well as tdUltramarine, are unsuitable to 
replace tdNirFP as acceptor. 
iRFP682 was derived from iRFP713 and reported to exhibit higher fluorescence in the absence 
of exogenous Billiverdin as co-factor, indicating a more efficient incorporation of endogenous 
BV (Shcherbakova and Verkhusha, 2013). Assuming that the increased brightness is caused 
by an increased molar extinction coefficient, we hypothesized that this could lead to higher 
FRET in the absence of BV as well. With a Förster radius similar to that of mKeima-tdNirFP, 
iRFP682 could be a suitable alternative (Tab. 2.2). iRFP682-UCL-mKeima, and to a larger 
extent, tdiRFP682-UCL-mKeima showed strong aggregation when expressed in HeLa cells 
(Fig. 2.14K-L). mKeima-UCL-tdiRFP682 was not expressed at all (not shown). This 
unexpected effect of tandem-dimerization can likely be explained by the completely different 
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structure of iRFPs compared to NirFP. In contrast to the β-barrel structure of NirFP and many 
other avGFP like proteins, iRFPs form a symmetrical bilobal conformation with the dimerization 
interface located between two symmetric PAS domains (Stepanenko et al., 2014) that, as our 
results indicate, cannot be blocked by the same tandem-dimerization approach. Despite the 
aggregation, we were able to acquire emission spectra (Fig. 2.14M) as well as FLIM 
measurements (Fig. 2.14N) in some cells. Both tested constructs exhibited 10% FRET 
efficiency, which increased to 40% upon BV addition. This shows that iRFP682-mKeima could 
be a good FRET pair if the aggregation issue could be solved. 
Finally, mGarnet, an RFP evolved from mKate, has a very high extinction coefficient 
comparable to iRFP713, but is a pure monomer and does not require a cofactor for maximal 
absorption (Tab. 2.1, Hense et al. 2015). Hence, mGarnet-UCL-mKeima could be a suitable 
FRET pair. However, moderate aggregation was found in 20% of the cells, which was 
overcome by changing the orientation of donor and acceptor (Fig. 2.14O-P). This change in 
orientation to mKeima-UCL-mGarnet increased the initial 3% FRET efficiency (in cells without 
aggregation) to 10% (Fig. 2.14Q). No contribution of mGarnet to the overall fluorescence was 
observed (Fig. 2.14R). Taken together, mKeima-UCL-mGarnet is clearly inferior to tdNirFP-
mKeima, however, we note that tandem-dimerization of mGarnet could increase its FRET 
efficiency, an approach we have not pursued so far. 
Testing other long Stokes shift red-fluorescent donors 
When we started to multiplex mTagBFP, mAmetrine and mKeima in the same cells, we noted 
that the low relative brightness of mKeima (16% of mAmetrine, 31% of mTagBFP; Fig. 3.4E) 
can be a major challenge in setting excitation powers high enough to achieve sufficient signal 
from mKeima and low enough to avoid phototoxicity or saturation of detectors by the very bright 
mAmetrine (Table 2.1). We, therefore, tested two additional donor fluorophores, mBeRFP 
(Yang et al., 2013) and hmKeima8.5 (Guan et al., 2015) that have been reported to be three 
times and two times brighter than mKeima, respectively. 
mBeRFP showed strong green fluorescence when it was tested initially (Fig. 2.10A), but since 
its higher brightness would improve multiplexing considerably and our unmixing approach 
could possibly tolerate the increased green fluorescence, we tested both tdNirFP as well as 
iRFP713, the top two acceptors so far, for FRET with mBeRFP. 
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Figure 2.15 – Assessment of alternative long Stokes shift red fluorescent FRET donors with selected 
acceptors 
A: Representative confocal images of HeLa cells transiently expressing mBeRFP-UCL-iRFP713 at 840 nm 2PE 
with aggregates shown in hotter colours. 
B: Fluorescence emission of HeLa cells transiently indicated constructs at 840 nm 2PE. 40 µM Biliverdin was 
added 24 hours prior to fixation 
C, D: Fluorescence lifetime distribution of HeLa cells transiently transfected with mBeRFP-LEHD-iRFP713 
treated with solvent control (C) or 4 µM STS (D) for 8 hours in the presence (solid lines) or absence (dashed 
lines) of 25 µM Z-LEHD-FMK. Blue and red shaded curves show distributions of UCL and donor-only controls, 
respectively. Cells were pre-treated with 40 µM Biliverdin 16 hours prior to addition of STS. 
E: FRET efficiency calculated from lifetime distributions in C-D. Bars show mean and standard deviation from at 
least 10 cells each and from a single experiment. 
F, G: Representative intensity (F) and lifetime (G) image of HeLa cells transiently expressing mBeRFP-UCL-
iRFP713 and treated with 4 µM STS for 8 hours showing low lifetime aggregates in shrunk cells. 
H: Relative enzymatic activity for mBeRFP-LEHD-iRFP713 computed from the respective lifetime distributions 
in C-D. 
I, J: Representative confocal images of HeLa cells transiently expressing tdNirFP-UCL-mBeRFP (I) or tdNirFP-
UCL-hmKeima8.5 (J) at 840 nm 2PE with aggregates shown in hotter colours. 
All data are from a single experiment and the average of at least 10 cells are shown per construct and condition. 
Scale bars in all panels are 30 µm. 
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mBeRFP-UCL-iRFP713 showed strong aggregation in about 50% of all cells, and in contrast 
to mKeima-UCL-iRFP713, already in healthy cells in the absence of STS treatment 
(Fig. 2.15A).  
Performing measurements on the cells that did not show aggregates, we observed the 
characteristic green emission of mBeRFP (Fig. 2.15B). As for mKeima-UCL- 
iRFP713, the aggregation increased in shrunk cells coinciding with a decrease in fluorescence 
lifetime and an increase in FRET efficiency from 20% to 28% in the presence of BV (Fig. 2.15C-
G). Still, FRET was reduced upon STS treatment for the sensor and rescued upon caspase-9 
inhibitor treatment (Fig 2.15H), indicating that it would be a suitable pair if aggregation was 
reduced. 
Last, we tested tdNirFP with mBeRFP as well as hmKeima8.5 but found that both pairs strongly 
aggregated in all cells precluding any further use (Fig. 2.15I-J).  Therefore, none of the LSS-
RFPs we tested is superior to mKeima, primarily because of enhanced aggregation when fused 
to acceptor chromophores. 
 Multiplexing more than three FRET pairs 
A significant advantage of our sensing platform compared to other possible strategies is the 
utilization of a single excitation laser line. On the one hand, this diminishes the requirement for 
sequential exposures and, on the other hand, it allows extending the number of biochemical 
events that could be measured in a single cell when used with additional excitation lines and 
an additional set of FRET pairs. With two or three excitation lines, it is conceivable to excite 
two to three additional FRET pairs, bringing the total number of FRET pairs for multiplexing up 
to six (Fig. 2.16A). We tested one of such pairs, Clover-mRuby2, as proof of concept.  
We found that Clover is well excited at 1010 nm 2PE (Fig. 2.16B). However, incomplete 
maturation of mRuby2 (see grey lines in Fig. 2.16B) was observed, indicating that there is a 
continuum of partially functional FRET pairs with heterogeneous FRET efficiency. The reason 
for this incomplete maturation is likely the green-to-red maturation of mRuby2 that is reported  
to be five times slower than for Clover (Lam et al., 2012) and is common for red fluorescent 
proteins (van der Krogt et al., 2008). 
When tested for FLIM in a pilot experiment as a caspase-7 sensor using QKDVKD as substrate 
cleavage motif, the incomplete maturation manifested in a wide fluorescence lifetime  
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distribution, that was exacerbated by STS treatment (Full width at half maximum 
(Control/STS): 330/450 nm; mAmetrine-UCL-msCP576h: 300/300 nm; Fig. 2.16C-D). We also 
Figure 2.16 – Characterization of Clover-mRuby2 as a FRET pair to extend the multiplexing platform 
A: Extension of the multiplexing platform using two additional excitation wavelengths for two more sets of FRET 
sensors 
B: Fluorescence emission in HeLa cells transiently transfected with indicated constructs at 1010 nm 2PE. Grey 
lines show spectra of 23 individual cells that are averaged in the blue line demonstrating incomplete and 
heterogeneous maturation of mRuby2. 
C, D: Fluorescence lifetime distribution of HeLa cells transiently transfected with caspase-7 biosensor Clover-
QKDVKD-mRuby2 treated with solvent control (C) or 4 µM STS (D) for 8 hours in the presence (solid lines) or 
absence (dashed lines) of 25 µM Z-DEVD-FMK. Blue and red shaded curves show distributions of UCL and 
donor-only controls, respectively. 
E, F: Fluorescence lifetime (E) and FRET efficiency (F) for indicated constructs computed from distributions 
shown in C-D. Bars show the mean and standard deviation of at least 10 cells each. 
B-F: Data are from a single experiment. 
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observed a decrease in fluorescence lifetime for both mClover-UCL as well as Clover-UCL-
Ruby2 in dead cells in the absence of clearly visible aggregates (Fig. 2.16E), and 
corresponding changes in FRET around a baseline of 20%, with a partial response of the 
caspase-7 sensor (Fig. 2.16E-F). Such a decrease in fluorescence lifetime in dead cells is  
reminiscent of iRFP713-containing pairs and could be indicative of similar molecular-crowding 
induced intramolecular FRET, which could be confounded by the incomplete maturation. Both 
issues would need to be addressed before being usable as fourth FRET pair. The recent 
development of the faster maturating mRuby3 (Bajar et al., 2016b) promises to be a potential 
alternative and remains to be tested. 
2.4 Discussion 
Simultaneous multiplexing of more than two spectrally-resolved FRET pairs in live cells has so 
far been challenging due to the lack of suitable pairs. Here, after a process of extensive 
screening and rational design of donor and acceptor combinations, we identified a set of three 
FRET pairs to enable the robust quantification of three biochemical events in the living cell 
(Fig. 2.17). This is of particular interest to monitor the dynamics of small three-nodes networks 
to directly measure their dynamics and heterogeneity across different cells or to falsify larger 
network models generated from ‘omics’ platforms and bioinformatics that are often not tested 
in living cells. 
 
Figure 2.17 – Summary of the complete FRET pair suite for three-colour FLIM  
A: Fluorescence emission of mTagBFP-UCL-sREACh (solid blue), mAmetrine-UCL-msCP576h (solid green), 
tdNirFP-UCL-mKeima (solid red) and respective donor-only controls (dashed lines) at 840 nm 2PE. Mean of 
three independent experiments with at least 20 cells per construct is shown.  
B: FRET efficiency of FRET pairs in A. Bars are mean and standard deviation of experiments in A. 
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While mTagBFP-sREACh has been developed by others (Niino et al., 2010), mAmetrine-
msCP576h and tdNirFP-mKeima have been developed in this work. By using spectrally 
separated donor fluorophores excitable at a single wavelength and dark acceptors, these pairs 
allow using the visible spectrum efficiently, minimizing spectral contamination between the 
pairs (Fig. 2.17A). All three pairs exhibit high FRET efficiencies above 30% and therefore  
conferring a high dynamic range to the caspase biosensors created by introducing substrate 
cleavage motifs into the FRET linker (Fig. 2.17B). 
 Strategies for future improvement of the FRET pairs for 
multiplexing 
mTagBFP-sREACh 
Although mTagBFP-sREACh proved to be a very suitable pair for multiplexing, the residual 
sREACh fluorescence emission decreases the signal-to-noise ratio of multiplexing. Therefore, 
a darker acceptor for mTagBFP is desirable for future optimization of this sensing platform. We 
found that ShadowG is a better acceptor showing a decrease of fluorescence compared to 
sREACh by about 2-fold, and will be used for the further steps in the ongoing development of 
this multiplexing platform. While this dissertation was in preparation, an improved version of 
sREACh named ShadowY has been reported to exhibit seven times less residual quantum 
yield and 50% increased extinction coefficient compared to sREACh resulting in an R0 of 
5.4 nm, comparable to sREACh (Murakoshi, 2017). Another potential acceptor could be Dark 
Venus, a non-fluorescent mutant of Venus that has been successfully used as a dark acceptor 
for the CFP mTurquoise (Klarenbeek et al., 2015). Importantly, tandem-dimerization of Dark 
Venus increased FRET efficiency from 32% to 49% compared to the monomer and abolished 
aggregation, similarly to our observation for tdNirFP. Therefore, it may be possible to improve 
the blue sensor utilizing tandem-dimers of sREACh (R0 increased from 5.4 nm to 6.1 nm), 
ShadowG (R0 increased from 5.6 nm to 6.3 nm), dark Venus (R0 5.1 nm) or ShadowY (R0 6.1 
nm), both to potentially increase the dynamic range of sensors and remove residual 
aggregation of the sensors. 
mAmetrine-msCP576h 
mAmetrine-msCP576h is an excellent FRET pair with high FRET efficiency and a completely 
dark acceptor, making it ideal for FRET-FLIM experiments in general and multiplexing in 
particular. The only limitation of this FRET pair is aggregation in highly expressing cells, effects 
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that can be easily avoided during careful generation of cell lines. Therefore, none of the 
strategies that we described was employed to reduce aggregation of the green sensor. 
However, on the basis of its tetrameric quaternary structure, we can speculate that an 
approach similar to the evolution of tetrameric DsRed into monomeric derivatives mRFP1, 
mCherry and tdTomato (Campbell et al., 2002; Shaner et al., 2004) including targeted 
mutagenesis of the dimer interface, circular-permutation and tandem-dimerization could be 
used to reduce aggregation. Tandem-dimer msCP576h has a nominal Förster radius of 6.3 
nm compared to 5.6 nm of the original protein, suggesting a high potential FRET gain. 
Alternatively, two mutants of mCherry with low quantum yield (<0.04), termed ‘dark mCherries’ 
have been created as monomeric dark acceptors for red/orange donor FPs (Nakahata et al., 
2016). With Förster radii of 5.3 nm and 5.1 nm, they may also be suitable alternatives for 
msCP576. 
tdNirFP-mKeima 
The development of tdNirFP-mKeima, the reddest genetically encoded long Stokes shift red-
fluorescent FRET pair reported so far, was the most challenging optimization we carried out. 
Yet, tdNirFP-mKeima may still benefit from substantial improvement to recover brightness and 
dynamic range, without compromising the long Stokes shift and aggregation propensity. 
Previously, orange/red FRET pairs have been reported by others, including long Stokes shift 
pairs dKeima570-tdFP615 (Miyamoto et al., 2015) and mCyRFP-mMaroon (Laviv et al., 2016), 
as well as short Stokes shift pairs TagRFP-mPlum (Grant et al., 2008), mKate2-iRFP713 and 
eqFP650-iRFP713 (Zlobovskaya et al., 2016), TagRFP-KFP (Rusanov et al., 2010),  and 
mRuby2-dark-mCherry/mRuby2-Ultramarine (Nakahata et al., 2016; see Tab. 2.1 for more 
information on all FPs). However, all these pairs have unfavourable spectral characteristics 
that do not allow a combination with our mTagBFP and mAmetrine pairs, being either too blue-
shifted leading to an increased spectral contribution to mAmetrine, or too red-shifted to be 
excitable with a single 840 nm excitation line. Nonetheless, as discussed in section 2.3.4, these 
pairs may be useful in extending our sensing platform with additional excitation lines. 
Alternative acceptors for mKeima 
New red fluorescent proteins are published frequently providing a continuous new crop of 
potential acceptors for mKeima. We estimated the Förster radius of recently published 
fluorescent proteins to compare these to tdNirFP-mKeima: mCardinal (5.3 nm), TagRFP675 
(5.2 nm) and mNeptune2.5 (4.9 nm), mMaroon (5.3 nm), TagRFP657 (4.7 nm), tdFP615 
(5.4 nm) and mPlum (4.3 nm) exhibit a shorter Förster radius compared to tdNirFP-mKeima 
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(5.8 nm). A new chromoprotein, sgCP,  that shares 79% sequence identity with cjBlue was 
recently published (Chiang et al., 2015). sgCP exhibits twice the cjBlue’s extinction coefficient 
and a nominal Förster radius of 5.8 nm, but considering its tetrameric structure will likely be 
prone to aggregation as cjBlue and require extensive optimization including tandem-
dimerization, circular permutation and/or targeted mutagenesis. Among the alternative 
acceptors we already tested, mGarnet showed the least amount of aggregation, but only 10% 
FRET efficiency. Varying the linker length and creating a tandem-dimer could, therefore, be 
simple ways to improve this FRET pair without the need to address aggregation that is present 
in all other acceptors tested. 
We also tested acceptors from the new and growing class of bacterial and plant phytochromes 
with most exhibiting red- and far-red emission. We identified phytochromes that could, in 
principle, act as good acceptor for FRET. The requirement of exogenous chromophore 
supplementation in cell culture may limit their applications, but phytochromes may be 
particularly useful in vivo, where endogenous Biliverdin is sufficiently high. For example, the 
FRET pairs mKeima-iRFP713, mKeima-iRFP682 and mBeRFP-iRFP713 could be extremely 
useful when combined with two-photon microscopy permitting deep tissue in vivo imaging. 
However, in our experimental conditions, we experienced a strong tendency to aggregate for 
these FRET pairs. Our limited attempts for monomerization were unsuccessful, but targeted 
efforts may unlock the potential of such FRET pairs. More generally, the failure of the tandem-
dimer of iRFP682, but also of Ultramarine, to reduce aggregation indicates that while tandem-
dimerization can be a successful tool (as shown for tdNirFP), it cannot be generalized for all 
donor and acceptor combinations. Notably, new monomeric IFP-derivatives with decreased 
co-factor dependency, mIFP (Yu et al., 2015) and miRFP (Shcherbakova et al., 2016), have 
been recently cloned and may be good candidates to overcome both aggregation and 
supplementation of Biliverdin.  
Replacing mKeima with a brighter LSS-RFP 
Finally, the most significant improvement that could be attempted in the future is increasing 
the low brightness of mKeima. mKeima exhibits a relative intensity of ~30% compared to 
mTagBFP and ~15% of mAmetrine and tendency to photobleach faster than the other donor 
fluorophores. mKeima’s brightness is thus not ideal because it requires finding a compromise 
between photo-toxicity, photo-bleaching and saturation of detectors imaging mAmetrine. As 
illustrated in the next chapter, this compromise can be found, but it requires careful 
standardization of the experiments, an experienced experimentalist and a compromise on the 
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eventual signal-to-noise ratio of the biochemical measurement. The only two available 
alternatives for mKeima are hmKeima8.5 (1.5-fold brighter) and mBeRFP (2.7-fold brighter), 
but they both resulted in stronger aggregation when used with tdNirFP as acceptor. We did not 
attempt further monomerization of these FRET pairs, but swapping of donor-acceptor (as for 
mKeima-mGarnet), utilization of other acceptors (e.g., Ultramarine and (td)iRFP682), may 
provide an improved LSS far-red FRET pair. 
Further optimization of the linkers or design principles of the FRET pairs (e.g. HiFRET 
(Grünberg et al., 2013)) may also provide significant improvements in the performance of this 
biochemical multiplexing platform. As issues such as aggregation have been observed by 
others to be dependent on cell lines (van der Krogt et al., 2008), using a different cell line could 
be a further strategy to improve these pairs. 
However, as we wanted to demonstrate the usefulness of this strategy in a biological 
application, we used this first triplet of FRET pairs to study cell death in response to DNA 
damage (see Chapter 3).  
 Extension of the FRET multiplexing platform 
Simultaneous quantification of three biochemical reactions by FRET is a critical strategic step 
to permit researchers to study biochemical networks in single living cells. The readout of more 
biochemical events may be desirable, especially compared the level of multiplexing achievable 
with Western Blotting or flow cytometry. Our approach provides already the essential 
advantage to interrogate individual living cells over time like no other technique can achieve. 
However, there are several approaches that could be used to extend the multiplexing even 
beyond three reactions.  
As illustrated in Figure 2.16A using additional excitation wavelength for additional FRET pairs 
is one possible option. For 1000 nm 2PE, the tested Clover-mRuby2, the improved Clover3-
mRuby3 pair or Clover3 with faster-maturing mScarlet (Bajar et al., 2016b; Bindels et al., 2017; 
Lam et al., 2012) could be combined with mCyRFP-mMaroon (Laviv et al., 2016). For excitation 
at 1200 nm, a number of red FRET pairs have been reported as described above, among 
which eqFP650-iRFP713 is the most red-shifted, but could suffer from BV dependency. 
Therefore, new combinations could be explored, using the bright mCardinal or mNeptune2.5 
as donors with iRFP682 or iRFP713 as acceptor. One challenge when designing such 
additional pairs is direct excitation of fluorescent acceptors in other FRET pairs, for example, 
exciting tdNirFP, mMaroon and Ruby3 with 1200 nm 2PE. Even if this contribution would be 
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small enough to allow unmixing, this would be significantly detrimental to the signal-to-noise 
ratio of the biochemical readouts. Therefore, the most suitable strategy is the use of dark 
acceptors like Ultramarine, cjBlue, sgBP and msCP576h. 
It should be also noted that increasing the number of fluorescence properties imaged can both 
extend the type of measurements that can be performed and the biochemical resolving power 
in microscopy. For instance, fluorescence polarization enables the measurement of homo-
FRET (FRET between two identical fluorescent proteins) or FRET between a chemically 
distinct but spectrally similar donor and acceptor pairs because of the significant depolarization 
of sensitized emission. mCherry variants have been described in such a configuration which 
would also fit well with a second excitation at 1000 nm 2PE as described above (Lindenburg 
et al., 2013). Furthermore, the detection of time-resolved spectra, other pairs or even all 
properties of fluorescence (polarization, lifetime and spectra) as in a hyper-dimensional 
imaging platform envisioned by our group (Esposito et al., 2013) can increase the multiplexing 
capabilities in fluorescence microscopy, either providing a better biochemical resolution or a 
growing number of FRET sensors that can be imaged simultaneously in a living cell. 
Finally, avoiding the development of new FRET pairs altogether, spatial separation of the same 
pair in different compartments would allow studying two spatially segregated biochemical 
events simultaneously with the same FRET pair. With targeting motifs available for a wide 
range of compartments, such segregation can be easily achieved (Komatsu et al., 2011) and 
has been previously used for multiplexing of three FRET sensors (DiPilato et al., 2004; Piljic 
and Schultz, 2008). Furthermore, a large number of non-FRET-based sensors consisting of a 
single fluorophore (Kunkel et al., 2005; Niino et al., 2010; Piljic and Schultz, 2008; Sergeeva 
et al., 2017) could be used to complement the current set of sensors provided they are 
spectrally separated from the FRET pairs. 
Apart from the availability of suitable FRET pairs, the number of fluorescent proteins that can 
be expressed in a cell without affecting viability will likely limit the extent of multiplexing. While 
high expression levels are needed for imaging, high expression of multiple proteins can affect 
cell viability and function, which we noticed when creating stable cell lines constitutively 
expressing our three-colour suite (see Chapter 3). Inducible expression systems (e.g. 
tetracycline-inducible promoter such as ‘Flp-In’ systems) allow to tightly confine transgene 
expression to the time of the experiment to avoid any effects on cell growth and viability during 
cell line maintenance. Furthermore, inducible promoters allow titration of the expression to 
optimally balance brightness with effects on viability. Transient transfections are an alternative 
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to overcome long-term effects on viability, but these are often toxic in the short-term and 
variable in efficiency. Finally, combining FRET pairs with cell-permeable organic FRET probes 
could be a potential way to avoid any effect of expression of genetic probes.  
In summary, an extension of the FRET multiplexing platform is not only biologically desirable 
but, as shown in this section, feasible with available tools and technologies.  
 Specificity of caspase linkers 
Whereas linker cleavage was efficient during STS-induced cell death, the rescue using 
irreversible caspase-inhibitor of the peptide-mimetic Z-VAD-FMK family was often incomplete 
when assayed by Western Blot and FLIM imaging of the sensors. Introducing different motifs 
(VDTTD, DEVDR) resulted in an increased, but still limited, specificity. It should be noted, that 
because the inhibitors are peptide-mimetics of the canonical VDVAD, DEVD and LEHD 
sequences, they suffer from the same, or in the case of VDVAD and DEVD, worse specificity 
than the actual sensors, further confounding the interpretation. For this reason, these motifs 
have been systematically optimized creating a new class of chemical inhibitors, and, if labelled 
with a fluorescent dye, activity-based probes for caspases (Berger et al., 2006; Edgington et 
al., 2009, 2012). However, because they contain non-natural amino acids, these tools cannot 
be used in genetically encoded sensor. 
Considering the available literature, a limited specificity of such substrate-based sensors is not 
surprising due the cross-talk and overlapping cleavage specificities between caspases (Berger 
et al., 2006; Delgado et al., 2013; Kitevska et al., 2014; McStay et al., 2008; Stennicke et al., 
2000). Therefore, when using consensus motifs found in cellular substrates, the observation 
of cross-talk can be expected, because it recapitulates the situation in the cell where multiple 
caspases cleave one substrate. Thus, speaking of a sensor for a given caspase (e.g., caspase-
2, -3 or -9) is a simplification used for clarity of language, a simplification widely used in the 
relevant literature, but when interpreting results we shall always consider that these sensors 
more accurately described as VDTTDase, DEVDRase and LEHDase activity sensors.   
Relative specificity is an issue for most measurements and perturbations in biology. Therefore, 
falsifying observations based on FRET sensors requires, like for any other assay, appropriate 
control experiments and execution of orthogonal assays. For instance, siRNA-mediated 
knockdowns have been widely used to study caspases (Dorstyn et al., 2012; Lassus et al., 
2002; Oliver et al., 2011). However, knockdowns can be of limited use when studying enzymes, 
since even a small percentage of remaining enzymes can be sufficient to fully cleave a caspase 
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linker. Complete genetic knock-outs are better suited for this reason but are more resource 
demanding and impossible for essential genes. Moreover, chronic depletion of specific 
proteins can induce adaptation of the related biochemical networks thus rendering them non-
representative of the biochemical networks an experimenter intended to study. Western Blot 
for caspase processing as an orthogonal assay can also contribute to understanding the 
involvement of different caspases, even though not all caspases require processing for activity. 
Combining immunoprecipitation of active caspases and Western Blot, the identity of the most 
upstream caspase can be assessed (Tu et al., 2006).  
Another explanation for limited specificity could be the experimental setup which uses a highly 
potent, but not well-characterized cell death inducer such as Staurosporine (Chae et al., 2000) 
and only assesses one, late endpoint. At this point, all caspases are fully activated and most 
cellular proteins proteolytically cleaved, not only by caspases but the many other proteases 
that get activated during the late stages of cells death. Indeed, studies assessing specificity of 
caspases (Berger et al., 2006; Kitevska et al., 2014; McStay et al., 2008; Stennicke et al., 
2000) either study caspases using recombinant proteins or in cell-free assays, or if studied in 
cells, perform end-point studies with high doses of inducer and a single time point. Studying 
caspase activation over time could, therefore, allow studying differences that these 
approaches are unable to observe. 
Indeed, several studies successfully used both fluorometric as well as FRET-based caspase 
sensors based on linker sequences used in this work to study DNA-damage (Lin et al., 2006; 
VDVAD and DEVD) or metabolite-stress induced intrinsic apoptosis (Viswanath et al. 2001; 
DEVD, IETD, LEHD), as well as TRAIL-induced extrinsic apoptosis (Albeck et al., 2008b; 
Spencer et al., 2009; DEVDR and IETD). All of these studies showed differential cleavage of 
the sensors, suggesting that under those conditions, the canonical sequences can indeed be 
highly specific.  
Accordingly, in the next chapter, we will use the optimized FRET pair suite developed here to 
study caspase activation in single cells in response to a more targeted inducer (Cisplatin) over 
extended periods of time and in combination with a number of inhibitors as well as Western 
Blotting as an orthogonal assay. Using this combination we can indeed show that there are 
cells that are responding with single sensors or different combination of sensors, strongly 
arguing that under those experimental conditions, the sensors developed in this chapter are 
specific. 
 
 Table 2.1 - Photophysical properties of fluorescent proteins discussed in this study. All 
values as reported in the given reference. N.d., not determined. Sorted in each class by 
ascending emission maximum.  
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Table 2.2 - Overview of all FRET pairs and configurations tested for multiplexing 
platform. D: Donor, A: Acceptor. Short linker: 14 amino acids, LGGTGSGSGSASGG. Long 
linker: 24 amino acids, SPGSTLGGTGSGSGSASGGPSGSA 
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68 3.1 Introduction 
 
Chapter 3 Non-genetic heterogeneity in the 
caspase response to Cisplatin-induced DNA 
damage 
3.1 Introduction 
 Intra-tumour heterogeneity leads to fractional killing and 
resistance in response to DNA damage 
Cells are constantly exposed to DNA damage caused by a multitude of endogenous and 
environmental sources. Such lesions can lead to mutations in genes as well as chromosomal 
aberrations, which in turn can result in the development of tumours and promote tumour 
progression (Jackson and Bartek, 2009). In response to DNA damage, a complex network of 
mechanisms - collectively referred to as the DNA Damage Response (DDR) - dedicated to 
sense and repair DNA lesions and signal their presence is activated to maintain genomic 
integrity. If the damage is incorrectly repaired or remains unresolved, tumour suppressive 
mechanisms may be engaged resulting in cell death or the permanent withdrawal from the cell 
cycle by senescence. DDR is compromised during the early evolution of most tumours 
confirming its critical tumour suppressive role (Bartkova et al., 2005; Gorgoulis et al., 2005; 
Halazonetis et al., 2008); therefore, the DDR has been one of the main pharmacological targets 
as cancer cells tend to be more sensitive to DNA damage compared to normal cells (Roos et 
al., 2015). Indeed, localized induction of DNA damage by radiotherapy and the systemic 
administration of genotoxic drugs are the most-widely used and effective first-line treatments 
for cancer (Matt et al., 2016). Unfortunately, the effectiveness of tumour therapy is frequently 
limited by tumour cells that exhibit tolerance or resistance to treatment (Holohan et al., 2013) 
resulting in the survival of a subset of cancer cells, a phenomenon often referred as ‘fractional 
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killing’. Cancer cells that survive chemo- or radiotherapy may then proliferate leading to 
relapse. Fractional killing may occur because of uneven distribution of a drug within the tumour 
mass (Tannock et al., 2002) and because of intra-tumour heterogeneity (Caiado et al., 2016). 
Role of intra-tumour heterogeneity in cancer treatment 
Genetic heterogeneity within a tumour is a major cause of drug resistance (Fig. 3.1; Caiado et 
al., 2016) and is caused either by pre-existing mutant cells that are, by chance, already 
resistant or by tumour cells that escape cell death by chance or by mechanisms of drug 
tolerance and then acquire additional mutations during therapy (Greaves and Maley, 2012; 
Reya et al., 2001). Frequently, mutations alter drug uptake and efflux mechanisms, binding 
sites of the drug on the target or other sites leading to reactivation of the target or its effectors. 
These mutations will, therefore, result in differential sensitivities to drug treatment of different 
mutant cells (Barranco et al., 1972). While genetic heterogeneity has been a focus of much 
research, recently, non-genetic heterogeneity between genetically identical cells has also been 
also identified as a key mechanism in the emergence of resistance in several cancers.  
Non-genetic heterogeneity arises from four interrelated and non-mutually exclusive 
mechanisms: epigenetic regulation, cellular differentiation hierarchies, the influence of the 
tumour environment, and stochastic fluctuations in gene expression (Fig. 3.1; Caiado et al., 
 
Figure 3.1 – Sources of intra-tumour heterogeneity 
Intra-tumour heterogeneity arises from heterogeneity in the gene expression of individual tumour cells which is 
determined by genetic and non-genetic factors. Adapted from Caiado et al., 2016. 
 
70 3.1 Introduction 
 
2016). Together, these processes cause heterogeneity in gene expression between tumour 
cells and can affect treatment sensitivity, just as genetic determinants do. 
For example, in an isogenic model of 10 colorectal cancers, Kreso et al. found that genetically 
identical cells exhibited variation in proliferation, persistence and resistance after 
xenotransplantation and that chemotherapy selected for a subset of such cells (Kreso et al., 
2013). Similarly, in melanoma, a subset of cells temporarily exhibits a slowdown in the cell 
cycle through chromatin changes. While the presence of this subset is required for sustained 
tumour growth and resistance to chemotherapy, the identity of these cells changes over time 
(Roesch et al., 2010). Similarly, Sharma and colleagues describe the presence of a subset of 
lung-cancer derived cells that showed resistance to drugs including Cisplatin and find that the 
resistant cell state is created transiently through epigenetic modification (Sharma et al., 2010).  
Therefore, accumulating evidence implicates non-genetic heterogeneity as a fundamental, yet 
underappreciated, determinant of resistance and in the response to cancer therapies. 
However, the molecular mechanisms underlying such heterogeneity are largely unknown. In 
this chapter, I attempt to falsify the hypothesis that cell-to-cell variation in the dynamics of 
signalling networks underlies the heterogeneity in response to DNA damaging drugs. In the 
following paragraphs, I will, therefore, introduce the most pertinent literature on non-genetic 
heterogeneity in response to cell death stimuli to give an overview of the field to which this 
dissertation aims to contribute to.  
Experimental evidence for non-genetic heterogeneity in response to cell death stimuli 
Non-genetic heterogeneity in response to pro-apoptotic stimuli appears to be universal across 
many different cell lines and kind of stimulus (Spencer and Sorger, 2011). Early single-cell 
studies carried out with time-lapse microscopy and flow cytometry have demonstrated that 
both the onset and mode of cell death is highly variable in genetically identical populations of 
cells (Goldstein et al., 2000; Tyas et al., 2000). Building on this work in a seminal paper, 
Gascoigne and Taylor performed time-lapse imaging of 15 different cancer cell lines and 
observed extensive inter- and intra-line difference in response to the same anti-mitotic drugs 
(Gascoigne and Taylor, 2008). Using single-cell proteomics, Cohen et al. demonstrated 
heterogeneity in protein dynamics in response to the DNA damaging agent Camptothecin 
(Cohen, 2008). Similarly, heterogeneity in TRAIL (tumour necrosis factor-related apoptosis-
inducing ligand)-induced extrinsic apoptosis has been extensively studied using a combination 
of time-lapse imaging and flow cytometry of caspase-8 and caspase-3 substrate cleavage 
sensors and computational models (Albeck et al., 2008a, 2008b). Importantly, this work from 
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Albeck and colleagues was the first comprehensive study of the dynamics of cleavage for two 
caspase substrates with sufficiently large sampling of cell populations to identify novel 
intermediate cell death states. Using the same model system and comparing identical sister 
cells, Spencer and Sorger showed that stochastic differences in protein expression can explain 
the fractional killing of TRAIL (Spencer et al., 2009). Later, Roux et al. found that the extent of 
caspase-8 activity in response to TRAIL relative to a threshold determines fractional killing and 
that the expression levels of c-FLIP and BCL-2 that vary between genetically identical cells, at 
least partially, set this threshold (Roux et al., 2015).  
Most recently, Paek et al. demonstrated that cell-to-cell variation in p53 dynamics, measured 
using time-lapse imaging, leads to fractional killing in response to the DNA-inducing agent 
Cisplatin (Paek et al., 2016). They describe a threshold level for p53 at which cell death is 
initiated. While the importance of signal thresholds had already been described in other studies 
(Chen et al., 1996; Gascoigne and Taylor, 2008; Kracikova et al., 2013), the novelty of Paek’s 
finding is that the threshold increases with time after Cisplatin treatment due to the induction 
of proapoptotic genes, predominantly from the family of Inhibitors of Apoptosis (IAPs). The 
presence of both heterogeneity in p53 dynamics as well as a dynamically moving threshold 
exemplifies the complexity of cell fate decisions and suggests novel approaches, such as 
treatment holidays, to address fractional killing in tumour therapy.  
While the studies above have provided invaluable insights into the mechanisms of fractional 
killing in genetically identical populations, the number of factors they were able to study 
simultaneously was limited, and therefore essential information was likely missed. For 
example, Paek and colleagues observed p53 at the single-cell level, while IAP levels that set 
the threshold were only studied at a population level (Paek et al., 2016). As Paek and 
colleagues pointed out, studying both p53 and IAP dynamics over time simultaneously in the 
same cell might further help in the rational design of treatments aiming to maximize the number 
of cells that respond. Therefore, there is a strong need for tools that allow monitoring multiple 
signalling events and cell fate in single cells over time to sufficiently map the complexity of the 
signalling pathways involved. Consequently, we decided to use the novel tools for multiplexed 
imaging described in the second chapter of this dissertation to study the heterogeneity of cell 
death in response to Cisplatin-induced DNA-damage.  
In the following sections, I will first introduce the mode of action of Cisplatin and the cellular 
response to DNA damage, followed by a description of the cell death pathways initiated by this 
response, with a focus on the role of caspases and their hierarchical activation. 
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 Cisplatin-induced DNA damage response  
Since its first approval in 1978, Cisplatin and its analogues Carboplatin and Oxaliplatin have 
become the first-line treatment for solid tumours including testicular, ovarian, cervical, head 
and neck and small-cell lung cancers (Basu and Krishnamurthy, 2010). Cisplatin is also used 
in combination with other anti-cancer agents as well as an adjuvant treatment after 
radiotherapy and surgery. However, the strong toxicity of Cisplatin on healthy tissue, especially 
in kidneys, and the frequent development of chemoresistance limit the effectiveness of 
Cisplatin.  
Mechanism of Cisplatin-mediated DNA damage 
Chemically, Cisplatin, or cis-diamminedichloroplatinum(II), is a neutral complex of divalent Pt 
with two chloride and two amine ligands (Kelland, 1993). It can cross the plasma membrane 
by passive or facilitated diffusion, as well as active transport, depending on the cellular context 
(Basu and Krishnamurthy, 2010). Once inside the cell, Cisplatin is aquated forming a potent 
electrophile that reacts with cellular nucleophiles, such as nucleic acids as well as thiol groups 
of proteins.  
Non-DNA targets of Cisplatin are predominantly thiol-rich Glutathione and Metallothionein, 
which lead to its detoxification and contribute to resistance (Cepeda et al., 2007). Cisplatin also 
binds to lipids in the plasma membrane, which can cause membrane damage and induction of 
cell death pathways (Speelmans et al., 1997). While these mechanisms contribute to the 
cellular response to Cisplatin, binding and damaging DNA is considered the predominant 
cytotoxic mechanism (Basu and Krishnamurthy, 2010). 
At the DNA, Cisplatin forms covalent bonds between the N7 position of the purine bases 
creating 1,2- or 1,3-intrastrand crosslinks and to a lower extent inter-strand cross-links (Fuertes 
et al., 2003). These DNA lesions are considered a major cause for the cytotoxic effect of 
Cisplatin because they interfere with DNA replication as well as the transcription of essential 
genes. If the DNA damage at stalled replication forks is not repaired, the fork can collapse. 
This fork collapse leaves DNA unprotected, which often results in double-strand breaks that 
activate DDR and cell death pathways. Here, I will first discuss the DDR pathways in response 
to Cisplatin and later introduce cell death mechanisms. 
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Figure 3.2 – Cell death response to Cisplatin-induced DNA damage 
In response to DNA damage induced by Cisplatin, a network of proteins is activated that ultimately leads to 
necrotic or apoptotic cell death. A complete discussion and references for the shown connections are presented 
in the main text. Not all involved proteins are shown for clarity. In particular, caspase-3 also promotes caspase-
2 and -9 activity by processing. Caspase-2 can also be activated by binding to DISC and in the absence of PIDD. 
More details on the events downstream of MOMP including all released outer membrane space proteins can be 
found in Fig. 3.3. Finally, pro-survival signalling that negatively regulates all shown cell death pathways at multiple 
points is omitted for clarity, but plays a crucial role in the cell death response as discussed in the main text. 
Layout based on Matt et. al, 2016, but strongly adapted. Abbreviations: PARP, Poly(ADP-Ribose) Polymerase; 
ATM, Ataxia Telangiectasia Mutated; ATR, Ataxia Telangiectasia And Rad3-Related Protein; CHK1/2, 
Checkpoint Kinase 1/2; PIDD, P53-Induced Death Domain Protein; JNK, C-Jun N-Terminal Kinase; p38, p38 
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DDR pathways in response to Cisplatin 
There are two well described Cisplatin-induced DDR pathways, one acting through the central 
tumour suppressor p53 and another through the tyrosine kinase c-ABL (Fig. 3.2). 
p53, a transcription factor and potent tumour suppressor, is a central hub in stress cellular 
responses and critical element of the DDR (Vousden et al., 2009). Under normal conditions, 
p53 expression is maintained at very low levels by a negative feedback loop with the E3 
ubiquitin ligase MDM2, a transcriptional target of p53. Upon DNA damage, the kinases CHK1 
and CHK2 are activated by upstream DNA-damage sensing kinases ATM and ATR and in turn, 
phosphorylate p53 resulting in its stabilization. Stabilized p53 then induces expression of a 
multitude of genes involved in the DDR, such as P21 which causes cell cycle arrest until the 
damage is repaired, DNA repair genes such as GADD45, and finally genes that induce cell 
death such as BAX, BAK, NOXA and PUMA (De Laurenzi and Melino, 2000). Furthermore, 
p53 promotes cell death by binding and inhibiting anti-apoptotic protein BCL-XL (Kutuk et al., 
2009) and inducing degradation of c-FLIP thereby activating a caspase-8-dependent cell death 
programme (Abedini et al., 2008). Although p53 plays a key role in Cisplatin-mediated cell 
death, p53-deficient cells still respond to Cisplatin, suggesting p53-independent mechanisms. 
One such mechanism is the activation of c-ABL which in turn activates JNK as well as p38 
MAPK (Kharbanda et al., 1995) in cells that are proficient for one of the major repair pathways 
for Cisplatin-crosslinks, mismatch repair. While JNK and p38 MAPK both regulate the 
expression of a wide range of pro- as well as anti-apoptotic genes, JNK also directly inhibits 
anti-apoptotic proteins BCL-2 and BCL-XL to induce apoptosis (Sui et al., 2014). Long-term 
activation of JNK and p38 MAPK also promotes caspase-8-dependent cell death by induction 
of the expression of FAS ligand, whose role is further discussed in section 3.1.4 (Brozovic et 
al., 2004). Finally, c-ABL directly stabilizes the p53 family member, P73, which can 
transactivate pro-apoptotic genes by binding to the p53 promoter (Wang et al., 1999). 
mitogen-activated protein kinase; FASL, Fas Ligand; FASR, Fas receptor (CD95); BCL-2/-XL, B-Cell 
CLL/Lymphoma-2/-XL; BID, BH3 (BCL-2 homology 3) Interacting Domain Death Agonist; PUMA, P53 Up-
Regulated Modulator Of Apoptosis; NOXA, Phorbol-12-Myristate-13-Acetate-Induced Protein; FADD, Fas 
Associated Via Death Domain; DISC, Death Inducing Signalling Complex c-IAP1/2, cellular Inhibitor of Apoptosis 
1/2; c-FLIP, Cellular FLICE-Like Inhibitory Protein; BAX, BCL2 Associated X; BAK, BCL2 Antagonist/Killer 1; 
SMAC, Second Mitochondria-Derived Activator Of Caspase also known as DIABLO, Direct IAP-Binding Protein 
With Low PI; AIF, Apoptosis Inducing Factor; CYTC, cytochrome-c; APAF1, Apoptotic Peptidase Activating 
Factor 1; XIAP, X-Linked Inhibitor Of Apoptosis; NAD, Nicotinamide adenine dinucleotide; ATP, Adenosine 
triphosphate. 
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Together, this description demonstrates the complexity of the DDR to Cisplatin. Arguably, not 
a single, but multiple mechanisms are active at the same time in the same cell or different cells 
in a population, determining their sensitivity to Cisplatin-induced cell death and  
suggesting underlying mechanism for the observed heterogeneity, as exemplified by role of 
cell-to-cell variation of p53 dynamics discussed at length above (Paek et al., 2016). 
As I will show next, the cell death pathways induced through DDR show a similar complexity 
and potential for heterogeneity. 
 Cisplatin induces two different types of cell death 
Apoptosis and necrosis constitute the two major cell death pathways in response to any death 
stimulus. In the first instance, the morphology of apoptotic and necrotic cells as well as their 
underlying signalling networks are rather distinct (Degterev and Yuan, 2008). 
Apoptosis is characterized by cell shrinkage, chromatin condensation and fragmentation, 
membrane blebbing and the formation of apoptotic bodies that contain cellular material. 
Because the membrane integrity is maintained and no intracellular components are exposed 
to the extracellular space, apoptosis is generally thought to produce no immune response 
(Degterev and Yuan, 2008). In contrast, necrosis is characterized by rounding of the cell, 
cytoplasmic swelling, dilation of organelles and the absence of chromatin condensation. 
Because the membrane integrity is not maintained, the release of intracellular material can 
trigger an immune response, which in turn can lead to local or systemic damage of tissue 
(Berghe et al., 2014). The effect of the immune response to necrosis is considered one 
important cause for cytotoxicity on healthy tissue that can lead to disruption of treatment (Crusz 
and Balkwill, 2015; Degterev and Yuan, 2008). Morphological classification has been the 
predominant way to identify cell death modalities. However, it is now established in the field 
that morphology is only of limited use and should only be used to inform biochemical 
investigation because different kind of cell death can exhibit similar phenotypes and a 
qualitative assessment of morphology is prone to misinterpretation (Galluzzi et al., 2012). 
Therefore, cell death modalities are defined by their biochemistry, rather than morphology.  
In that regard, historically, apoptosis has been described as a “programmed cell death” that is 
controlled by cellular signalling and induced by specific intracellular and extracellular triggers. 
In contrast, necrosis was considered an “uncontrolled” form of cell death triggered by a general 
collapse of the cell, for example to damage to the lipid membranes by reactive oxygen species 
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and a depletion of cellular energy. However, it is increasingly accepted that necrosis is also 
tightly regulated by cellular signalling in response to many types of damage if not all (Berghe 
et al., 2014). Depending on the underlying biochemical mechanisms, many different forms of 
necrotic, non-apoptotic, cell death have been described, including Necroptosis, Parthanatos, 
Oxytosis, Ferroptosis, NETosis, Pyronecrosis and Pyroptosis (Galluzzi et al., 2012). 
Cisplatin can cause apoptosis and necrosis in the same cell population 
Cisplatin can give rise to apoptosis (Henkels and Turchi, 1997), necrosis (Guchelaar et al., 
1998; Matsumoto et al., 1997; Pérez et al., 1999) or both (Montero et al., 2002; Pestell et al., 
2000; Segal-Bendirdjian and Jacquemin-Sablon, 1995) in the same cell population.  
It has been suggested that the energetic status of the cell determines whether a Cisplatin-
treated cell dies from apoptosis or necrosis (Fuertes et al., 2004), because Cisplatin and other 
chemotherapeutic drugs lead to a depletion of ATP in a time-dependent manner (Zhou et al., 
2002) and the level of ATP has been found to determine the cellular decision between 
apoptosis or necrosis (Eguchi et al., 1997; Leist et al., 1997). This is in line with the general 
definition of apoptosis as ATP-dependent and necrosis as an ATP-independent mechanism 
(Galluzzi et al., 2012).  
The depletion of ATP has been connected to a hyperactivation of PARP (Poly-ADP-Ribose 
Polymerase) that is triggered in response to DNA damage and promotes DNA repair (Dulaney 
et al., 2017). PARP activity utilizes NAD whose depletion leads to a breakdown of the electron-
transport chain and loss of ATP production. Additionally, PARP also inhibits Hexokinase, the 
first enzyme in Glycolysis, leading to a further interference with cellular metabolism and ATP 
depletion (Andrabi et al., 2014). PARP hyperactivation and ATP/NAD depletion are hallmarks 
of one kind of necrotic cells death, termed Parthanatos (Andrabi et al., 2008; Los et al., 2002). 
During Parthanatos, PARP not only depletes cellular energy, but directly causes the release 
of AIF (apoptosis-inducting-factor) from the mitochondria which induces large DNA 
fragmentation once it entered the nucleus, which was recently suggested to be the actual 
cause of cell death (Berghe et al., 2014; Fatokun et al., 2014; Fig. 3.3). Whether the necrotic 
cell death in response to Cisplatin is indeed Parthanatos remains to be experimentally 
validated. 
Deficient caspase activation as a cause of necrotic cell death 
However, there are indications that PARP plays a role in Cisplatin-induced cell death and that 
it is linked to caspase activation. During apoptosis, PARP is inactivated through caspase 
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cleavage, maintaining sufficiently high ATP levels to perform the ATP-dependent execution of 
apoptosis and preventing Parthanatos (Cepeda et al., 2007). This notion supports the 
hypothesis in which in response to Cisplatin, and possibly other pro-apoptotic stimuli, necrosis 
functions as a backup mechanism if apoptosis cannot be performed efficiently, and necrosis 
should be considered as “defective apoptosis”. The observation that caspase inhibition induces 
a switch from apoptosis to necrosis strongly supports this (Lemaire et al., 1998). Furthermore, 
Vakifahmetoglu et al. showed that Cisplatin induces necrotic cell death in a Cisplatin-resistant 
cell line in the absence of PARP processing and caspase activity, while in a different line, 
Cisplatin induces apoptotic cell death including the characteristic PARP processing by active 
caspases (Vakifahmetoglu et al., 2008). Notably, the cell line that died of a necrotic cell death 
is more resistant to Cisplatin than their apoptotic counterparts, suggesting that the induction of 
different cell death pathways is linked to fractional killing (a concept discussed in section 3.1.1). 
Further evidence that caspases play a crucial role in the response to Cisplatin comes from two 
studies that showed that a failure to activate caspase-9 results in a reduced sensitivity to 
Cisplatin in testicular germ cell cancer and ovarian cancer (Liu et al., 2002; Mueller et al., 
2003). 
Together, these studies put caspases in the focus of the investigation of Cisplatin-induced cell 
death heterogeneity, suggesting that deficiencies in caspase processing can lead to a 
defective apoptosis shifting cell death from apoptosis to necrosis and possibly giving rise to 
Cisplatin-resistance. However, whether cell-to-cell differences in caspase activation are the 
cause for the non-genetic heterogeneity observed in terms of fractional killing as well as the 
type of cell death in response to Cisplatin remains unknown. 
Therefore, in the following section, I will formally introduce caspases as key mediators of 
apoptotic cell death and end with a discussion of their role in response to DNA-damage.   
 Caspase activation in apoptosis 
Caspases (cysteine-aspartic proteases) are a family of proteolytic enzymes that have functions 
in inflammation (caspases-1, -4, -5, -11 and -12) as well as cell death (Shalini et al., 2014). 
Depending on the position in the proteolytical cascade, cell death caspases are classed as 
initiator caspases (caspase-2, 8, 9, 10) that are activated upstream closest to the stimulus and 
executioner caspases (caspase-3, 6, 7) that are activated by initiator caspases and are 
responsible for the dismantling of the cell (Galluzzi et al., 2012). 
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Caspases are expressed as inactive proenzymes consisting of a large and a small subunit 
(Shalini et al., 2014). In addition, initiator caspases contain an internal oligomerization domain, 
the death effector domain (DED) for caspase-8 and -10 and the caspase recruitment domain 
(CARD) for caspase-2 and -9. DED and CARD domains mediate homodimerization of 
caspases which is facilitated by the binding to macro-molecular scaffolding complexes such 
as the death-induced signalling complex (DISC; caspase-8, -10), the apoptosome (caspase-9) 
or the p53-induced death domain protein complex (PIDDosome, caspase-2). The dimerization 
is required and sufficient for their activation. However, cleavage of the inter-subunit linker and 
removal of the dimerization domains by other caspases or autocatalytic processing can further 
enhance their activity. In contrast, effector caspases are expressed as constitutive dimers 
which are fully activated when cleaved at the inter-subunit by initiator caspases (Julien and 
Wells, 2017). The special dual role of caspase-2 as initiator and executioner caspase will be 
discussed in section 3.1.5. 
Caspases are also tightly regulated by several mechanisms, predominantly through post-
translational modification as well as direct inhibition. For example, phosphorylation by Cyclin-
dependent kinase 1 and other kinases (Andersen et al., 2009) inhibits caspase-2 activity. 
Caspase-9 is the target of a large number of kinases including ERK, CDK1, AKT and P38 
MAPK, all capable of preventing caspase-9 activation (Li et al., 2017). Additionally, active 
caspase-9 can be directly inhibited by binding of p53 or XIAP (X-linked Inhibitor of Apoptosis). 
XIAP belongs to the Inhibitor of Apoptosis family (IAP) which also includes other anti-apoptotic 
members cellular IAPs 1 and 2 (cIAP1/2), melanoma-IAP (ML-IAP) and Survivin (Fulda and 
Vucic, 2012). Among those, only XIAP has been shown to directly bind and inhibit caspases 
(caspase-3, -7 and -9; Eckelman and Salvesen, 2006). The other anti-apoptotic IAPs affect 
caspases in indirect ways. For instance, cIAPs bind SMAC tightly preventing SMAC-dependent 
inhibition of XIAP; furthermore, cIAPs exhibit E3 ubiquitin ligase activities and regulate the 
stability of many proteins involved in cell death, including caspase-3, caspase-7 and other IAPs 
(Fulda and Vucic, 2012). 
As already indicated, caspases are key initiators and effectors in apoptotic cell death, 
warranting a closer look into this key process. As such, apoptosis can be divided into intrinsic 
and extrinsic pathways depending on the origin of the apoptotic stimulus (Galluzzi et al., 2012). 
Mechanisms of intrinsic apoptosis 
In intrinsic apoptosis (Fig. 3.3), a variety of intracellular stressors such as DNA damage, 
oxidative stress or unfolded proteins results in the insertion and opening of pores consisting of  
3.1 Introduction         79 
 
the proteins BAX and BAK that permeabilize the outer membrane (a process termed MOMP, 
mitochondrial outer membrane permeabilization). The insertion of BAX/BAK is tightly 
controlled by opposing classes of proteins, the anti-apoptotic BCL-2 family including BCL-2 
and BCL-XL and the pro-apoptotic BH3-only protein family including BID, PUMA and NOXA 
(Matt and Hofmann, 2016; Fig. 3.2). BH3-only proteins are transcriptionally induced by key 
components of the DDR including p53, p63, p73 and JNK. MOMP is induced if the BH3-only 
proteins have reached sufficient levels to neutralize the inhibitory effect of the BCL-2 family 
proteins on BAX/BAK (Matt and Hofmann, 2016). Subsequently, MOMP leads to a) the release 
of a number of toxic proteins (CYTC, DIABLO, HTRA2, AIF, ENDOG) from the mitochondria 
to the cytoplasm; b) the dissipation of the mitochondrial potential Δψm which disrupts the  Δψm-
dependent ATP synthesis, and c) the build-up of reactive oxygen species due to CYTC-loss-
 
Figure 3.3 – Caspase-dependent and caspase-independent intrinsic apoptosis 
Intracellular stresses, such as DNA damage, can lead to mitochondrial outer membrane permeabilization 
(MOMP) through the insertion of the pore proteins BAX and BAK. MOMP results in the loss of membrane 
potential (Δψm) and release of intermembrane space (IMS) proteins CYTC, DIABLO, HTRA2, AIF and ENDOG 
which induce caspase-dependent or caspase-independent apoptosis. For further details see main text. The 
illustration is taken from Galluzzi et al., 2012. Abbreviations (that are not mentioned in Figure 3.2): IM, inner 
membrane; IMS, intramembrane space; OM, outer membrane; PTPC, permeability transition pore complex; 
HTRA2, high temperature requirement protein A2; ENDOG, endonuclease G; ROS, reactive oxygen species. 
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induced failure of the respiratory chain. Together, these events result in the induction of cell 
death by two non-mutually-exclusive pathways, one caspase-dependent and the other 
caspase-independent whose occurrence depends on the physiological and experimental 
conditions (Fig. 3.2 and 3.3; Galluzzi et al., 2012). 
Caspase-dependent intrinsic apoptosis is induced by the CYTC- and ATP-dependent 
assembly of the apoptosome. Binding of CYTC to the apoptosome induces the dimerization of 
caspase-9 which is sufficient to activate its protease function, leading to processing and 
activation of caspase-3 and caspase-7. Caspase-3 and -7 target a large number of substrates 
involved in cell cycle, DNA repair, cytoskeleton, signalling and other crucial processes whose 
cleavage ultimately results in the DNA fragmentation and dismantling of the cell. The activity 
of caspase-3, -7 and -9 is further enhanced by the inhibition of IAP family proteins by DIABLO 
(also known as SMAC) and HTRA2.  
In caspase-independent intrinsic apoptosis, HTRA2 damages the cytoskeleton whereas AIF 
and ENDOG cause DNA fragmentation, which, together with the breakdown of the cellular 
metabolism, leads to cell death (Fig. 3.3). 
Extrinsic apoptosis as alternative path leading to apoptotic cell death 
Extrinsic apoptosis is induced by a plethora of extracellular ligands which bind to a family of 
death receptors, including FASR (binding FASL, or FAS ligand; also known as CD95), TNFR 
and TRAILR (Berghe et al., 2014). The ligands can hereby both originate from neighbouring 
cells as well as being expressed by the same cell (Fig. 3.2). In the most common case, ligand-
binding to the receptor induces the assembly of the so-called “death-inducing signalling 
complex” (DISC) consisting of the adapter protein FADD bound to caspase-8 and the pro-
survival proteins cIAP1/2 and c-FLIP, which can regulate caspase-8 activity and are 
themselves tightly regulated. Under conditions permissive for caspase-8 activation, caspase-8 
can trigger apoptosis either by processing caspase-3 and caspase-7 directly or by cleaving 
Bid which will then induce MOMP thus activating the intrinsic pathway (Galluzzi et al., 2012). 
Cisplatin can activate both the intrinsic as well as extrinsic apoptotic pathway 
Cisplatin has been found to induce both the extrinsic and intrinsic apoptotic pathways in 
different cell lines (Basu and Krishnamurthy, 2010; Cepeda et al., 2007; Fig. 3.2). However, 
whether genetically identical cells can trigger both the extrinsic and intrinsic pathway remains 
a matter of active debate (Basu and Krishnamurthy, 2010). It is tempting to speculate that a 
possible co-occurrence of intrinsic as well as extrinsic apoptosis could be an underlying 
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mechanism for the heterogeneous response to Cisplatin within a clonal population. Therefore, 
to characterize the mechanisms underlying the heterogeneity in response to Cisplatin, it is 
necessary to monitor the activation of multiple caspases (covering both intrinsic and extrinsic 
pathway) and cell fate (apoptotic or necrotic) at the same time and the same cell for extended 
periods of time. With our novel imaging platform, we can overcome this limitation of state-of-
the-art techniques and simultaneously observe the activation of at least three caspases and 
monitor cell fate.  
This new capability will not only permit us to investigate the role of caspase dynamics in 
determining cell fate but also directly test two opposing and strongly debated hypotheses 
involving the role of caspase-2 and -9 in response to DNA damage. 
 Order of caspase-2 and -9 activation in response to DNA-
damage 
Whether caspase-2 is active upstream or downstream of caspase-9 in DNA damage has been 
the source of much discussion (Fava et al., 2012; Kumar, 2009; Miles et al., 2017; Olsson et 
al., 2014; Zhivotovsky and Orrenius, 2005). Among the caspases, caspase-2 is unique 
because, depending on the context, it can function both as initiator and executioner caspase 
(Fava et al., 2012). For instance, the CARD-dimerization-induced activation mechanism and 
the cleavage of Bid to induce MOMP are shared with initiators caspase-9 and -8, respectively. 
However, in support of a role as executioner, caspase-2 is not required for the processing of 
executioner caspases (Van de Craen et al., 1999), it is activated by caspase-3, -8, -6 and -7  
and it cleaves cytoskeletal substrates such as PARP, golgin-160 and spectrin contributing to 
the ordered dismantling of the cell (Van de Craen et al., 1999; Fava et al., 2012; 
Vakifahmetoglu-Norberg et al., 2013). One context in which there is evidence for a role of 
caspase-2 both as an initiator, as well as executioner caspase, upstream or downstream of 
caspase-9 is DNA-damage induced apoptosis. Thus, in the following, I will introduce existing 
evidence for activation of caspase-2 and -9 specifically in response to DNA damage. 
Caspase-2 as initiator caspase in the DNA damage response 
Several mechanisms for caspase-2 as initiator caspase in response to DNA damage have 
been reported (see also Fig. 3.2). In the presence of CHK1 inhibition caspase-2 is activated 
via PIDD in p53-deficient HeLa cells in response to ionizing-radiation-induced DNA damage 
leading to a caspase-3, -8 and -9-independent apoptosis (Ando et al., 2012; Sidi et al., 2008). 
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Caspase-2 activation can also occur in the absence of PIDD (Manzl et al., 2009) as well as by 
binding to the DISC complex as part of the extrinsic apoptotic pathway (Olsson et al., 2009). 
Activated caspase-2 can then cleave MDM2 which leads to stabilization of p53 and 
augmentation of the DNA damage response and protection from cell death in U2OS and a 
number of lung cancer cell lines (Oliver et al., 2011). Alternatively, caspase-2 can process an 
inhibitory splice variant of p53-family member p63 which leads to the de-inhibition of the pro-
apoptotic variant which in turn transactivate pro-apoptotic genes such as PUMA and NOXA in 
several cell lines (Jeon et al., 2012). Finally, caspase-2-deficient mouse embryonic fibroblasts 
show defects in the DNA damage response, increased resistance to treatment and accelerated 
tumorigenesis in a mouse model, suggesting a role as a tumour suppressor (Ho et al., 2009; 
Puccini et al., 2013a). Thus, caspase-2 has an important role in the DNA damage response, 
at least under certain conditions. 
Caspase-9 as initiator caspase in the DNA damage response 
In contrast to caspase-2, caspase-9 has been firmly characterized as an initiator caspase that 
is activated upon MOMP-induced apoptosome assembly and whose only reported substrates 
are caspase-3 and -7 (Yin et al., 2006). As mentioned earlier, caspase-9 has been shown to 
be crucial for efficient induction of apoptosis in response to DNA-damaging agents, including 
Cisplatin, in testicular germ cell cancer as well as ovarian cancer (Liu et al., 2002; Mueller et 
al., 2003). Both studies show that in Cisplatin-resistant cells, caspase-9 is neither activated 
nor processed. Mueller et al. further show that inhibition of caspase-9 in Cisplatin-sensitive 
cells leads to an increase in tolerance clearly pointing to caspase-9 as a key factor mediating 
chemoresistance. Importantly, Cisplatin still activates a caspase-2/-3-dependent apoptosis 
response upon pharmacological caspase-9 inhibition, but only at higher doses, corroborating 
caspase-9 as a factor in drug resistance. Finally, a role for caspase-9 in chemoresistance has 
also been described for head and neck cancer cells (Kuwahara et al., 2003) as well as other 
DNA damaging agents such as Cyclophosphamide (Schwartz and Waxman, 2001), 
Adriamycin, Etoposide and 5-Fluorouracil (Wu and Ding, 2002). In summary, caspase-9 has 
been attributed a key role in DNA-damage induced cell death and resistance. 
Hierarchical activation of caspase-2 and -9 remains an open question 
Different studies have identified either caspase-2 or caspase-9 as the apical initiator caspase. 
However, only a few studies have reported on direct measurements of the relative timing of 
caspase-2 and caspase-9 activation which is required to obtain direct evidence of their relative 
timing. Table 3.1 shows all studies we could identify that investigated both caspases in 
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response to DNA damage, classed by the apical caspase. It is notable that both classes cover 
a wide range of DNA damaging agents and cell lines, indicating that the underlying 
mechanisms are likely not specific for cell lines or agents. The two major methods used were 
the assessment of procaspase cleavage by Western Blot and fluorometric assays using 
caspase-specific peptide sequences. The combination of these methodologies is considered 
essential to study initiator caspases because processing is not required for the activity of 
initiator caspases, and both techniques were used to find apical caspase-2 and -9. For 
perturbation, genetic knockouts, siRNA-mediated knockdowns as well as caspase inhibitors 
were used, with no clear bias for one method for one apical caspase notable. Thus, comparison 
of the experimental conditions alone is not sufficient to explain the contradicting results in the 
order of caspase-2 and -9, warranting further investigation. 
Finally, and most importantly, the time resolution of studies in Table 3.1 varied greatly from 
1 hour to 24 hours with a wide range of time points. Considering that the time from MOMP to 
caspase-3 activation has been measured to be around 10 min (Tyas et al., 2000), even a 
1-hour time resolution is insufficient to resolve fast caspase activation dynamics. 
Conclusive remarks 
In summary, the current literature on the order of caspase-2 and caspase-9 provides evidence 
that either may act as an apical caspase. However, it is severely limited by the low temporal 
resolution inherent to the techniques used. Furthermore, only bulk cell populations have been 
studied which, as described in sections 1.1 and 3.1.1, will mask non-genetic heterogeneity. It 
is conceivable that different experimental protocols studying caspase activation on population 
averages would classify the response of the same cell line treated with the same drug into an 
artificial class where either caspase-2 or -9 are the leading initiator caspases.  
Insufficient experimental evidence based on live single-cell measurements is available to date 
to dissect cell death phenotypes and the related kinetics of biochemical events to address this 
issue. As introduced above, this is an important problem to study, not only for academic 
purposes. Genetic alterations or drug-induced perturbations of caspase networks are 
mechanistically linked to chemoresistance. Therefore, it is of fundamental importance to 
dissect if and how cell-to-cell variability in caspase networks (e.g., their kinetics, order and 
extent of activation) is linked to the heterogeneity of cell fate, which may result in transient 
populations of chemoresistant cells. 
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By applying our multiplexed biochemical imaging technique to the study of Cisplatin-induced 
cell death, we can overcome existing methodological limitations and directly characterize 
differences in caspase network dynamics that can lead to different type of cell death in 
genetically identical, but heterogeneous cell populations. 
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Table 3.1 - Collection of studies of caspase activation hierarchy in response to DNA 
damage. Only studies that assess caspase-2 and caspase-9 activation have been included. If 
not explicitly shown, MOMP has not been assessed in the particular study. C: caspase. 
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3.2 Material and methods 
Detailed information for all reagents used in this study can be found in Table S4. 
 Molecular cloning 
The general description of the cloning strategy used to engineer caspase sensors is described 
in section 2.2.1 with oligonucleotides listed in Table S1. 
Co-expression vectors expressing mTagBFP-VDTTD-sREACh (‘B’), mAmetrine-DEVDR-
msCP576h (‘A’) and tdNirFP-LEHD-mKeima (‘K’) on one polyprotein were created by linking 
sensors with the two most efficient (Kim et al., 2011) self-cleaving viral P2A (porcine 
teschovirus-1 2A; ATNFSLLKQAGDVEENPGP) and T2A (Thoseaasigna virus 2A; 
EGRGSLLTCGDVEENPGP) linkers. The linkers were flanked upstream by a GSG peptide to 
further enhance cleavage efficiency (Szymczak et al., 2004). Nucleotide sequences that had 
been previously optimized to prevent recombination between 2A sites have been used (Tab. 
S1; Szymczak et al., 2004). Cloning was performed using the scarless SapI approach 
described for the creation of tdNirFP (section 2.2.1). In short, the single sensors described in 
Chapter 2 were amplified using PCR with primers carrying parts of the 2A site and SapI 
restriction sites. After ligation of the SapI-digested PCR products, the fusion was ligated into a 
fresh pcDNA3.1(-) backbone. First, vectors BA and BK were created with a single P2A site. To 
add the K sensor to BA, BA and K were PCR amplified with primers introducing the T2A 
sequence.  
The caspase-8 FRET sensor was derived from the caspase-2 sensor by replacing the linker in 
mTagBFP-VDTTD-sREACh with the peptide AAALGGTGSGSIETDGGIETDGGT carrying two 
tandem copies of the IETD motif (Luo et al., 2003). Cloning was performed using restriction 
digest and linker ligation as described in section 2.2.1. 
 Creation of stable cell lines 
HeLa cell lines stably expressing the caspase-2 sensors (B, see 3.2.1) or the BK and BAK co-
expression systems were created as follows. 150,000 parental HeLa (see section 2.2.2 for 
origin and culture conditions) were plated on 3.5 cm dishes 24 hours prior to the transfection 
with 250 ng (B) or 750 ng (BK, BAK) plasmid DNA using JetPRIME (Polyplus) at ~50% 
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confluency and according to the manufacturer’s instructions with medium replaced 6 hours 
after transfection. 24 hours after transfection, confluent cells were trypsinized and replated on 
10 cm dishes; clones integrating the transgenes were selected by adding 800 ng/ml G418 
(Invitrogen) to the medium. The selection medium was replaced every 3-4 days. After four 
weeks of continuous selection, polyclonal populations were sorted by FACS (Beckton 
Dickinson Influx cell sorter) for expression of two donor fluorophores (Filter sets: mTagBFP 
excitation 405 nm - emission 460/50 nm; mAmetrine excitation 405 nm – emission 520/35 nm). 
Sorted bulk populations were collected in 24-well plates and kept under 800 ng/ml G418 
selection. To create monoclonal cell lines, single cells from the sorted polyclonal populations 
were FACS sorted as above but into 96-well plates and expanded to 6-well size (~4-weeks) 
under continuous selection. Poly- and monoclonal cell lines were then maintained under 
minimal selection (200 ng/ml G418). Expression of the sensors was validated by flow 
cytometry, Western Blot and microscopy. 
 Fluorescence emission spectra 
Fluorescence emission spectra were acquired as described in section 2.2.4. To optimize the 
emission ratio of co-expressed donors, the two-photon laser wavelength was tuned to 840 nm, 
860 nm and 880 nm.  
 Viability assay (SRB) 
3,000 parental HeLa and 6,000 HeLa-BAK cells (numbers adjusted for the difference in growth 
rate) were plated in 50 µl full medium (DMEM with 10% FCS, Pen/Strep supplemented with 
200 ng/ml G418 for HeLa-BAK) on 11 wells of a 96-well plate in triplicate. The first column was 
used as medium-only control. 50 µl full medium containing 2 µM LCL161 (LKT Laboratories) 
or equal amounts of DMSO were added to the wells 24 hours later resulting in a final 
concentration of 1 µM. After an additional 24 hours, Cisplatin (Sigma) was added to the cells 
in a 9-step two-fold serial dilution starting from 400 µM. For untreated and buffer-only control, 
the maximum concentration for 0.9% NaCl (1:5) or Cisplatin (400 µM) were used.  
For titration of U0126 and Afuresertib (Fig. 3.28), 6,000 HeLa-BAK cells were plated in 100 µl 
and treated 48 hours later with a twofold serial dilution both drugs, starting at 5 µM and 10 µM 
respectively, as described for Cisplatin.   
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After 24 hours incubation with either Cisplatin or U0126/Afuresertib, the medium was removed 
and cells fixed with 50 µl of 1% trichloroacetic acid (Sigma) overnight at 4°C. To stain cellular 
protein, 50 µl of 0.057% Sulforhodamine B (SRB) in 1% acetic acid (Sigma) was added and 
incubated for 30 min at room temperature. SRB was removed and wells washed 3x with 1% 
acetic acid. After air-drying the plate at room temperature overnight, SRB was resuspended in 
100 µl 10 mM Tris pH 8.0 (Sigma) and the absorbance at 510 nm recorded using a Tecan 
plate reader. The analysis was performed by subtraction of the buffer-only control absorbance 
from all samples followed by normalization to the untreated control in Microsoft Excel. Mean 
and standard deviation were calculated from the normalized values and plotted in GraphPad 
Prism version 5 (GraphWorks). 
 Flow cytometry and cell cycle profiling 
To measure sensor co-expression by flow cytometry (Fig. 3.4D), 300,000 parental HeLa were 
plated on 6 cm dishes and transfected with a total of 1.5 µg plasmid DNA for controls, B/A 
equimolar co-transfection and BA co-expression plasmid using JetPRIME (Polyplus) according 
to the manufacturer’s instructions. 24 hours after transfection, cells were harvested by 
trypsinization, pelleted by centrifugation (1000 rpm for 5 min at room temperature), washed 
once with PBS, and fixed by adding 2 ml 70% Ethanol drop-wise to the pellet while vortexing 
followed by incubation at 4°C overnight. After fixation, cells were pelleted and washed twice 
with ice-cold PBS, and resuspended in PBS for analysis. Flow cytometry was performed on an 
LSRFortessa (BD Biosciences; filter sets: mTagBFP: excitation 405 nm - emission 450/50 nm, 
mAmetrine: excitation 405 nm - emission 525/50 nm). Manual compensation was performed 
for the sensor co-expression using mTagBFP-sREACh and mAmetrine-msCP576 single 
transfections. Data were analysed using FACSDiva (BD Biosciences).  
For validation of stable cell lines (Fig. 3.5E), ~ 1x106 exponentially growing cells were 
harvested, processed and analysed as described above. To also measure mKeima 
fluorescence, an additional filter set (excitation 405 nm - emission 610/20 nm) was used on an 
LSRFortessa. Data were analysed using FlowJo X (version 10; FlowJo). 
For cell cycle profiling (Fig. 3.5F), 400,000 parental HeLa cells and 600,000 HeLa-BAK cells 
were plated on 6 cm dishes in full medium containing 2 mM Thymidine (Sigma). After 16 hours, 
cells were washed twice with PBS and fresh medium was added. After 8 hours of release, 
2 mM Thymidine was added directly to the dishes and removed 16 hours later. Cells were 
harvested for flow cytometry as described above for stable cell line validation. After the final 
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two PBS washes, DNA was stained by addition of 10 µM (1:500) DRAQ5 (Biolegend) in PBS 
for 15 min followed by analysis using an LSRFortessa (filter set: excitation 640 nm - emission 
730/45 nm). The cell cycle phases were determined using the univariate Dean-Jett-Fox 
algorithm in FlowJo X.   
 Western Blot 
For the Cisplatin time-lapse experiments (Fig. 3.6, 3.7, 3.26), 450,000 parental and 900,000 
HeLa BAK cells were plated on 6 cm dishes. For Figure 3.26, fresh medium with 1 µM LCL161 
or DMSO was added to half of the plates 20 hours after plating. After 20 hours of incubation, 
cells were washed once with PBS and fresh medium containing 1 µM LCL161 or DMSO and 
100 µM Cisplatin or 0.9% NaCl added. At the indicated time points, cells were harvested by 
removing the supernatant followed by a single wash in PBS and incubation with Trypsin/EDTA 
for 5 min at 37°C. Detached cells were resuspended twice in full medium and combined with 
the supernatant prior to centrifugation at 1000 rpm for 5 min at 4°C. In the final wash step, 
50 µl of the volume was saved for RNA extraction and the remainder pelleted and frozen 
at -80°C until processing. 
For titration of LCL161, 300,000 parental HeLa and 600,000 HeLa-BAK cells were plated on 
6-well plates and 24 hours later treated with a serial two-fold dilution of LCL161 prepared in 
fresh medium starting at 8 µM (Fig. 3.25D-E) or 1 µM (Fig. 3.25F-G; here, 12-well plates with 
50% of cells were used). Cells were harvested 16 hours as described above. 
To quantitate the effect of U0126 (Sigma) and Afuresertib (Stratech) on Erk and Akt levels by 
Western Blot (Fig. 3.28B), 300,000 HeLa-BAK cells were plated on 3.5 cm dishes and 
~20 hours later treated with one or both inhibitors in full medium. The total DMSO 
concentration was kept constant for all samples. Cells were harvested after 2 hours as 
described above. 
For all samples, cell lysis and Western Blotting was performed as described in section 2.2.5 
using Licor Odyssey. Detailed information for primary and secondary antibodies used in this 
chapter can be found in Tab. S4. Quantification of the bands was performed in Image Studio 
version 5.25 (Licor) and analysed in Microsoft Excel. Graphs were plotted in GraphPad Prism. 
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 RNA extraction, cDNA synthesis and quantitative PCR 
For RNA extraction, parental HeLa and HeLa-BAK cells were grown and treated as described 
for Western Blot analysis of the Cisplatin time lapse (section 1.1.7). Cell pellets stored for RNA 
extraction were resuspended in 350 µl RLT buffer (Qiagen RNeasy Plus Mini Kit; cat. # 74134) 
supplemented with 1:100 β-Mercaptoethanol (Sigma). Lysis was performed by passing 
through a QIAshredder column (Qiagen, cat. # 79654). Lysates were then stored at -80°C until 
processing using the RNeasy Plus Mini Kit as per the manufacturer’s instructions. In the final 
step, RNA was eluted twice with 30 µl H2O and stored at -80°C. 
cDNA synthesis was performed using the Cloned AMV First-Strand cDNA Synthesis Kit 
(Invitrogen, cat. #  12328040). First, 1 µg ng RNA was denatured at 65°C for 5 min in a 12 µl 
mix containing random hexamer primers (final concentration in 20 synthesis mix: 2.5 ng/ml), 
oligo (dT)20 primers (2.5 µM) and dNTP (0.5 mM). Next, the cDNA synthesis mix was added 
containing DTT (5 mM), RNAseOUT (40 units) and Cloned AMV Reverse transcriptase (15 
units). The synthesis was performed in a three-step reaction, 10 min at 25°C, 50 min at 50°C 
and 5 min at 85°C to terminate the reaction. cDNA was diluted to 50 µl in H2O stored at -20°C 
until further use. 
For quantitative PCR, for each primer pair a master mix containing Lightcycler 480 SYBR 
Green Master Mix (Roche Diagnostics, cat # 4887352001; final concentration: 1x) and 250 nM 
of each forward and reverse primer (Tab. S1) was prepared and 19 µl pre-laid into the wells of 
a white-walled LightCycler 480 Multiwell 96-well plate (Roche Diagnostics, cat. # 4729692001). 
1 µl cDNA was added for each sample in triplicates and mixed by pipetting. The sealed plate 
was then spun down at 1,500 g for 1 min and the PCR performed on an LC480 Light Cycler 
(Roche Diagnostics). The PCR protocol was as follows: 
Pre-incubation  95°C for 10 sec 
Amplification 45 cycles of denaturation (95°C for 10 sec), annealing (60°C for 10 sec), 
elongation (72°C for 10 sec) 
Melting curve 95°C for 5 sec followed by 65°C for 1 min 
After PCR, the amplicon size and specificity of the reaction were confirmed by running the 
content of each well on a 2% Agarose gel stained with SYBR Safe (Invitrogen) at 135V for 
30min. qPCR data were analysed in Microsoft Excel using the ΔΔCT-method with GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase) amplification as a control for all samples. 
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Triplicate ΔΔCT values were averaged and plotted along with upper (mean +standard 
deviation) and lower (mean –standard deviation) using GraphPad Prism. 
 Growth curves 
60,000 HeLa parental and 60,000, 90,000 and 120,000 HeLa-BAK cells were plated in 
triplicates on a 12-well plate in full medium (supplemented with 200 ng/µl G418 for HeLa-BAK). 
Approximately 8 hours after plating, cells were transferred into an IncucyteTM (Essen 
Bioscience), an incubator equipped with an imaging system to measure confluency. 
Measurements were performed automatically every 2 hours for five days and confluency data 
analysed in Microsoft Excel. Mean and standard deviation were plotted using GraphPad Prism. 
Single images were exported from the Incucyte software to create figure 3.5H. 
 Annexin-V / 7-AAD / TMRM imaging assay 
15,000 parental HeLa cells were plated on 8-well LabTek II chambered coverglass (Nunc, cat. 
# 155409). ~48 hours later the medium was removed, wells were washed twice with PBS and 
the staining solution added. The solution was prepared in Leibovitz (L-15) medium 
supplemented with 10% FCS and Pen/Strep and contained the indicated final concentrations 
of the following reagents: Cisplatin or 0.9% NaCl (100 µM), FITC-labelled Annexin-V 
(Biolegend; 1:200), 7-AAD (7-amino-actinomycin D; Biolegend; 1:200), CaCl2 (2.5 mM; 
required for Annexin-V binding to phosphatidylserine) and TMRM (Tetramethylrhodamine, 
methyl ester; 20 nM). After addition of the staining solution, cells were transferred to the 
microscope and incubated at 37°C on stage for at least 30 min before starting imaging. Imaging 
was performed using a Nikon Ti wide field microscope equipped with an sCMOS camera 
(Andor Zyla). Images of four channels (bright field; FITC, TRITC for TMRM; Cy5 for 7-AAD) 
were acquired every 15 min for 16 hours at a resolution of 2560 x 2160 pixels with no binning 
using a Plan Fluor 40x Oil DIC objective (Nikon). Five fields of view were collected per sample. 
Image analysis was performed manually using Fiji (ImageJ, NIH) by drawing a region of 
interest around the whole cell for all three channels followed by export of data to Microsoft 
Excel. Single-cell traces for all channels were normalized to minimum and maximum. The 
difference between the FITC and 7-AAD signal (ΔAV-7AAD) at each time point was calculated 
from the normalized single-cell traces. Traces and maximum values were plotted in GraphPad 
Prism. 
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 Cell cycle imaging (FUCCI) 
15,000 parental HeLa cells were plated on 8-well LabTek II chambered coverglass (Nunc). 
24 hours later, 18 µl of each of the two components (Geminin-emGFP and TagRFP-Cdt1) of 
the baculoviral Premo™ FUCCI Cell Cycle Sensor (BacMam 2.0; Invitrogen) were added 
directly to the wells containing 300 µl full medium. After an additional 24 hours, cells were 
washed twice with PBS and imaging medium (Leibovitz (L-15) with 10% FCS and Pen/Strep) 
added containing a final concentration of 100 µM Cisplatin or 0.9% NaCl. Imaging was 
performed as described in section 3.2.9 using the FITC and TRITC cube for emGFP and 
mTagRFP, respectively. Image analysis was performed in Fiji. Cells with a clear emGFP or 
TagRFP signal in the first frame were analysed for the occurrence of the first morphological 
sign of cell death (shrinking or blebbing) in the brightfield channel. Data were plotted in 
GraphPad Prism. 
 Sample preparation for time-lapse FLIM  
For each time-lapse FLIM experiment, two 8-well LabTek II chambered coverglass slides 
(Nunc) were prepared. On the control slide, 15,000 parental HeLa cells were plated in all wells 
and 24 hours later transiently transfected using JetPRIME with DNA plasmids expressing 
donors, the uncleavable controls and two acceptors (sREACh, tdNirFP). The transfection 
medium was removed 4-6 hours later. 24 hours after transfection, control cells were washed 
twice and 300 µl imaging medium (Leibovitz (L-15) with 10% FCS and Pen/Strep) added to all 
wells followed by FLIM acquisition as described in the next section. For the sample used for 
time lapse, either 15,000 HeLa parental or 30,000 HeLa-BAK cells were plated. When required 
(Fig. 3.13, 3.16), transfection was performed as described for the control slide. 
When used, inhibitors or corresponding solvent controls were added to the sample slide either 
6 hours after transfection (caspase-Inhibitors at 25 µM each, LCL161 at 1 µM) or 2 hours 
before starting imaging (U0126 at 7.5 µM, Afuresertib at 5 µM) by adding 400 µl of fresh DMEM 
with 10% FCS, Pen/Strep and 200 µg/ml G418 prepared with the inhibitors at the indicated 
final concentrations. For details on all inhibitors, see Table S4. After imaging of the control 
slide, the slide utilized for time-lapse imaging was prepared by washing twice with PBS and 
adding 400 µl imaging medium containing Cisplatin at 100 µM, 0.9% NaCl and inhibitors at the 
same concentration used for pre-treatments. 
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For the double-thymidine block and release experiment shown in Figure 3.15, cells were 
prepared as above with the following additional steps. 2 mM Thymidine (Sigma) was added at 
the time of plating followed by two washes with PBS and addition of fresh medium 16 hours 
later. After another 8 hours, 2 mM Thymidine was added to the medium and removed as for 
the first block either after 16 hours (i.e. 7 hours before the start of imaging, for G2 cells) or 23 
hours (i.e. at the time of starting imaging, for G1 cells). Directly prior to imaging, all samples 
were changed to imaging medium containing Cisplatin as described above. 
U2OS cells (received from ECACC, cat. # 92022711) were used exactly as parental HeLa cells 
with the exception that 25,000 cells were plated and 200 ng of the BAK co-expression plasmid 
was transiently transfected using JetPRIME. 
 Multicolour fluorescence-lifetime imaging and data 
analysis 
Samples were imaged at 37°C on a Leica SP5 confocal microscope (Leica Microsystems) 
equipped with a Chameleon Vision 2 Ti:Sapphire laser (Coherent) for two-photon excitation. 
Images were acquired with three parallel, hybrid photomultiplier tubes (HyD - two by Leica 
Microsystems and one additional by Becker & Hickl) with 256x256 pixel resolution using a 40x 
oil objective (Leica HCX PL APO CS 40.0x1.25 OIL UV). The detectors were mounted at a 
customized non-descanned port using a Leica Quad adapter to split the optical path for two 
HyD of Leica and an additional channel not supported by the Leica SP5. After a short pass 
680 nm filter, the emission light was split by a 565 nm dichroic mirror. The transmitted light 
passes through a filter set for mKeima (624/40 nm) positioned in front of the Becker & Hickl 
detector. The reflected light was further split by a 506 nm dichroic onto the two remaining 
detectors with filter sets for mTagBFP and mAmetrine (mTagBFP: 483/30 nm, mAmetrine: 
543/30 nm). The detectors were read-out by fast electronics based on multi-hit time-to-digital 
converters (Surface Concept) which were controlled by in-house developed MATLAB software 
(Mathworks).  
For each field of view, a z-stack of 75 images spanning 25 µm was acquired within 48 seconds. 
For controls, a single z-stack for two fields of view per well was acquired. For the time-lapse 
samples, z-stacks of 12 fields of view were automatically acquired every 15 min for 16 hours. 
Videos S1, S5 and S7 were generated from the images acquired with the Leica LAS software 
for the detectors for mTagBFP and mAmetrine. Image processing was performed in Fiji by 
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creating maximum projections for every time point followed by the creation of a composite 
image from both channels. 
FLIM data were analysed using an in-house developed data pipeline in MATLAB by Dr Kalina 
Haas and Dr Alessandro Esposito (see also Fig. 8C-E). In short, stored photon streams were 
processed to generate 3D image stacks and summed over the axial direction to create an 
‘extended focus’ image. In the resulting FLIM movies, single cells were segmented 
(predominantly by the author) and tracked with semi-automatic algorithms and always 
manually curated. Unmixing of biosensors was achieved by transforming the fluorescence 
signals extracted from individual cells by multi-dimensional phasor-transforms (Digman et al., 
2008; Esposito et al., 2013; Popleteeva et al., 2015). Utilizing the control measurements of 
single sensors and fluorophores this algorithm was used to unmix the contribution of individual 
molecular species (cleaved sensors, uncleaved sensors, residual sensitized emission and 
background autofluorescence). The relative enzymatic activity (REA) for each caspase and 
cell was computed as the fraction of cleaved substrates normalized to cleaved and uncleaved 
sensors. Using a threshold of 10% change in REA between the first and last three time-points 
for each caspase, cells were classified according to their caspase activation (Fig. 3.8D). 
Confidence intervals of the mean trajectories were calculated using bootstrapping. To obtain 
true caspase activation dynamics of a given population, single-cell REA trajectories were 
synchronized at the time point of 50% caspase-3 and traces clipped to included ~3 hours 
before and after that value. For the estimation of activation rate and maximum REA level, a 
sigmoid was fitted into the single-cell trajectories. Graphs were plotted in MATLAB by Drs Haas 
and Esposito and adapted for further analysis and presentation by the author. Figures were 
prepared using MATLAB and GraphPad Prism. 
 Morphological classification of death phenotypes 
The morphological classification was performed manually for all experiments using FLIM 
movies showing tracked cells in MATLAB. For each cell, three parameters could be assigned, 
i) the first frame of cell shrinking (defined as continuous loss in cell size of more than ~10% 
and judged visually), ii) the last frame of cell shrinking and iii) the first frame of cell blebbing 
(defined as the appearance of a visually discernible and persistent membrane protrusions). If 
cells were completely detached and rounded to near-perfect spheres, the subsequent blebbing 
(i.e. formation of apoptotic bodies and/or secondary necrosis) was not recorded. Cells that only 
showed parameters i) and ii) were classified as ‘shrunk’, those that only showed iii) as ‘bleb’ 
and those that showed all three as ‘shrunk-bleb’. Blind classification was performed 
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independently by three researchers. In the event of disagreement, a majority consensus 
determined the final assignment to phenotypic classes. The time of cell death was defined as 
the first frame of cell shrinking or blebbing, calculated as the average of the three scorers and 
plotted in GraphPad Prism. 
3.3 Results 
 Validation of FRET sensors and cell lines for multiplexed 
caspase imaging 
Development and characterization of the expression system 
To study the activity of caspase-2, -3 and -9 simultaneously in single cells, the three optimized 
sensors developed in Chapter 2 (i.e. caspase-2: mTagBFP-VDTTD-sREACh; caspase-3: 
mAmetrine-DEVDR-msCP576h; caspase-9: tdNirFP-LEHD-mKeima; named henceforth B, A, 
K according to the respective donor) were sub-cloned into a co-expression vector separated 
with viral 2A sites that are autocatalytically cleaved post-translationally (Szymczak et al. 2004; 
Fig. 3.4A-C). The use of a multicistronic vector with self-splicing peptides ensures the 
equimolar expression of fluorescent proteins, in contrast to internal ribosomal entry sites 
(IRES) where levels of upstream and downstream genes differ more widely (Goedhart, 2011). 
The 2A peptides reduced the variation in expression of the blue and green sensors that are 
expressed at similar ratios across the population as shown in Fig. 3.4D. The emission spectra 
of the HeLa cells transfected with the “BAK” plasmid for the co-expression of three sensors 
confirm that the sensors are well expressed and at relative levels of brightness that we 
expected from their reported molecular brightness (Fig. 3.4E; Tab. 2.1) rather than because of 
uneven expression of the constructs. 
Development and validation of stable cell lines 
Next, monoclonal HeLa cell lines stably expressing single-sensor (HeLa-B) and as well as co-
expression systems ‘BK’ and ‘BAK’ (HeLa-BK and HeLa-BAK) were derived to avoid the 
toxicity caused by transient transfections, variability in expression and, more in general, to 
simplify the experimental procedures. HeLa cells were chosen as cell line because, in early  
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pilot experiments with transient transfection of the BK vector, HeLa exhibited marked 
differences between caspase-2 and -9 activation in response to Cisplatin (data not shown). 
Most importantly, HeLa cells have been used previously to study caspase-2, -3 and -9 
dynamics in response to Cisplatin (Lin et al., 2006; Mueller et al., 2003; Vakifahmetoglu et al., 
2008) and originate from a cervical tumour, for which Cisplatin is an important drug (Basu and 
Krishnamurthy, 2010).  
 
Figure 3.4 – Co-expression systems for caspase sensors 
A-C: Schematics of co-expression systems. FRET-based biosensors for caspase-2 (mTagBFP-VDTTD-
sREACh, ‘B’), caspase-3 (mAmetrine-DEVDR-msCP576h, ‘A’) and caspase-9 (tdNirFP-LEHD-mKeima. ‘K’) are 
linked with self-cleaving P2A or T2A peptide linkers. The label above each construct indicates the sensors used. 
Molecular models of sensors in A-B courtesy of Alessandro Esposito. 
D: Comparison of co-transfection of B and A sensor (top left) with the BA co-expression system shown in panel 
A (top right) and corresponding controls (bottom) by flow cytometry.  
E: Fluorescence emission spectrum of co-expression systems shown in A-C with excitation at 840 nm for 2PE, 
sensors transiently expressed in HeLa cells. Emission spectra of single sensors shown as shaded areas in the 
background. Data is from a minimum of five cells per spectrum and from one experiment. 
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Western Blotting, emission spectra and flow cytometry measurements confirmed sufficient 
expression in a number of clones (Fig. 3.5A-E). A possible complication using 2A peptides is 
partial cleavage resulting in a mix of fused and single proteins, which, in our experiments, could 
lead to intramolecular FRET and other artefacts. However, Western Blotting did not show high 
molecular weight bands when lysates of HeLa-BK and HeLa-BAK clone were probed with 
antibodies for fluorescent proteins, confirming the full cleavage of the 2A peptides we used 
(Fig. 3.5A).  
For further experiments, HeLa-BAK clone #7 (subsequently referred to as HeLa-BAK) was 
chosen and further validated. Notably, only two clones of HeLa-BAK out of the seven picked 
initially proliferated and only one clone showed expression. This is in line with reports 
describing the difficulty of obtaining stable cell lines with high and maintained expression of 
multiple fluorescent proteins (Aoki et al., 2012). HeLa-BAK cells exhibited a slightly higher 
S/G2 population (Fig. 3.7F), proliferate at a slower rate (Fig. 3.7G) and appear to have 
decreased viability (see dead cells in Fig. 3.7H and increased sub-G1 peak in panel F), likely 
due to the high constitutive expression of the construct. However, these differences do not 
appear to be substantial and, most importantly, HeLa-BAK cells exhibit similar sensitivity to 
Cisplatin as well as similiar dynamics of procaspase processing compared to the parental cell 
line (Fig. 3.5I and Fig. 3.6). Also, Western Blot analysis of procaspase and PARP processing 
(Fig. 3.6A) reveals that HeLa-BAK might trigger apoptosis earlier than the parental cell line, 
but with no apparent changes in the dynamics (Fig. 3.6D). Moreover, in a number of 
experiments (Fig. 3.13, 3.17), parental HeLa cells transiently transfected with single- or co-
expression caspase sensor plasmids as well as non-transfected cells have been used as 
controls. Consistently, we have never observed differences between transfected HeLa 
parental cells and HeLa-BAK stable cells in experiments described in the following figures. 
Together, these observations indicate that HeLa-BAK cells are a suitable model system to 
study caspase activation dynamics in response to Cisplatin. 
Optimization of the excitation wavelength 
We have observed that the three donor fluorophores exhibit different brightness. To identify 
the most suitable excitation wavelength to image HeLa-BAK cells, spectral imaging of HeLa-
BAK cells was used to estimate the contribution of fluorescence emission of the different 
donors to the total emission. Increasing the excitation wavelength resulted in a net increase  
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Figure 3.5 – Validation of stable HeLa cell lines for caspase sensors 
A: Western Blot of lysates from HeLa cells stably expressing single sensor for caspase-2 and co-expression 
systems BK and BAK described in Figure 3.4. Untransfected (UT) cells were run as control. The tRFP antibody 
detects tdNirFP and mTagBFP and the GFP (JL-8) antibody mAmetrine and sREACh. Double-bands are due to 
cleavage during denaturation and high molecular weight bands observed for mAmetrine-msCP576 (both 
discussed in Chapter 2). The shift of the 2A fusions (lanes 3, 4, 9-12) compared to the single sensors (lanes 2, 
6-8) is due to additional 22aa (~2.4kD) of the 2A linker. 
B-D: Fluorescence emission spectra of stable monoclonal cell lines as in panel A  were acquired at 840 nm 
(panel B) and 840, 860, 880 nm (panel C-D) for 2PE. In D, spectra of HeLa cells transiently expressing single 
sensors are plotted as coloured lines. 
E: Flow cytometry measurement of donor fluorescence of fixed monoclonal cell lines from B-D and parental 
control cells. Vertical lines show peak fluorescence in parental controls as reference. 
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of the mKeima fluorescence, however, it also caused loss of mTagBFP signal and a sharp 
increase of the fluorescence emitted by sREACh in the BK construct; this indicates direct 
excitation of sREACh which would interfere with unmixing (Fig. 3.5C-D). Therefore, the 
excitation wavelength optimal for imaging the HeLa-BAK cells was set at 840 nm. 
Initial observation of caspase dynamics from ensemble measurements 
Studying the cell population by Western Blot to validate the sensors already provided us with 
some insight into the behaviour of key cell death factors in Cisplatin-treated HeLa cells 
(Fig. 3.6). First, caspases-2, -3, -9, -8 and PARP are all processed in response to 100 µM 
Cisplatin starting around 8 hours and showing a gradual response. The 100 µM concentration 
of Cisplatin was selected to guarantee the triggering of cell death in a majority of cells, 
corresponding to four times the EC50 values (or EC90; Fig. 3.5I). The apparent gradual 
response is the result of averaging the switch-like response of single cells that die at widely 
different points after treatment (Video S1; Tyas et al., 2000) as discussed in the introduction. 
Importantly, this response is mirrored by the processing of caspase sensors on Western Blot, 
confirming the appropriate response of the biosensors with an additional line of evidence (Fig. 
3.7). Also, at the end of the experiment (~16 hours), a certain amount of procaspases, as well 
as of biosensors, remain unprocessed; this indicates that a subpopulation of cells does not 
activate caspases and/or does not die, as expected by the chosen Cisplatin concentration. The 
order of caspase activation cannot be established at a 4 hours time resolution, a resolution 
that is not uncommon for population studies of this kind (Tab. 3.1). The only striking difference 
is observed for caspase-8 which is processed later than the other three caspases in both cell 
lines, suggesting that under these conditions the caspase-8-mediated extrinsic pathway might 
be not activated initially (Fig. 3.6B-C). It is important to notice that, even though HeLa cells 
express human Papilloma Virus E6 protein that subdues p53 levels, p53 is both stabilized as 
well as phosphorylated on serine-15 (by CHK1 and CHK2) in response to Cisplatin (Fig. 3.6A).  
F: Cell cycle analysis of DRAQ5-stained BAK #7 monoclonal cell line compared to parental HeLa cells. Shaded 
area under the curve corresponds to G1, S and G2 populations derived using the Dean-Jett-Fox algorithm. 
A-F: Data are from one experiment for each panel shown. 
G-H: Cell growth of parental HeLa cells (plated at 60,000 cells per 12-well) and BAK #7 cells (plated at 60,000, 
90,000 and 120,000 cells per 12-well) as measured by confluency in an IncucyteTM imaging system. Shown are 
mean and standard deviation of three wells per sample for one experiment. Panel H shows representative 
images of growth curves in panel G taken at 96 hours for parental cells and BAK cells (plated at 120,000 cells). 
I: Viability of parental and HeLa BAK cells at increasing doses of Cisplatin measured using the SRB assay. 
Mean and standard deviation of three technical replicates for one experiment are shown. One-phase decay fitted 
using GraphPad, EC50: Parental, 26.5 µM; BAK, 23.08 µM (non-significant difference; 1-way ANOVA). 
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This is in line with a previous report describing that in response to Cisplatin, p53 is stabilized 
in HeLa cells coinciding with the Cisplatin-mediated downregulation of E6 (Wesierska-Gadek 
et al., 2002). Therefore, in contrast to the majority of applications, HeLa cells can be considered 
p53-proficient in response to Cisplatin.  
In summary, we successfully cloned and validated a monoclonal cell line expressing all three 
FRET sensors and confirmed the suitability for studying Cisplatin-induced cell death in a bulk 
population using Western Blot. 
 Deconvolution of single-cell caspase dynamics and non-
genetic heterogeneity 
Following their validation, we used HeLa-BAK cells on our multicolour FLIM platform to study 
caspase dynamics in single cells (Fig. 3.8A-B). Novel detection technologies and data analysis 
pipelines tailored to achieve biochemical multiplexing have been developed by co-workers Dr 
Kalina Haas and Dr Alessandro Esposito as part of a team effort to establish a live single-cell 
biochemistry methodology. Here, I will, therefore, provide only a brief overview of these 
developments to the extent required to interpret the presented data. Full details and materials 
will be available elsewhere (manuscripts in preparation). 
Setup of the sensing platform 
The platform consists of a two-photon laser scanning microscope combined with very efficient 
photon-counting hybrid photomultiplier tubes as detectors at the non-descanned port of a Leica 
SP5 microscope. Fast FLIM measurements in excess of one order of magnitude of commercial 
solutions available at the time of the engineering of the system were achieved by the 
development of fast electronics based on multi-hit time-to-digital converters (Fig. 3.8C).  
Figure 3.6 – Dynamic response of caspases, p53 and PARP after treatment with Cisplatin 
A: Representative Western Blot of lysates from parental HeLa cells and HeLa-BAK cell line treated with 100 µM 
Cisplatin and harvested at indicated time points. Asterisks for p53 blots indicate bands of caspase-2 and 
caspase-9 from a previous detection on the same membrane. For caspase-2, -3 and -9 high and low exposures 
are shown to visualize all bands. 
B-C: Quantification of procaspase (C2/3/9: caspase-2/3/9) levels for parental HeLa (B) and HeLa-BAK cells (C) 
treated analysed as in A. Mean and standard deviation of four independent experiments are shown. 
D: Comparison of dynamics of procaspase cleavage plotted B-C for HeLa parental (solid line) and HeLa BAK 
cells (dashed line). 
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This configuration allows to image 75 optical slices covering 25 µM in 48 sec with very low 
excitation power (<1 mW at 840 nm) thus minimizing phototoxicity (Video S1). The imaging of 
a larger volume, rather than a single optical section, is necessary because dying cells detach 
from the surface and move away from the initial focal plane. Because of the fast acquisition 
and the low excitation power, we were able to acquire up to 12 fields of views sequentially in 
a fully automated mode with a 15 min time resolution and for a duration of at least 16 hours. 
Data were analysed using an in-house developed data pipeline. Briefly, stored streams of 
photons were processed to generate 3D image stacks, subsequently summed over the axial 
direction to form an ‘extended focus’ image that provides in focus 2D multicolour FLIM images 
with high signal. The FLIM movies were tracked and segmented with semi-automatic  
 
Figure 3.7 – Dynamic response of the BAK sensor after treatment with Cisplatin as measured by Western 
Blot 
A-B: Western Blot of lysates from HeLa BAK cells treated with 100 µM Cisplatin and harvested at indicated time 
points and plotted for caspase sensors as indicated and as in 3.5A. Lysates from HeLa parental cells run as a 
control. The same membrane was simultaneously probed with tRFP (A) and GFP (B) antibodies. Ponceau S 
staining is shown to confirm equal loading. 
C: Ratio of cleaved over uncleaved sensor quantified from Western Blot in panel A. 
All data from a single experiment. 
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Figure 3.8 – Experimental setup and data analysis for three-colour live-cell caspase imaging 
A: Schematic of experimental setup. 
B: Representative images of HeLa-BAK cells treated as shown in panel A extracted from time-lapse movie 
(Video S1). Shown are composite images of maximum projections from the mTagBFP and mAmetrine channel. 
C: Setup of the custom-built imaging platform for three-colour live-cell imaging. 75 optical slices are acquired 
using a two-photon laser scanning microscope (TPLSM), spectrally split onto three hybrid photomultiplier tubes 
which are read-out by fast bespoke electronics. Data is analysed using a pipeline developed in-house resulting 
in the calculating of relative enzymatic activities (REA) for three sensors. For further details see main text.  
D: Illustration of the algorithm used to determine activation of caspases. A caspase is considered active if the 
difference between the average of REA at the first and last three time points is larger than 10% percent of the 
first three. 
E: Illustration of the approach used to compute bootstrapped average caspase dynamics starting from 
asynchronous single-cell REA traces. C-E: Images courtesy of Dr Alessandro Esposito.  
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algorithms and always manually curated. Unmixing of biosensors was achieved by 
transforming the fluorescence signals extracted from individual cells by multi-dimensional 
phasor-transforms (Digman et al., 2008; Esposito et al., 2013; Popleteeva et al., 2015). 
Utilizing control measurements of single sensors and fluorophores, this bespoke algorithm 
permitted us to fingerprint the complex photophysical data we acquired and to unmix the 
contribution of individual molecular species (cleaved sensors, uncleaved sensors, residual 
sensitized emission and background autofluorescence). The relative enzymatic activity (REA) 
for each caspase and cell was computed as the fraction of cleaved substrates normalized to 
cleaved and uncleaved sensors (Video S2). Therefore, analysis of the photophysical properties 
of the samples is carried out in the background and the data pipeline provides only meaningful 
biochemical data. The trajectories of the three caspases for each cell can be then depicted as 
a function of time (Fig. 3.8C). This approach allows us to acquire and analyse both 
morphological (Fig. 3.8B) as well as biochemical information (Fig. 3.9, 3.10A; Video S2) of 
hundreds of single cells over 16 hours in a single experiment.  
Heterogeneity in caspase activation 
Caspase traces of 564 Cisplatin-treated HeLa-BAK cells from 12 independent experiments are 
depicted in Figure 3.10A. It confirms the large degree of heterogeneity in the time of caspase 
activation (Tyas et al., 2000; Video S1). However, this multiplexed single-cell analysis also 
revealed the previously unnoticed existence of at least three distinct subpopulations (Fig. 
3.10C; video S2). These populations would not be visible with ensemble measurements as 
illustrated by the population average of all the single-cell traces that is akin to the dynamics 
observed by Western Blot (Fig. 3.10B) or without biochemical multiplexing. The lower 
maximum REA for caspase-9 recapitulates the results from Chapter 2, where, independently 
of the FRET pair, a maximum of 50% REA was observed for caspase-9, and 80-90% for 
caspase-2 and -3 (Fig. 2.9 and 2.13).  
We observed a population of cells that activate all three caspases (‘c2/c3/c9 responsive’) and 
that on average trigger caspase-3 activity at around 8.8 hours as estimated from the half-
maximum of the sigmoidal curves (Fig. 3.10E; video S2A). As shown in panel D, 50% of the 
cells belong to the population. There is also a population of cells that activate caspase-2  
and -3, but not caspase-9 (Fig. 3.10A, C, and D; video S2B ‘c2/c3 responsive’). The 
classification into ‘responsive’/’non-responsive’ was performed by employing a 10% threshold 
on the individual traces of single cells, i.e. a caspase is considered activated if the difference 
between the averages of the first and last three time points is larger than 10% (Fig. 3.8D).  
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Figure 3.9 – Raw data of three-colour caspase FLIM imaging  
REA trajectories of 77 HeLa-BAK cells treated with 100 µM Cisplatin and imaged for 16 hours as described in 
Fig. 3.8A and C. Blue, caspase-2; Green, caspase-3; Red, caspase-9. Shown are all cells from a single 
experiment. 
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Employing this threshold, the c2/c3-responsive population constitutes 20% of the total 
population (Fig. 3.10D). In this population, caspase-3 activation is triggered at around 11.3 
hours, significantly later than in the c2/c3/c9 population (Fig. 3.10E). There is also a population 
of cells that do not activate any caspase within the duration of the experiment, constituting 17% 
of the total population (Fig. 3.10A, C, D). Of this population, 66% show no morphological signs 
of cell death and, therefore, we classify these cells as surviving (Fig. 3.11A). The cells that die 
without caspase activation exhibit morphological evidence (cell shrinking) of cell death at 
around 12.5 hours, significantly later than comparable cells that activate any number of 
monitored caspases (10.7 hours Fig. 3.11B). Finally, there are smaller populations of cells that 
show activation of single caspases as well as a combination of all (Fig. 3.10A, D), although at 
lower levels than the predominant populations (Fig. 3.12 C-E, discussed below). 
Single-cell caspase dynamics 
Because the time of caspase activation is heterogeneous across the population, the average 
dynamics shown in Figure 3.10 mask the true caspase dynamics of single cells. To avoid this 
artefact, we first synchronised the individual biochemical trajectories using the 50% of maximal 
activation for caspase-3 as a reference point. Synchronized REA values for the c2/c3/c9-
responsive, c2/c3-responsive and asynchronous non-responsive traces were then used to 
estimate the bootstrapped average and confidence intervals (see also Fig. 3.8E).  
Bootstrapped REA values are shown as a function of time relative to synchronization (Fig. 
3.12A-E). Here, the sharp activation of caspases contrasts the shallow responses measurable 
on population averages, and the differences between the c2/3/9- and c2/3- populations are 
unambiguous. In the c2/3/9-responsive population, caspase-2 and -3 appeared to be activated  
Figure 3.10 – Deconvolution of heterogeneity in caspase activation in response to Cisplatin 
A: Relative enzymatic activity for caspase-2, -3 and -9 shown for 564 individual HeLa-BAK cells classed into 
three largest groups and sorted by time of caspase-3 activation after treatment with 100 µM Cisplatin. Data is 
from 12 independent experiments. 
B: Average of REAs for caspase-2, -3, and -9 of all 648 HeLa BAK cells from 12 experiments. Bootstrapped 
averages with 95% confidence intervals are shown.  
C: REA averages for classes shown in A and plotted as in B. 
D: Prevalence of classes of HeLa BAK cells determined by caspase activation. 648 cells from 12 experiments 
are included. 
E: Time after Cisplatin treatment at which caspase-3 activity reaches 50% for all cells and c2/c3/c9 and c2/c3 
classes from 12 experiments. Number of cells shown in brackets. Median and interquartile range are overlaid in 
red. Significance was tested using the Kruskal-Wallis Test followed by the Dunn’s Multiple Comparison Test. 
A-C: Adapted from representation by Dr A Esposito. 
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simultaneously, while the activation of caspase-9 is significantly delayed by ~ 20 min (Fig. 
3.12A, H). In contrast, in the c2/c3-responsive population, caspase-2 activation is delayed by 
~10 min relative to caspase-3 and the maximum REA level is reduced by 20% compared to 
the c2/c3/c9 population. We also observed that in the smaller populations, single caspase 
sensors are weakly, but significantly, activated in the absence of any response from the other 
sensors (Fig. 3.12 C-E). Not only does this demonstrate the power and sensitivity of this 
sensing approach to detect even small subpopulations with minimal activation of the sensors 
but it also addresses concerns about the specificity of the sensors directly. The measurement 
of cells that cleave individual sensors argues strongly in support of specificity of the chosen 
substrate cleavage motifs. 
To further characterise the single-cell kinetics, we fitted a sigmoidal function to the single-cell 
traces to be able to accurately calculate the rate of caspase activation (Fig. 3.12F) and the 
maximum REA (Fig. 3.12G). In the c2/c3/c9 population, caspase-2 and-3 exhibited very  
similar activation rates as well as maximum REA, while caspase-9 was clearly activated slower 
and to a lower maximum REA. In the c2/c3 population, the rate is reduced for both caspase-2 
and -3 along with the maximum REA. Together, these observations suggest that caspase-2, -
3 and -9 form a highly interdependent network in which activation of all caspases is required  
 
Figure 3.11 – Characteristics of cells not activating any caspase 
A: Prevalence of cell fate phenotype for 118 HeLa-BAK cells that do not show caspase activation in response 
to 100 µM Cisplatin within 16 hours. Data from 12 independent experiments. 
B: Time of appearance of the first morphological sign of cell death (cell shrinking) for all HeLa-BAK cells that 
activate either any or no caspase in response to 100 µM Cisplatin. Number of cells shown in brackets. Median 
and interquartile range are overlaid in red. Significance was tested using the Kruskal-Wallis Test followed by the 
Dunn’s Multiple Comparison Test. Data from 12 independent experiments. 
 
110 3.3 Results 
 
 
Figure 3.12 – Single-cell caspase dynamics and subpopulations 
A-E: Relative enzymatic activity for caspase-2, -3 and -9 (blue/green/red) in indicated classes after 
synchronization of single-cell traces using 50% of caspase-3 activity as reference point. Shown are bootstrapped 
averages and confidence intervals. Number of cells per panel A-E: 315, 119, 24, 21, 21.  
F-G: Distribution of maximum activation rate (F) and REA at the end of the experiment (G) calculated from 
sigmoidal fits for each caspase and classified into the two pre-dominant caspase response classes. 
H: Summary of caspase dynamics (panels A-B) and relative timing (time of 50% caspase-3 activation shown in 
3.10G) for c2/c3/c9 and c2/c3 populations. 
All data is from 12 independent experiments. 
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for maximum activation rate, REA as well as the time of activation. In the absence of caspase-
9 or multiple caspases, the network response is slowed and subdued, accompanied by a delay 
in the triggering of caspase activation (Fig. 3.12H). 
 Mechanism of caspase-9 inhibition and delay 
Next, we further investigated possible mechanisms that could affect caspase-9 activation and 
therefore determine the prominent c2/c3 population.  
Caspase-9 deficiency is independent of FRET sensor and HeLa cell line used 
We first sought to rule out any technical explanations for the lack of caspase-9 activation. The 
caspase-9 sensor is unique within our suite of sensors, because of the presence of the tandem-
dimer whose sterical effect on the linker required the extension of the linker to restore caspase 
cleavage (Fig. 2.13). To rule out that this difference in sensor architecture leads to a delay in 
cleavage of the linker, we transiently expressed the co-expression construct BA containing 
short caspase-2 and -9 linkers and thereby matching sensor designs. As shown in Figure 
3.13A-D, we still detected a population that lacked caspase-9 activation and triggered 
caspase-2 later than the c2/c3-population (medians 7.8 hours vs 11.1 hours). This excluded 
any influence of the particular sensor architecture on caspase-9 activity. We also used the 
same dual-expression vector with linker for caspase-2 and caspase-3 and found as expected 
only one population of cells that activated both caspase-2 and caspase-3 (Fig. 3.13E-F). While 
all cells activated either caspase-2 and-3 or none at all, we found that the c2/c3 cells still 
clustered into two populations in regard to the time of caspase activation, suggesting the 
presence of a delayed population that, based on our earlier observations, does not activate 
caspase-9 (Fig. 3.13D).  
The transient transfection of dual-caspase sensors permitted us to i) confirm the presence of 
a delayed c2/c3 population that is independent of the sensor used for caspase-9 monitoring 
and ii) demonstrate that the caspase-9 negative population is not an artefact specific to the 
HeLa-BAK clone #7, further validating both sensors and cell line. 
Execution of MOMP does not determine c2/c3 population identity 
The failure to sufficiently trigger MOMP has been described as a mechanism for delayed or 
completely abolished cell death (Tait et al., 2010). Thus, we hypothesized that the populations 
with reduced or completely abolished caspase activation could fail to induce MOMP resulting 
in the lack of caspase-9 activation (which is activated after MOMP). However, when staining  
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Figure 3.13 – Confirmation of subpopulations and dynamics with two-colour sensors 
Parental HeLa cells were transiently transfected with caspase-2/-9 (A-C) and caspase-2/-3 (E-F) co-expression 
systems (mTagBFP-VDTTD-sREACh-P2A-mAmetrine-DEVDR/LEHD-msCP576h) and treated with 100 µM 
Cisplatin followed by multiplexed imaging. Data are from one experiment. 
A-B: REA trajectories for caspase-2 (blue) and -3 (green) for c2/c9 and c2 population. Single-cell trajectories 
were synchronized using 50% caspase-2 activation. Bootstrapped averages and confidence intervals are 
shown.  
C: Prevalence of detected caspase response classes for cells expressing the caspase-2/-9 sensor construct. 
D: Time of 50% caspase-2 activity after Cisplatin treatment for both co-expression systems and classes shown 
in A-B and E. Number of cells shown in brackets. Median and interquartile range are overlaid in red. Significance 
was tested using the Kruskal-Wallis Test followed by the Dunn’s Multiple Comparison Test. 
E: REA trajectory for c2/c3-responsive cells for caspase-2/-3 sensor construct created as described in A-B. 
F: Prevalence of detected caspase response classes for cells expressing the caspase-2/-3 sensor construct. 
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intact mitochondria with TMRM (Tetramethylrhodamine) in parental HeLa cells that undergo 
Cisplatin-induced cell death, we found that all cells that showed clear death morphology 
showed a complete and rapid loss of TMRM corresponding to a complete MOMP (Fig. 3.14A-
B; Video S3). This was also confirmed using the HeLa-BAK cell line (Video S4). We found that 
on average MOMP precedes the appearance of cell death signs by ~17 min (Fig. 3.14C). 
Considering the time resolution of 15 min, this value is likely overestimated, because shorter 
time intervals than 15 min will all be counted as 15 min. Together, these results suggest that 
the lack of caspase-9 activation in the c2/c3 population is not due to a failure to execute MOMP.  
The cell cycle phase does not influence caspase-9 activation 
Caspase-9 activity is known to be modulated by a number of factors whose activity is cell cycle-
dependent, including CyclinB1/Cdk1 (Allan and Clarke, 2007) and p53 (Chee et al., 2013). 
This suggests that the position in the cell cycle at the time of Cisplatin addition could affect 
caspase-9 activity and, therefore, it could cause the emergence of the c2/3/9 and c2/3 
populations. 
 
Figure 3.14 – Measurement of mitochondrial outer membrane permeabilization 
A: Representative fluorescence and DIC images of the same field of view before and after treatment of TMRM-
stained HeLa parental cells with 100 µM Cisplatin for 16 hours. Cells were imaged every 15 min. 
B: Quantification of the fraction of TMRM-negative (i.e. MOMP-positive) cells treated as in A. Number of cells 
from a total of three fields of view and one experiment shown in brackets. 
C: Time difference between the loss of TMRM staining and the first appearance of a morphological sign of cell 
death (shrinking or blebbing) for TMRM-negative cells shown in B. CI, confidence interval. 
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Therefore, HeLa-BAK were synchronized in G1 using a double-thymidine block and cell cycle 
analysis performed to determine the time after release at which the majority of the cells was 
either in G1 or S/G2 phase (Fig. 3.15A-C). We then treated HeLa-BAK at those times with 
Cisplatin and performed multiplexed imaging of caspase-2, -3 and -9 as usual. We observed 
no difference between G1- and S/G2-treated cells in any of the parameters assessed (Fig. 
3.15, D-J), suggesting that the cell cycle phase at the time of treatment does not influence 
caspase-9 activity nor the time of cell death.  
We noticed that the double-thymidine block was less efficient in HeLa-BAK cells compared to 
HeLa parental cells, in agreement with the reduced proliferation rate discussed earlier (Fig. 
3.15A). Thus, at the time of treatment, ~30% of the cells are in the ‘undesired’ cell cycle phase 
which could mask potential differences (Fig. 3.15B-C). Therefore, to avoid synchronization, we 
treated asynchronously growing HeLa parental cells expressing the FUCCI cell cycle marker 
(Fig. 3.15K) with Cisplatin and recorded the time of the appearance of any death morphology 
(Fig. 3.15L). Again, there was no clear difference between cells that expressed the G1 or the 
S/G2 marker at the time of treatment. However, as the number of cells that were treated in G1 
is small, this conclusion ought to be confirmed with further repeats of this assay. 
Figure 3.15 – Prevalence of caspase populations is independent of the cell cycle phase at the time of 
treatment 
A: Cell cycle profiles of DRAQ5-stained HeLa parental and HeLa-BAK cells at indicated times after release from 
a double-thymidine block. 
B-C: Proportion of cells in G1 and G2/S phases at 0 hours (B) and 7 hours (C) after release based on profiles in 
panel A. 
D-E, G-H: caspase-2/-3/-9 dynamics of HeLa-BAK cell treated with 100 µM Cisplatin at 0 hours (D-E) or 7 hours 
(G-H) after release from a double-thymidine block. Synchronized, bootstrapped averages and confidence 
intervals for two classes are shown. 
F, I: Prevalence of detected caspase response classes for cells treated at 0 hours (F) or 7 hours (I) after release 
from a double-thymidine block. 
J: Time of 50% caspase-3 activity after treated with 100 µM Cisplatin for all cells shown in F (G1) and I (S/G2). 
Number of cells shown in brackets. Median and interquartile range are overlaid. Significance was tested using 
the Kruskal-Wallis Test followed by the Dunn’s Multiple Comparison Test. 
K: Schematic of the FUCCI system used to identify the cell cycle phase. 
L: Time to the first appearance of death morphology (shrinking or blebbing)  of parental HeLa cells expressing 
the FUCCI system treated with 100 µM Cisplatin. Cells showing only red fluorescence in the first frame were 
counted as G1, and cells showing green fluorescence as S/G2. Number of cells shown in brackets. Median and 
interquartile range are overlaid. Significance was tested using the Kruskal-Wallis Test followed by the Dunn’s 
Multiple Comparison Test. 
All data are from single experiments each for A-C, D-J and L, respectively. 
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Figure 3.16 – Caspase-8 dynamics and its implication in cell fate determination 
A: Dynamics of caspase-3 (green) and caspase-8 (blue) activation for parental HeLa cells treated with 100 µM 
Cisplatin treatment. Synchronized, bootstrapped averages and confidence intervals are shown. 
B: Prevalence of cells that show an early activation in caspase-8 activity that precedes caspase-3 activation 
(marked with an asterisk in D). 
C: Time of 50% caspase-3 activity for cells depending on the appearance of an early activation in caspase-8 
activity. Median and interquartile range are overlaid in red. 
D: Single-cell traces of cells averaged in A. Cells showing an early activation in caspase-8 are marked with an 
asterisk. 
All data from a single experiment. 
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In summary, using two independent methods, we could show that caspase-9 activity in 
response to Cisplatin is independent of the cell-cycle state at the time of treatment. 
Caspase-8 as a candidate to set caspase-9 activation 
As depicted in Figure 3.2, Cisplatin-induced DNA damage can lead to the activation of 
caspase-8 via JNK and p38, which can induce cell death both by triggering MOMP and 
caspase-9 activation, as well as direct activation of caspase-3 bypassing MOMP.  
Combining sensors for caspase-3 and -8, we observed early activation of caspase-8 preceding 
caspase-3 activity (manifested as a slow ‘rise’ reported by Albeck et al., 2008) in 28% of the 
cells (Fig. 3.16A-C). The full activation occurs ~20 min after caspase-3, indicating activation of 
the known feedback loop between caspase-3 and -8, and is likely corresponding to the late 
caspase-8 processing observed on Western Blot (Fig. 3.6). The proportion of cells with early 
caspase-8 activity is similar to the proportion of c2/c3 cells observed in other experiments (Fig. 
3.16B, D). Moreover, such cells also show a ~2 hours delay in the onset of caspase-3 
activation, reminiscent of the c2/c3 cells (Fig. 3.16C), suggesting that caspase-8 activity does 
indeed determine this population. However, to fully validate this hypothesis, caspase-8 and 
caspase-9 activity needs to be monitored simultaneously, an experiment that is currently being 
performed.   
In summary, we confirmed that the delay of caspase-9 activation and lack of activation in a 
population of cells is independent of the HeLa cell line used, the sensor architecture, cell cycle 
state, and are currently investigating a potential role of caspase-8. Next, we used the full depth 
of information obtained with the sensing approach to connect caspase activation dynamics 
with cell fate.   
 A continuum of Cisplatin-induced apoptotic and necrotic cell 
death 
When studying the intensity images derived from the biochemical trajectories, we observed 
the presence of different cell death phenotypes (Fig. 3.17A-B; Video S5). The large majority of 
cells (72%) exhibited rapid (usually completed within 15 min) cell shrinkage, detachment from 
the culture surface and subsequent appearance of membrane blebbing and apoptotic bodies 
(‘shrunk’ phenotype). A small population of the cells (4%) instead showed no apparent 
shrinking, but pronounced membrane blebbing while remaining attached to the surface (‘bleb’ 
phenotype). Another group of cells was characterized by an initial shrinking that remained  
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incomplete (i.e. cells did not round up perfect spheres; see Fig. 3.17A central panels for direct 
comparison of ‘shrunk’ and ‘shrunk-bleb’) followed by the appearance of membrane blebbing, 
thus, exhibiting characteristics of both ‘bleb’ and ‘shrunk’ phenotypes (‘shrunk-bleb’ 
phenotype). Finally, 20% of the cells did not show any discernible death phenotype. While the 
assignment of the ‘shrunk’ phenotype was usually unambiguous, an apparent continuum 
between the remaining phenotypes complicated the phenotypic assignment. Therefore, all 
cells were scored blindly by three researchers and the final assignment determined by majority 
consensus (see Material and Methods for details on scoring and criteria).   
The ’shrunk’ phenotype constitutes all key morphological determinants for apoptosis (cell 
shrinkage, detachment and blebbing), while the ‘bleb’ phenotype is more reminiscent of 
necrotic cell death (blebbing in the absence of shrinkage; Berghe et al., 2014; Degterev and 
Yuan, 2008; Galluzzi et al., 2012). To determine the mode of cell death, we performed an 
Annexin-V/7-AAD (7-amino-actinomycin D) co-staining assay on parental HeLa cells, 
considered the gold standard for distinguishing apoptotic from necrotic cell death (Vermes et 
al., 1995). Fluorescently-labelled Annexin-V (AV) binds to exposed phosphatidylserine (PS) in 
the plasma-membrane, whereas 7-AAD stains DNA, but can only enter if the membrane 
integrity is lost. In apoptotic cells, PS exposure precedes loss of membrane integrity, whereas 
in the necrotic cells initial loss of membrane integrity means that both events co-occur. We 
also co-stained the same cells with TMRM to determine the timing relative to MOMP (quantified 
earlier in Fig. 3.14).  
 
Figure 3.17 – Heterogeneity of cell death morphology in response to Cisplatin 
A: Representative images of HeLa-BAK cells showing distinct morphologies when undergoing cell death in 
response to 100 µM Cisplatin based on 12 independent experiments. Note that for ‘shrunk-bleb’ cells, the field 
of view includes a ‘shrunk’ cells (lower cell) for direct comparison. Scale bars are 10 µM. 
B: Prevalence of cell death morphologies defined in A for HeLa-BAK cells undergoing Cisplatin-induced cell 
death in 12 independent experiments. 
C, E: Representative images of parental HeLa cells stained with Annexin-V-FITC, TMRM and 7-AAD before at 
after treatment with 100 µM Cisplatin undergoing the ‘shrunk’ (C) or ‘bleb’ (E) cell death phenotype. 
D, F: Quantification of normalized fluorescence in three channels for single cells shown in C, E. 
G-H: Difference in fluorescence intensity between Annexin-V-FITC and 7-AAD signal at each time point after 
Cisplatin addition. Cells from three fields of view and one experiment are shown; number of cells in brackets. 
Curves are shown as classified accordingly to the phenotypes defined in panel A. 
I: Maximum of curves in G-H classified by phenotype. Number of cells in brackets. Mean and standard deviation 
are overlaid. Horizontal dashed line indicates median of all cells. Significance was tested using the Mann-Whitney 
test. 
C-I: Data from one experiment with three fields of view. 
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As shown in Figure 3.17C-F, AV precedes 7-AAD staining in ‘shrunk’ cells, while it co-occurs 
in ‘bleb’ cells. MOMP occurs in all cells that exhibit any cell death phenotype and precedes AV 
staining (see also Fig. 3.14). Quantifying the time delay between AV and 7-ADD for multiple 
cells confirmed that ‘shrunk’ exhibit a significantly longer delay than ‘bleb’ cells (Fig. 3.17G-I), 
suggesting that ‘shrunk’ cells are mostly apoptotic cells (62% above median delay of all cells), 
whereas ‘bleb’ cells are predominantly necrotic (40% above median delay of all cells). ‘Shrunk-
bleb’ cells showed a delay similar to bleb cells, suggesting there are closer to necrotic cell 
death (20% above median delay of all cells). However, we expect that with more numbers of 
‘bleb’ and ‘shrunk-bleb’ cells analysed the two populations could diverge more clearly. Aiming 
to further delineate the identity of the necrotic cell death, we treated HeLa with the potent 
pan-caspase inhibitor Q-VD-OPh (Fig. 3.18). Pan-caspase-inhibition protected the vast 
majority of cells from Cisplatin-induced apoptotic as well as necrotic cell death, indicating the 
caspases are required for both cell death pathways in our experimental model.  
 
 
Figure 3.18 – Cell death in response to Cisplatin is caspase-dependent 
A: Representative images of HeLa-BAK cells pre-treated for 24 hours in presence or absence of 25 µM pan-
caspase inhibitor Q-VD-OPh, before and after treatment with 100 µM Cisplatin. 
B: REA trajectories for caspase-2/-3/-9 (Blue, green, red) shown as bootstrapped averages with confidence 
intervals for cells pre-treated with Q-VD-OPh as in A. 
C-D: Prevalence of cell death phenotypes after 16 hours treatment with 100 µM Cisplatin in the absence (C) or 
presence (D) of Q-VD-OPh. 
Data from three field of views each in one experiment. 
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Comparing timing and dynamics of caspase activation with cell death phenotypes 
Analysing the timing of the appearance of the cell death phenotype (i.e. the first frame in which 
a cell shows either shrinking or blebbing, referred to as ‘time of death’) as well as the time of 
50% caspase-3 activation (measured from the single-cell REA trajectories) for each 
phenotype, we found that ‘bleb’ cells are delayed by 2.5 to 3.5 hours compared to ‘shrunk’ 
cells, respectively (Time of death median 10.2 hours vs 13.8 hours; 50% c3 median 9.4 hours 
vs 11.6 hours; Fig. 3.19A-D). ‘Shrunk-bleb’ cells exhibit an intermediate timing both for the time 
of cell death and time of caspase-3 activation (medians 11.8 hours and 10.0 hours, 
respectively). We also confirmed the presence of ‘shrunk’ and ‘bleb’ phenotypes and a similar 
delay between them in parental HeLa cells (Fig. 3.19E).  
We noted that there was a consistent difference between the two time-metrics (time of death 
and time of 50% caspase-3 activation) across all twelve experiments analysed in this set, with 
caspase-3 activation preceding the occurrence of any cell death morphology.  The time 
difference increased from ~50 min for ‘shrunk’ cells to ~130 min for ‘bleb’ cells, suggesting a 
slower execution of cell death in bleb cells which could be biologically important (Fig. 3.19K).  
However, while determining the exact time of the appearance of the first morphological sign of 
death was usually unambiguous for cell shrinking, determining the first occurrence of  
Figure 3.19 – Correlation between cell death timing, phenotype and caspase activation 
A: Frequency distribution of the time of appearance of different cell death phenotypes of HeLa-BAK cells treated 
with 100 µM Cisplatin for 16 hours. 
B: Data as in panel A but shown for single cells. Number of cells indicated in brackets. Median and interquartile 
range are overlaid in red. Significance was tested using the Kruskal-Wallis Test followed by a Dunn’s Multiple 
Comparison Test. 
C: Frequency distribution of time for 50% caspase-3 activity by cell death phenotype. 
D: Data as in panel C but shown for single cells. Number of cells indicated in brackets. Median and interquartile 
range are overlaid in red. Significance was tested using the Kruskal-Wallis Test followed by a Dunn’s Multiple 
Comparison Test. 
E: Time of appearance of cell death phenotypes for parental HeLa cells treated with 100 µM Cisplatin for 16 
hours. Median and interquartile range are overlaid in red. Significance was tested using the Mann-Whitney test. 
F-G: Time of cell death morphology (F) and time to 50% caspase-3 activity (G) for cells in B and D shown by 
caspase response class (c2/c3/c9 or c2/c3). Median and interquartile range are overlaid in red. 
H-J: Prevalence of caspase response classes for different death phenotypes. 
K: Correlation between the time of 50% caspase-3 activity and time of appearance of the death phenotype after 
Cisplatin treated shown for single cells and classified by death phenotype and caspase response class (data as 
in F/G). Lines are approximations to aid illustration. 
All data from 12 independent experiments. 
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membrane blebbing was difficult and is likely prone to a large error. Therefore, we decided to 
show both time metrics in all further experiments.  
Next, because the time difference between the c2/c3/c9 and c2/c3 populations was similar to 
the difference between ‘shrunk’ and ‘bleb’ cells, we hypothesized that they corresponded to 
the same population. However, when both time of death, as well as caspase-3 activation, was 
sub-divided into phenotypes and caspase responsiveness, we observed both the c2/c3/c9 and 
c2/c3 populations exhibit all phenotypes at approximately equal proportions, arguing against 
an overlap between caspase responsiveness and death phenotype (Fig. 3.19F-G). When we 
analysed the cells belonging to each phenotype regarding the prevalence of different caspase 
responsiveness, no clear difference could be observed, again suggesting a limited overlap 
between caspase responsiveness and death phenotype (Fig. 3.19H-J). We also computed 
 
 
Figure 3.20 – Comparison of caspase dynamics of cell death phenotypes 
A-C: Relative enzymatic activity for caspase-2, -3 and -9 of indicated cell death phenotypes. Single-cell traces 
were synchronized to 50% caspase-3 activity. Bootstrapped averages and confidence intervals from 12 
independent experiments are shown. 
D-F: Pair-wise overlays of graphs shown in A-C. 
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boot-strapped caspase trajectories for the three caspases, but, despite a markedly lower 
caspase-9 activation in ‘bleb’ and ‘shrunk-bleb’ cells, we could not unambiguously identify a 
difference in caspase activation between the different phenotypes (Fig. 3.20).  
Taken together, these results suggest that a subdued caspase response is at least partially 
connected with a change in the cell death phenotype toward necrosis. In the next section 
(3.3.5), we will assess this connection further using targeted perturbation of the network. 
U2OS osteosarcoma cells show heterogeneity in caspase activation and cell death 
phenotype 
Next, we asked whether the large extent of non-genetic heterogeneity in caspase activation 
and cell death modes is a more general feature in the response to Cisplatin-induced cell death 
by using a different cell line. Thus, we used the osteosarcoma cell line U2OS transiently 
expressing the caspase-2/3/9 co-expression system that was used to create the HeLa-BAK 
cell line for multiplexed caspase imaging. 
In response to Cisplatin, the majority (57%) of the U2OS cells did not activate caspases (Fig. 
2.21A-B), of which 95% show no cell death phenotype. Of those cells that show caspase 
activation, c2/c3/c3 cells are the largest population (31% of total). The remainder activates 
either c2/c3 or c3 and c9 alone (4%, 3%, 6%, respectively), but considering the low number of 
cells, this classification remains uncertain. As for HeLa cells, we observed a high degree of 
heterogeneity in the time at which caspases are triggered (Fig. 3.21A; video S7). U2OS also 
showed a similar order of caspase activation with caspase-3 activated first, followed closely by 
caspase-2 (Fig. 3.21C). Caspase-9 was delayed by ~15 min relative to caspase-3. Moreover, 
the heterogeneity in cell death was recapitulated, too, with the ‘bleb’ phenotype  
constituting the largest group (Fig. 3.21D). Also, ‘bleb’ cells showed a ~2-hour delay in 
caspase-3 activation and a ~2.5h delay in the appearance of the death phenotype (Fig. 3.21E-
F), in concordance with results obtained in HeLa cells. Interestingly when comparing 
phenotype and caspase responsiveness, we found that ‘bleb’ cells were twice as likely to die 
in the absence of any caspase activation as ‘shrunk’ cells (Fig. 3.21G-H), suggesting that, at 
least in U2OS, failure to sufficiently activate the caspase network is a cause for a switch to a 
necrotic cell death. In HeLa cells, such a clear difference between caspase responsiveness 
and phenotype could not be observed in response to Cisplatin. 
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In summary, we could not only show that the pronounced non-genetic heterogeneity in cell 
death dynamics and death phenotypes is not limited to one cell line, but also demonstrate that 
there is considerable heterogeneity between genetically different cell lines. 
 
Figure 3.21 – U2OS cells show heterogeneity in caspase activation and cell death phenotype 
A: Relative enzymatic activity for caspase-2, -3 and -9 shown for individual U2OS cells transiently transfected 
with the BAK co-expression system and treated with 100 µM Cisplatin. Three caspase response classes are 
shown and cells within each class sorted by time of caspase-3 activation after treatment.  
B: Prevalence of caspase response classes. 
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 Perturbation of the caspase network 
Next, we used different small molecule inhibitors to gain further insight into the caspase 
dynamics and the role it plays in the determining cell fate in the Cisplatin-induced DNA damage 
response in HeLa cells. 
Caspase inhibitors interfere with caspase dynamics and cell fate 
First, we monitored caspase-2, -3, and -9 dynamics and death morphology in HeLa-BAK cells 
in the presence of irreversible peptidomimetic inhibitors against individual caspases (Fig. 3.22-
24; also see chapter 2 for the use of these inhibitors for sensor validation).  
In the presence of the caspase-2 inhibitor Z-VDVAD-FMK (Fig. 3.22C-D, J), we observed fewer 
cells that responded with all three caspases, while the frequency of c2/3-only cells remained 
unaltered. However, in these cells, caspase-2 exhibited slower kinetics compared to the other 
caspases and matched controls. Crucially, we observed a significant increase of cells (from 
~2% to 17% of the total) that only cleaved the caspase-2 substrate sensor and cells that 
processed both the caspase-2 and -9, but not caspase-3 sensors (2% to 7%; Fig. 3.22F). In 
both cell populations, caspase activity reached only very low maximal levels of cleavage, 
suggesting that low activation of caspase-2 is insufficient to trigger a complete response of the 
caspase network (Fig. 3.23A-B).  
This coincided with an increase of necrotic phenotypes to 15% compared to 8% in matched 
controls but no significant change in the time of cell death or caspase-3 activation, although 
we noticed a trend to earlier caspase-3 activation (median difference ~105 min) and cell death 
(median difference ~60 min) in particular in ‘shrunk’ cells and is similar in all other inhibitors 
(Fig. 3.24E-H). This coincided with a delay of the occurrence of ‘bleb’ and ‘shrunk-bleb’ cells 
for all inhibitors relative to the control by 1-2 hours (median time to bleb: ctrl: 11.7 hours, iC2: 
C: Caspase-2/-3/-9 activation dynamics for the c2/c3/c9-responsive cells. Bootstrapped averages synchronized 
to 50% caspase-3 activity and confidence intervals are shown. Panels A and C adapted from Dr A Esposito. 
D: Prevalence of cell death phenotypes. 
E-F: Time of 50% caspase-3 activity (E) or appearance of cell death (F) for different cell death phenotypes.  
Median and interquartile range are overlaid in red. Number of cells shown in brackets. Significance was tested 
using the Kruskal-Wallis Test followed by a Dunn’s Multiple Comparison Test. 
G-J: caspase response classes of Cisplatin-treated U2OS cells shown for each death phenotype. 
All data are from one experiment with a total of 119 cells. 
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12.3 hours; 13.3 hours; iC9: 12.6 hours). Due to the limited number of cells and experiments, 
the significance of these trends remains to be confirmed. 
 
Figure 3.22 – Caspase inhibition affects caspase dynamics and topology 
A-H: Relative enzymatic activity of caspase-2, -3 and -9 in HeLa-BAK cells treated with 100 µM Cisplatin. Cells 
were pre-treated for ~20 hours with 25 µM of caspase inhibitors (iC2: Z-VDVAD-FMK, iC3: Z-DEVD-FMK, iC9: 
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The caspase-3 inhibitor Z-DEVD-FMK led to an even stronger decrease in the prevalence of 
the c2/3/9-responsive phenotype (from 43% to 18%) and resulted in an increase in cells 
activating two or one caspases (Fig. 3.22E, F, K, 3.23E-F). Z-DEVD-FMK strongly increased 
the proportion of cells with a necrotic phenotype (8% to 29%) and is the only inhibitor that 
clearly increased the number of cells that do not show any death phenotype (5% to 10%; Fig. 
3.24C).  
The most prominent effects of caspase-9 inhibition with Z-LEHD-FMK is a pronounced shift 
from the c2/3/9-responsive population (43% to 24%) to the c2/9-only population (from 36% to 
55%; Fig. 3.22J-L). It also increased the prevalence of cells that activate only caspase-2 or 
caspase-2 and -9 (Fig. 3.22G, H, L, 3.23C, D). Furthermore, the caspase-9 inhibitor increased 
the proportion of cells that die from a necrotic phenotype (8% to 25% of the total; Fig. 3.24D). 
In summary, all caspase inhibitors resulted in a net decrease of all caspase activities in all 
populations (Fig. 3.22, 3.23) and increased the prevalence of populations that are rare or 
nonexistent in the unperturbed caspase network response (Fig. 3.24). Therefore, perturbation 
of a single caspase prevents efficient activation of the whole network. Moreover, all inhibitors  
Z-LEHD-FMK). Shown are synchronized, bootstrapped averages and confidence intervals for two caspase 
response classes. Data from two independent experiments. 
I-L: Prevalence of caspase response classes for cells treated as in A-H. 
 
Figure 3.23 – Dynamics of minor caspase response classes upon caspase inhibition 
The relative enzymatic activity of caspase-2, -3 and -9 in HeLa-BAK in indicated caspase response classes not 
shown in Fig. 3.22. Shown are synchronized, bootstrapped averages and confidence intervals for caspase 
response classes that contain ≥ 5% of cells. Number of cells per panel: 18, 7, 5, 6, 19, 8, 7, 5. Data from two 
independent experiments. 
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Figure 3.24 – Effect of caspase inhibition on cell death timing and phenotype 
A-D: Prevalence of cell death phenotypes of HeLa-BAK cells treated with 100 µM Cisplatin and indicated caspase 
inhibitors as described in Fig. 3.22. 
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showed a shift from apoptotic to necrotic cell death phenotypes (Fig. 3.24A-D). Compared to 
Cisplatin alone, caspase inhibition also strongly increased the proportion of cells not activating 
all three caspases in the population undergoing a necrotic cell death, whereas the effect among 
the apoptotic phenotypes was less pronounced (Fig. 3.24G-N). Collectively, these results 
confirm the existence of positive feedbacks, either direct or indirect, between caspases. When 
individual caspases are inhibited the resulting perturbed network is unable to trigger cell death 
efficiently resulting in a shift to necrotic forms of cell death. 
Perturbation of caspase networks with clinically relevant inhibitors 
If confirmed, the observation that changes in the caspase activation dynamics lead to a shift 
between different cell death types in a heterogeneous population could have profound 
implications for the treatment of cancer, where a rapid, apoptotic, inflammation-free cell death 
of all tumour cells is often considered beneficial (Crusz and Balkwill, 2015). We, therefore, 
used two sets of clinically relevant inhibitors to understand whether perturbation of the caspase 
dynamics allows us to shift cell death types. 
Inhibition of IAP family proteins using LCL161 
IAP family proteins (introduced in section 3.1.4) play a key role in controlling both extrinsic and 
intrinsic pathways of apoptosis by restraining the activity of key caspases either through direct 
inhibition of caspase-3, -7 and -9 (XIAP) or indirectly by affecting the stability of key factors in 
the pathway, including Smac/Diablo and caspase-3/-7 (Fulda and Vucic, 2012; Kocab and 
Duckett, 2016). IAPs are frequently overexpressed in human tumours and have been 
associated with the development of resistant and poor survival (Lopes et al., 2007; Nakagawa 
et al., 2006). To target IAPs for cancer treatment, a number of drugs are currently undergoing 
clinical trials alone and in combination with other agents including DNA damaging agents such 
as Cisplatin (Fulda, 2015). In response to Cisplatin and other DNA damaging drugs, expression 
of IAP family members cIAP1, cIAP2, XIAP and ML-IAP has been shown to be induced 
E-F: Time of the appearance of a death phenotype (E) or 50% caspase-3 activity (F) shown as a function of 
caspase inhibitors and classified by cell death phenotype. Shown are single cells and median and interquartile 
range are shown overlaid in red. Significance was tested using the Kruskal-Wallis Test followed by a Dunn’s 
Multiple Comparison Test. 
G-N: Prevalence of caspase response classes by death phenotypes and caspase inhibitors used. 
Data is from the two independent experiments shown in Fig. 3.23. 
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(Altena et al., 2015; Duale et al., 2007; Hussner et al., 2012), suggesting a biological function 
to delay caspase activation to allow time for DNA repair and the integration of  pro-survival 
signals. Accordingly, using one clinical IAP inhibitor, LCL161, Paek et al. showed that inhibition 
of IAPs lowers the apoptotic threshold permitting cells with lower p53 induction to die earlier 
(Paek et al., 2016). However, whether IAP inhibition affects caspase dynamics and the 
prevalence of different cell death types in combination with Cisplatin remains an open question.  
We found that in parental HeLa cells and HeLa-BAK cells cIAP1 and cIAP2 transcription levels 
were upregulated transiently at 4 hours after Cisplatin addition (Fig. 3.25A-C), followed by a 
decrease of protein levels of cIAP1/2 and XIAP after 8 hours of Cisplatin treatment (Fig. 3.26A-
D) confirming observations by Paek et al and others. Next, we determined the lowest – non- 
lethal – effective dose of LCL161 that resulted in maximum degradation of cIAP1 and cIAP2, 
used previously as a marker for LCL161 effectiveness (Ramakrishnan et al., 2014) (Fig. 3.25D-
H). By using such a low dose (1 µM), we could ensure that any change in cell death is due to 
the combination with Cisplatin, not LCL161 treatment alone. With Western Blot analyses, we 
showed that LCL161 substantially decreases cIAP1 and cIAP2 levels but – at the same time 
– LCL161 did not change the time course of IAP degradation and procaspase processing (Fig. 
3.26). SRB viability assays also showed that LCL161 does not sensitize HeLa cells to Cisplatin 
at the chosen dose of 1µM (Fig. 3.25I). In summary, on a population-based level, low-dose 
IAP treatment appeared to have no discernible effect. We, therefore, asked next whether an 
effect could be visible at the single-cell level. 
Figure 3.25 – Validation of LCL161, a small molecule inhibitor of inhibitor of apoptosis (IAP) family 
proteins 
A-C: mRNA levels normalized to GAPDH of three IAP family proteins in response to treatment with 100 µM 
Cisplatin shown for parental HeLa and HeLa-BAK cells. Shown are mean with upper and lower limits of four 
independent experiments. 
D, F: Parental HeLa and HeLa BAK were treated with indicated doses of LCL161 for 16 hours (D) or 1 hour (F) 
and lysates used for Western Blot. The asterisk indicates a reported non-specific band of unknown origin for c-
IAP2 (Varfolomeev et al., 2007 and antibody data sheet). 
E, G: Quantification of Western Blot in D and F. 
H: Representative DIC images acquired with a BIO-RAD ZoeTM imager for HeLa parental cells treated with 1 µM 
LCL161 or DMSO as solvent control for 16 hours. 
I: Viability of parental HeLa and HeLa-BAK cells in response a 24-hour treatment with increasing doses of 
Cisplatin. Cells were pre-treated with 1 µM LCL161 or DMSO for 16 hours prior to addition of Cisplatin. DMSO 
samples are from same data as shown in Fig. 3.6I. Mean and standard deviation for technical replicates of one 
experiment are shown. 
D-I: Data from a single experiment each for panels D-E, F-G, H and I. 
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Thus, we performed multiplexed caspase-2/-3/-9 imaging using HeLa-BAK cells. Cells were 
pre-treated with LCL161 for 16 hours and we confirmed that prolonged exposure to LCL161 
and time-lapse imaging in the absence of Cisplatin did not affect cell viability (Fig. 3.27A). At 
the single-cell level, low-dose LCL161 caused a decrease in the activation rate of caspase-2 
and caspase-3 and the maximum REA (Fig. 3.27B, E and quantified in panel H-I). Additionally, 
the prevalence of the c2/3 population increased from a 19% found in matched controls to 29%  
upon LCL161 treatment, an increase that is matched by a drop of the c2/c3/c9 population (Fig. 
3.27D, G). These changes were also accompanied by a significant delay in the time of cell 
death (median time to death: 10.8 hours to 12.9 hours; Fig. 3.27J). The same trend was 
observed in the time of caspase-3 activation (Fig. 3.27K). This delay coincides with an increase 
in the prevalence of necrotic phenotypes (from <2% to 18%; Fig. 3.27L-M). However, when 
analysing the caspase response by phenotype in LCL161-treated cells, necrotic cells show no 
enrichment in non-c2/c3/c9 responses (Fig. 3.27N-O). 
Taken together, these results suggest that the subtle caspase network perturbation by low, 
nontoxic doses of clinically relevant inhibitor results in a shift in cell fate from apoptosis to 
necrosis; these differences are invisible to population measurements, but are important, 
because the type of cell death can have a strong influence on treatment efficiency in vivo, by 
promoting or avoiding an inflammatory response (Crusz and Balkwill, 2015).  
Since we could not demonstrate that the c2/c3 population is identical to the necrotic cells (Fig. 
3.19) and necrotic cells were not always over-represented in non-c2/c3/c9 populations (Fig. 
3.27N-O), we hypothesized that caspase-9 is dispensable for the execution of either death cell 
fate (apoptosis or necrosis) in HeLa cells; however, caspase-9 is required for a fast execution 
of cell death that in turn favour apoptosis over necrosis. When caspase-9 activity is reduced 
naturally in a population of cells or by perturbation of the caspase network through direct 
inhibition with caspase inhibitors (Fig. 3.23-25) or indirectly by inhibition of IAPs (Fig. 3.27), 
cells execute cell death slower and are thus more likely to die from necrosis. 
Figure 3.26 – Effects of LCL161 on procaspase processing and IAP dynamics 
A: Western Blot of lysates from parental HeLa and HeLa-BAK cells treated with 100 µM Cisplatin and harvested 
at indicated time points. Cells were pre-treated with 1 µM LCL161 for 16 hours prior to Cisplatin addition. The 
asterisk indicates a reported non-specific band of unknown origin for c-IAP2 (Varfolomeev et al., 2007 and 
antibody data sheet). 
B-G: Quantification of Western Blot in A for IAP (B-D) and procaspase (E-G) levels. 
All data from a single experiment. 
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Inhibition of MEK and AKT kinases affects caspase dynamics and cell fate 
To test this hypothesis, we decided to use a perturbation that would enhance caspase 
activation. If our hypothesis was correct, a perturbation of the network that leads to faster and 
higher caspase activation should exacerbate the apoptotic phenotype in contrast to necrosis.  
The activity of caspases is regulated by a number of post-translational modifications including 
phosphorylation (Parrish et al., 2013). Among others, caspase-9 is inhibited through 
phosphorylation by ERK at Thr125 (Allan et al., 2003) and AKT kinases at Ser196 (Cardone 
et al., 1998).  
In a pilot experiment, we used U0126, a MEK inhibitor which prevents ERK activation (Akinleye 
et al., 2013), and Afuresertib, a clinical-grade Akt inhibitor (Spencer et al., 2014), to derepress 
caspase-9 and accelerate cell death induced by Cisplatin. As for LCL161, we used doses that 
in the absence of Cisplatin did not affect viability (Fig. 3.28A-C) to attribute any changes in fate 
to the drug combination. We found that use of the inhibitors, either alone or in combination, 
resulted in an increased activity of all caspases as judged by the maximal REA values of each 
caspase with the effect being most pronounced in the c2/c3/c9 population when both inhibitors 
are used in combination, suggesting a synergism (Fig. 3.28D-K). Indeed, the synergism is 
demonstrated in the time of cell death and caspase-3 activation, where the combination, but 
not the single treatments, resulted in earlier death and caspase activation (Fig. 3.28T-U). 
Importantly, in support of our hypothesis, acceleration of cell death did not increase the 
Figure 3.27 – IAP inhibition alters caspase dynamics, time and frequency of type of cell death in response 
to Cisplatin 
A: Representative images of HeLa-BAK cells treated with 1 µM LCL161 for a total of 32 hours before and after 
16 hours of imaging of caspase dynamics. Scale bar is 50 µm. 
B-C, E-F: Relative enzymatic activity of caspase-2, -3 and -9 in HeLa-BAK cells treated with 100 µM Cisplatin. 
Cells were pre-treated for ~16 hours with 1 µM of LCL161 (E-G) or DMSO (B-D). Shown are synchronized, 
bootstrapped averages and confidence intervals for two caspase response classes. Vertical bars in E-F indicate 
maximum REA of matched DMSO control in B-C for direct comparison.  
D, G: Prevalence of caspase response classes for cells treated as B-C and E-F, respectively. 
H-I: Distribution of maximum activation rate (H) and REA at the end of the experiment (I) calculated from 
sigmoidal fits for each caspase in the c2/c3/c9 response class only.  
J-K: Time of the appearance of a death phenotype (J) or 50% caspase-3 activity (K) with or without LC161 and 
classified by cell death phenotypes. Shown are single cells with median and interquartile range overlaid in red. 
Significance was tested using the Kruskal-Wallis Test followed by a Dunn’s Multiple Comparison Test. 
L-M: Prevalence of cell death phenotypes in the absence (L) and presence (M) of LCL161 treatment. 
N-O: Caspase response classes in the presence of LCL161 shown for ‘shrunk’ (N) and combined ‘bleb’/’shrunk-
bleb’ cells. 
Data from four independent experiments. 
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prevalence of the necrotic phenotype (Fig. 3.28P-S). Finally, no striking difference in the 
prevalence of the c2/c3/c9- and c2/c3- populations could be observed, suggesting that 
phosphorylation of caspase-9 by ERK and AKT is not responsible for determining caspase-9 
activity in these populations (Fig. 3.28L-O). We acknowledge that these results are  
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preliminary and subject to high uncertainty owing to the small number of cells analysed, and 
require confirmation.  
Still, if confirmed in further experiments, the effect of MEK and AKT inhibition supports the 
hypothesis that the dynamics of the caspase network is critical to determine a balance between 
apoptosis and necrosis. The activation of caspases is heterogeneous in time and typology. 
However, when caspases are activated, cell death will occur, but the longer a cell spends to 
trigger apoptosis, the more likely it will die from necrosis or survive. Clinical interventions 
should be therefore designed not just to trigger cell death, but to act on caspase network 
dynamics to unleash a prompt apoptotic response.  
3.4 Discussion 
Non-genetic heterogeneity of genetically identical tumour cells is an emerging concept 
underlying early oncogenesis, progression and treatment of cancers (Almendro et al., 2013; 
Caiado et al., 2016; Liang et al., 2014). In this work, we focussed on the role of non-genetic 
heterogeneity in response to the clinical DNA-damaging drug Cisplatin. In the first instance, 
non-genetic heterogeneity to Cisplatin treatment leads to so-called ‘fractional killing’, where 
only a fraction of cells are killed, an effect that can be determined by cell-to-cell variation in 
p53 dynamics (Berndtsson et al., 2007; Paek et al., 2016). Moreover, cells can trigger different 
Figure 3.28 – Inhibition of MEK and AKT kinases accelerates caspase dynamics and cell death 
A: Viability of HeLa-BAK cells treated for 20 hours with increasing doses of MEK inhibitor U0126 and AKT inhibitor 
Afuresertib. 
B: Western Blot of lysates from HeLa-BAK cells treated with 7.5 µM U0126, 5 µM Afuresertib or both for 2 hours. 
The ratio between phosphorylated and unphosphorylated Erk and Akt is indicated relative to the vehicle control 
as a measure of pathway activation. 
C: Representative DIC images of HeLa-BAK cells treated for 20 hours on the microscope stage with indicated 
inhibitors in the absence of Cisplatin. Images were acquired using a BIO-RAD ZoeTM imager. 
D-K: Relative enzymatic activity of caspase-2, -3 and -9 in HeLa-BAK cells treated with 100 µM Cisplatin. Cells 
were pre-treated for 2 hours with 7.5 µM U0126, 5 µM Afuresertib or both as indicated. For the c2/c3/c9 
population, vertical bars indicate maximum REA of the matched DMSO control for direct comparison. Shown are 
synchronized, bootstrapped averages and confidence intervals for two caspase response classes.  
L-O: Prevalence of caspase response classes for cells as treated in D-K. 
P-S: Prevalence of cell death phenotypes for cells as treated in D-K. 
T-U: Time of 50% caspase-3 activity (T) or the appearance of a death phenotype (U) for cells from all caspase 
response classes. Shown are single cells with median and interquartile range overlaid in red. Significance was 
tested using the Kruskal-Wallis Test followed by a Dunn’s Multiple Comparison Test. 
Data are from a single experiment each for panels A, B, C, and D-U. 
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cell death programs such as apoptosis, necrosis and a plethora of different other death sub-
types (Montero et al., 2002; Pestell et al., 2000; Segal-Bendirdjian and Jacquemin-Sablon, 
1995) with implications for the overall effectiveness of treatment. Mechanistic insights into non-
genetic heterogeneity in response to chemotherapeutic drugs are scant and better models 
describing cell fate choices are necessary. Better models will eventually permit to design 
chemical interventions in order to maximize the desired phenotypic output, including avoiding 
fractional killing and triggering more desirable cell death programmes, aiming to optimize the 
efficiency of treatment.  
Caspases mediate the response to Cisplatin treatment 
Studies comparing genetically distinct cell lines that are resistant or sensitive to Cisplatin have 
suggested caspases as key factors in the response to drug treatment. Resistant cells do not 
activate specific caspases or caspases in general in response to Cisplatin (Kuwahara et al., 
2003; Liu et al., 2002; Mueller et al., 2003; Vakifahmetoglu et al., 2008) and show an increase 
in necrotic phenotype (Vakifahmetoglu et al., 2008). In genetically identical cells, heterogeneity 
with respect to timing and dynamics of individual caspases has been described (Spencer et 
al., 2009; Tyas et al., 2000) as well. However whether non-genetic heterogeneity in the 
dynamics of the network of caspases contributes to the response to Cisplatin is broadly 
uncharacterized because of lack of suitable single-cell assays, a limitation we have now 
overcome. Most previous work on caspases studied as an interconnected network of enzymes 
has been done by ensemble measurements and lacked the spatio-temporal resolution to study 
cell-to-cell variability. 
Using our novel three-colour multiplexing platform, we could show for the first time that 
heterogeneity in the dynamics and network topology of caspase-2, -3 and -9 determines timing  
and type of cell death in a clonal population. Cells with insufficient activation of the caspase 
network die later suggesting an increased tolerance to Cisplatin. Such cells also showed an 
increased prevalence of necrotic cell death. Crucially, targeted perturbation of the caspase 
network using low doses of clinical inhibitors of IAP proteins, MAPK pathway and AKT kinase 
permitted us to alter the timing and cell fate after Cisplatin treatment highlighting the 
importance of single-cell biochemical measurements in designing cancer treatments. The 
dynamics and heterogeneity of the biochemical networks driving the phenotypes that drugs 
are aimed to trigger or to target should be regarded as actionable targets in their own virtue. 
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 Deconvolution of subpopulation in caspase dynamics 
A key finding of this work is the existence of three major populations of cells with distinct 
caspase activation order, dynamics and time of cell death (Fig. 3.29A-B). One population 
activates all caspase-2, -3 and- 9 (‘c2/c3/c9-population’), and one lacks caspase-9 activation 
and triggers cell death on average 2.5 hours later (‘c2/c3-population’). We also found a 
population of cells that do not activate any caspase, of which one-third dies with a delay similar 
to the c2/c3-population. Two-thirds of the cells that do not activate caspases survive until the 
end of the 16-hour-experiment we performed, suggesting a significant presence of fractional 
killing as reported previously (Berndtsson et al., 2007; Paek et al., 2016). 
Identification of a putative caspase-2 and caspase-3 feedback loop 
The two populations that activate caspases have in common that caspase-3 activation appears 
to be upstream of MOMP as well as caspase-9 activation. In the c2/c3/c9 population, caspase-
3 activation appears near simultaneous with caspase-2, while in the c2/c3 population, 
caspase-3 precedes caspase-2 activation by ~10 min (Fig. 3.12H). The large number of cells 
measured for both populations (315 and 119, respectively) and the high reproducibility across 
the 12 experiments analysed for this quantification provided high confidence about the relative 
timings of caspase-2 and -3.  
Mechanistically, the near-simultaneous activation of caspase-2 and -3 suggests the existence 
of a positive feedback loop that increases the levels of active caspases rapidly, resulting in 
bistable dynamics. While a feedback from caspase-3 to caspase-2 has been previously shown 
in vitro and in cells (Van de Craen et al., 1999; Inoue et al., 2009), a caspase-2-mediated 
processing of caspase-3 has so far not been reported, although hinted to (Puccini et al., 
2013b). However, caspase-2 cleaves substrates containing the IETD motif present in  
procaspase-3 in vitro (Thornberry et al., 1997) and early unpublished studies have shown that 
caspase-2 exhibits procaspase-3 processing capabilities in vitro (Sharad Kumar, personal 
communication).  
This possibility has been perhaps dismissed because of the limited specificity of the sensor 
constructs for the respective caspases. However, we observed a delayed caspase-2 response 
in c2/c3 cells and identify cells that only show activation of an individual caspase sensor, 
suggesting specificity (both in the absence (Fig. 3.12) and presence of caspase inhibitors (Fig. 
3.23)). These observations are possible only by biochemical multiplexing in living cells;  
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therefore, it has not been possible to evaluate the specificity of substrates in the cell until now. 
Taken together, our data suggest that the optimized motifs, thoroughly discussed in Chapter 2 
of this dissertation, have sufficient specificity to discern the activities of different caspases. 
In c2/c3 cells (Fig. 3.29B), the delay between caspase-3 and -2 suggests that the putative 
feedback loop between caspase-2 and-3 is less efficient or inactive. Indeed, we observed a 
 
Figure 3.29 – Hypothetical model of caspase dynamics and cell fate in response to Cisplatin 
A: In the c2/c3/c9 population caspase activation is predominantly triggered via activation of caspase-2 which 
activates caspase-3 thereby initiating a feedback loop. Both caspase-2 and -3 cleave BID to induce MOMP 
leading to initial caspase-9 activation. Caspase-3 can process caspase-9 from the lower to higher activity form 
which then enhances caspase-3 activity in a feedback loop. Caspase-9 activity is further enhanced by an implicit 
XIAP-mediated feedback loop where active caspase-3 sequesters XIAP away from caspase-9. Together, this 
results in a switch-like activation of caspase-3 (graph inset). 
B: In c2/c3 cells, low levels of cIAP1/2 promote late caspase-3 activation via caspase-8, which subsequently 
activates caspase-2. This activation is insufficient to trigger the caspase-2/-3 feedback loop and results in sub-
optimal activation of caspase-3 which is not sufficient to process caspase-9 into its high-activity form, thus, 
interrupting the caspase-9/-3 feedback loop. Additionally, XIAP levels are insufficient to effect caspase-9 activity 
through the caspase-3 to -9-arm of the feedback loop. Together, these changes result in a shift of caspase-3 
activity to a more gradual and subdued response (graph inset). 
C: Model of the effect of XIAP expression levels on caspase dynamics based on the models by Legewie et al. 
(2006) and Schmid et al. (2013). Very low levels lead to spontaneous caspase activation, while very high levels 
prevent caspase activation completely.  High intermediate levels allow an efficient and fast activation of 
caspase-3, as observed in the c2/c3/c9 population, while at a lower level, the XIAP-mediated feedback loop is 
abrogated, resulting in shallower and less efficient caspase-3 activation. Based on our experimental results, the 
difference between HeLa and U2OS could be due to different XIAP expression levels as indicated. 
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decrease in maximal enzymatic activity and activation rate (Fig. 3.12) indicating a sub-optimal 
caspase-2 and -3 activation. Thus, the proposed feedback loop appears necessary for an 
optimal caspase activation. Two non-mutually exclusive mechanisms might explain the 
deregulation of a feedback loop in c2/c3 cells. First, we will discuss how a change in the 
upstream mechanism leading to triggering caspase-3 could affect the loop, and, second, 
investigate the role of caspase-9. 
A switch from caspase-2- to caspase-8-induced network in c2/c3 cells could affect 
caspase dynamics and time of cell death 
Processing and activation of caspase-3 depend on caspase-8 and caspase-9 activities (Van 
de Craen et al., 1999), or — as we suggest in this study — on the activity of caspase-2. A 
direct activation of caspase-3 in the absence of either of these three initiator caspases in 
response to DNA damage has not been observed so far. We therefore hypothesized that in 
c2/c3/c9 cells, caspase-2 is activated slightly before caspase-3, at a time difference below our 
time resolution, through mechanisms that have been shown to activate caspase-2 directly in 
response to DNA damage, including the formation of the PIDDosome (Ando et al., 2012) or 
PIDDosome-independent mechanisms (Manzl et al., 2009; Olsson et al., 2009, 2014; 
Vakifahmetoglu et al., 2006). Caspase-2 then activates caspase-3 through processing forming 
the suggested feedback loop leading to efficient, switch-like caspase activation. While the 
small time difference between caspase-2 and -3 argues for a direct mechanism, at this stage, 
we cannot exclude any indirect mechanisms involving additional proteins. 
In contrast, in c2/c3 cells, caspase-2 is activated downstream of caspase-3. With caspase-9 
not activated, caspase-8 remains the only candidate for caspase-3 activation in those cells. 
Indeed, we provided some preliminary support for a role of caspase-8 upstream of caspase-3 
in a population of cells that trigger caspase-3 activity later (Fig. 3.16). The ~25 min delay of full 
caspase-8 activation relative to caspase-3 is in line with previous single-cell studies (Kawai et 
al., 2005) and likely due to the amplification loop between caspase-3 and -8 (Viswanath et al., 
2001). Experiments to study caspase-8, -3 and -9 simultaneously are currently ongoing to 
confirm that the cells with early caspase-8 activation are identical to the c2/c3-population. If 
confirmed, a caspase-8-mediated pathway in c2/c3 cells could also explain the subdued 
caspase-3/-2 response, possibly because the described feedback loop is insufficiently induced 
when caspase-3 is triggered by caspase-8 and not by caspase-2. However, we are not aware 
of any experimental reports that directly compare the efficiency of the caspase-2 and caspase-
8-mediated caspase response. Notably, caspase-8 has been shown to activate caspase-2 in 
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response to DNA damage using Western Blot (Olsson et al., 2009), but our data so far suggest 
that caspase-3 is the preferential target for caspase-8 processing. Imaging caspase-2, -3 and 
-8 together using our platform will allow us to address their relative timing at a single-cell level. 
The relevant experiments are currently in preparation. On a further note, the cause for a switch 
from caspase-2 to caspase-8-mediated caspase-3 activation remains an open question. In a 
later section, we will discuss how IAP family proteins could be involved in this mechanism. 
Apart from being a possible explanation for the deregulation of the putative caspase-2/-3 
feedback loop, the activation of caspase-3 via caspase-8 in c2/c3 cells could also explain the 
~2.5 hours delay of caspase activation compared to c2/c3/c9 cells. Caspase-8 activation 
requires de novo expression of FAS ligand to induce the formation of the caspase-8-activating 
DISC complex which requires at least several hours (Brozovic et al., 2004; Micheau et al., 
1997; Müller et al., 1998). In contrast, factors crucial for caspase-2 activation including the 
PIDDosome are generally considered to be constitutively expressed and quickly activated in 
response to DNA damage (Ando et al., 2012). Inhibition of de novo protein synthesis with 
Cycloheximide would allow testing this hypothesis experimentally.  
In summary, we showed evidence that caspase-2 and -3 are activated upstream of caspase-9 
activation in Cisplatin-treated HeLa cells and suggest a positive feedback loop that is required 
for complete and fast caspase activation. In a population of cells, characterized by the absence 
of caspase-9 activation, cell death is delayed by ~2.5 hours possibly because of a caspase-8-
dependent activation. Next, I will discuss the role of caspase-9. 
 
Caspase-9 could promote caspase-3 activation in a second feedback loop 
The c2/c3/c9 and c2/c3 populations are not only characterized by the differences in 
caspase-2/-3 dynamics but crucially by the presence or absence of caspase-9 activation (Fig. 
3.29A-B). In the former population, caspase-9 is consistently activated ~25 min after caspase-2 
and -3. Notably, the delay between caspase-3 activation and the occurrence of a death 
phenotype is about 22 minutes. In independent experiments, we estimated the delay between 
cell shrinkage and MOMP to about 17 minutes. These measurements and the canonical model 
for caspase-9 activation suggest that caspase-9 acts downstream of MOMP and slightly 
precedes the dramatic morphological changes occurring during apoptosis (Fig. 3.29A). 
Caspase-9 is activated by CYTC aiding apoptosome assembly (Rodriguez and Lazebnik, 
1999) when, after MOMP, CYTC translocates to the cytoplasm. The primary role of caspase-
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9 is thought to activate caspase-3 (Galluzzi et al., 2012); however, our data suggest that 
caspase-3 is active before caspase-9, probably even before the occurrence of MOMP. 
Therefore, caspase-9 seems to be dispensable for caspase-3 activation. However, those cells 
that robustly trigger caspase-9 activated caspase-3 early and at higher rates, suggesting that 
the known caspase-3 – caspase-9 feedback loop (Blanc et al., 2000; Lakhani et al., 2006; Wu 
et al., 2016) is dispensable during Cisplatin response in HeLa cells, but is crucial for a fast 
response. This notion is supported by the observation that caspase-9 activation occurs at a 
time before caspase-3 reaches its maximum activity, suggesting that caspase-9 activity is 
required for full caspase-3 activation (Fig. 3.12A), which in turn could be required for the 
caspase-2/-3 loop discussed earlier. 
Importantly, a loop between caspase-3 and caspase-9 could also explain the apparent lack of 
caspase-9 activation in the c2/c3 population. Caspase-9 exhibits two activity states in vitro, an 
early moderate activation followed by a later high activity state promoted by caspase-3 
cleavage (Wu et al., 2016). Thus, for full activation caspase-9 requires caspase-3 processing. 
In c2/c3 cells, the reduced caspase-3 activation could be insufficient to process caspase-9, 
which therefore remains in the moderate activity form. This lower activity could be below the 
detection limit of the caspase-9 sensor in analogy to what we and others have observed for 
caspase-8 (Fig. 3.16; Albeck et al., 2008), leading to an apparent lack of caspase-9 activation 
in this population. Clearly, this poses the question what comes first, the insufficient activation 
of caspase-3 that leads to a low caspase-9 activity, or a low caspase-9 activity that leads to 
insufficient caspase-3 activation. We are carrying out experiments addressing this question 
using a caspase-9 sensor with a double substrate as for the caspase-8 experiments.  
However, whether caspase-9 is working upstream of caspase-3 or not, our data 
incontrovertibly demonstrate the existence of non-genetic heterogeneity in caspase-9 
activation. In some cells, caspase-9 contribute to a prompt apoptotic response, in others, the 
caspase-9 is not prominent and the activation of all caspases is reduced.  
Lack of caspase-9 has no clear effect on time from caspase-3 activation to cell death 
Interestingly, the reduction of caspase-2 and -3 activities in c2/c3 cells relative to the c2/c3/c9 
population seems to have limited effect on the lag-time between caspase-3 activation and the 
onset of cell shrinkage. This surrogate measure for the speed of the execution of cell death 
was estimated at ~25 min in both populations (Fig. 3.19K). This suggests that once caspase-3 
is activated apoptosis is executed efficiently and independently of caspase-9.  
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This observation also raises the more general question whether the lack of caspase-9 is the 
cause for the characteristic delay of the c2/c3 population. While the lack of caspase-9 
activation is a striking marker of the c2/c3 population and possibly affects the efficiency of 
caspase activity in a feedback loop, its activation after caspase-2 and -3 argues that it cannot 
be a causal mechanism for the delay of the initial caspase induction and cell death. Also, the 
shift from caspase-2 to caspase-8 discussed above appears to be a good explanation for the 
delay in cell death. Together, this suggests that both the lack of caspase-9 activation as well 
as the shift to a delayed, caspase-8 mediated caspase network, could be the result of a 
common mechanism. Therefore, caspase-9 could, in our experiments, function as a marker 
for the identification of this mechanism, whose discovery could aid rational design of treatments 
to alter cell fate in response to DNA-damage.  
 IAP family proteins as a common mechanism for caspase-9 
inhibition and delay in cell death 
Therefore, we studied several candidates for the mechanism of caspase-9 inhibition. As we 
have established a new, formerly untested, technique, we also invested significant time in 
excluding possible sources of artefacts. However, different FRET pairs (Fig. 3.13) and cell 
lines (HeLa parental with transient transfection (Fig. 3.13), HeLa-BAK (Fig. 3.12) and U2OS 
(Fig. 3.21)) all confirmed the delay between caspase-3 and caspase-9 upon treatment with 
Cisplatin. Interestingly, in U2OS the c2/c3 population was negligible suggesting inter-cell line 
variability in the underlying mechanism as we will discuss below. 
Next, we tested the hypothesis that inhibition of caspase-9 activation is dependent on cell cycle 
as CDK-dependent mechanisms of caspase inhibitions are known and cell cycle is a common 
source of non-genetic heterogeneity. We show that there is no cell cycle dependency in the 
phenotypes observed (Fig. 3.15). We also tested the possibility that partial MOMP (Ichim et 
al., 2015) in a subpopulation of cells could cause the observed heterogeneity. However, all 
dying cells execute MOMP efficiently (Fig. 3.14).  
We also used two inhibitors against MEK and AKT, kinases that are known to inhibit caspase-9. 
Interestingly, MEK and AKT inhibitors combined do increase caspase-9 activity significantly 
resulting in a faster apoptotic response. However, these inhibitors failed to abrogate the c2/c3 
population, suggesting that MAPK and PI3K pathway activities do not cause the heterogeneity 
in caspase-9 activation we have observed (Fig. 3.28).  
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IAP family proteins as key candidates to set caspase dynamics and cell fate 
However, when using LCL161 to inhibit IAPs, the prevalence of the c2/c3-population increased 
significantly. The corollary to this observation is that, paradoxically, the inhibitory IAPs promote 
caspase-9 activation in untreated HeLa cells. At the same time, the activation rate and 
maximum activity were reduced for all caspases when IAPs are inhibited (Fig. 3.27) also in the 
c2/3/9 population. This apparently paradoxical observation is in agreement with a model for 
XIAP-mediated feedback loop with caspase-3 proposed by Legewie and colleagues (Legewie 
et al., 2006; Schmid et al., 2012). When XIAP expression is very low, caspase-3 activation 
occurs spontaneously in the absence of a pro-apoptotic stimulus, a phenomenon we did not 
observe (Legewie et al., 2006; Fig. 3.29C). However, intermediate levels of XIAPs interfere 
with caspase-3/-9 positive feedback loop resulting in a shallower, less efficient, response of 
the proteases. With increasing XIAP levels, the activation of caspase-3 becomes sharper and 
more efficient up to a point where all caspase activity is inhibited (Fig. 3.29C). Our experimental 
results are coherent with these predictions. Therefore, this model would also predict that cell-
to-cell variability in XIAP expression or activity would alter caspase-9 activity and the overall 
dynamics of the caspase network.  
Moreover, variation in the expression or activity of two other IAPs might play a similar role in 
the time of onset of caspase activation and subsequent cell death. cIAP1 and 2 inhibit the 
formation of a version of the caspase-8 activating DISC complex (Petersen et al., 2007; 
Varfolomeev et al., 2007b; Vince et al., 2007). Accordingly, in recent studies, LCL161 treatment 
was shown to promote caspase-8-mediated cell death (Qin et al., 2014; Yang et al., 2016). 
Pending confirmation of our preliminary results that identify caspase-8 as the apical caspase 
in the c2/c3 population, LCL161 would increase this caspase-9-negative population as 
observed here. 
Interestingly, a recent study suggested a differential role for IAPs in caspase-8-dependent or 
independent apoptosis in response to Cisplatin (Paek et al., 2016). In HCT116 treated with 
Cisplatin, cIAP1/2 inhibit caspase-8 dependent apoptosis, whereas XIAP and MLIAP inhibit 
caspase-8 independent apoptosis, and together they appear to set a threshold for p53 
activation to induce the respective type of apoptosis. This study was limited to the imaging of 
p53 dynamics of single cells and did not provide single-cell information about caspase network 
or IAPs dynamics; however, this work suggests that the complex interactions of the IAPs with 
the apoptotic machinery can have a profound effect on cell fate choices in response to DNA 
damage. In support of a differential role for IAPs in fine-tuning the caspase response, we 
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observed that cIAP1/2, but not XIAP, are induced transcriptionally at an early time point (Fig. 
3.25). This difference in the IAPs dynamics could delay the caspase-8 dependent pathway 
facilitating early apoptosis by caspase-8-independent mechanisms in the absence of LCL161. 
In summary, we can speculate that the c2/c3 population might be characterized by low levels 
of IAPs, where low XIAP results in a less efficient caspase-9/-3 activation feedback loop and 
a subdued caspase response, while low levels of cIAP1/2 might promote caspase-8 dependent 
apoptosis with a lag-time relative to the c2/c3/c9-population (Fig. 3.29).  
Monitoring and modulating IAP levels could elucidate their role at a single-cell level  
The direct experimental falsification of the hypothesis that cell-to-cell variability in IAPs causes 
the heterogeneity in caspase dynamics and cell death timing we observed would require 
single-cell measurements of IAP expression. As the level of multiplexing we have achieved 
was already unprecedented, we could not directly test this hypothesis with fluorescence-based 
assays run simultaneously with the multiplexing of caspase activities. Furthermore, IAP 
measurements in live cells would ideally be done by labelling IAPs at the endogenous gene 
locus using gene editing such as CRISPR/Cas9 in order to not inhibit caspases with ectopic 
expression of IAPs.  
Finally, U2OS cells did not exhibit a substantial c2/c3 population.  We are therefore evaluating 
XIAP expression levels of the two cell lines and its heterogeneity in expression with flow 
cytometry to test if XIAP heterogeneity alone could explain the different phenotypes we 
observed. If our model was of more general validity, siRNA-mediated knockdown of XIAP or 
treatment with LCL161 should shift U2OS cells to a more HeLa-like phenotype, including an 
increase in the c2/c3 population and a decrease in the caspase dynamics (Fig. 3.29C).  
In summary, simultaneous monitoring of three caspases in response to Cisplatin allowed us to 
identify two populations with distinct caspase dynamics and time of cell death. Direct single-
cell measurements of cascades of caspases suggest a shift from caspase-2 to caspase-8-
mediated induction of the caspase network plausibly determined by differential activities of IAP 
family proteins. Furthermore, caspase-2 or caspase-9 have been both described as apical 
caspases in response to DNA damage (Tab. 3.1), but our results clearly suggest a role for 
caspase-2 upstream of caspase-9 in Cisplatin-treated HeLa cells (in line with Lassus et al., 
2002; Olsson et al., 2009; Robertson et al., 2002; Vakifahmetoglu et al., 2008). Next, we aimed 
to understand whether the observed differences in caspase dynamics not only determine the 
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time of cell death but also the type of programmed cell death (e.g., apoptosis or necrosis) 
triggered.  
 Heterogeneity in the type of cell death 
Cisplatin-treated HeLa cells show a continuum of apoptotic and necrotic cell death 
We confirmed that genetically identical cells can trigger both apoptotic and necrotic cell death 
in response to Cisplatin as observed by others (Montero et al., 2002; Pestell et al., 2000; Segal-
Bendirdjian and Jacquemin-Sablon, 1995). For simplicity, we classified three phenotypes, 
‘shrunk’, ‘bleb’ and ‘shrunk-bleb’ that exhibited classical morphological characteristics of 
apoptosis, necrosis or both, respectively (Fig. 3.17). However, the classification was not 
unambiguous and required blind marking from different scientists. The presence of 
intermediate phenotypes suggests a continuum of cell death phenotypes, rather than the 
existence of very precise cell categories. With Annexin-V/7AAD co-staining we confirmed the 
coincidence between the ‘shrunk’ and ‘bleb’ scored cells as apoptotic and necrotic, 
respectively (Fig. 3.17), and with ‘shrunk-bleb’ cells potentially being necrotic. Nonetheless, 
we note that there is likely overlap between the classes and in particular regarding the ‘shrunk-
bleb’ phenotype that consistently shows intermediate characteristics.  
 
 
Identification of the type of necrotic cell death in response to Cisplatin 
A large number of different types of necrotic cell death types have been described in the 
literature (Berghe et al., 2014; Galluzzi et al., 2012). One form of regulated necrosis, termed 
‘necroptosis’ has received considerable attention in recent years (Wallach et al., 2016). 
Experimentally, necroptosis is usually induced by combining pan-caspase inhibition, IAP 
inhibition and induction of the extrinsic pathway using TNFα (Feoktistova et al., 2011; Tenev 
et al., 2011). These conditions are reminiscent of those linked to the mechanism we 
hypothesized for c2/c3 cells that exhibit lower caspase activation, IAP inhibition and shift to the 
extrinsic pathway. Moreover, necroptotic cells are reported to resemble our ‘bleb’ phenotype 
defined by the occurrence of membrane blebbing in the absence of cell shrinkage (Gong et 
al., 2017). However, the co-occurrence of Annexin-V and 7-AAD excludes necroptosis as a 
mechanism for the necrotic phenotypes observed in our study, because in contrast to other 
necrotic pathways, in necroptosis, PS externalization precedes loss of membrane in integrity 
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(Gong et al., 2017). Furthermore, since ‘bleb’ cells still activate caspases, contrary to the 
definition of necroptosis, and HeLa cells do not express RIPK3, necroptosis is likely not the 
type of necrosis we observed. 
Parthanatos, a form of necrotic cell death characterized by hyperactivation of PARP and 
ATP/NAD+ depletion, is an alternative identity for the necrotic cell death observed in our 
experiments (Fatokun et al., 2014). As introduced in section 3.1.3, Cisplatin has been shown 
to result in a depletion of ATP in a time-dependent manner (Zhou et al., 2002) and the level of 
ATP has been found to determine the cellular decision between apoptosis or necrosis (Eguchi 
et al., 1997; Leist et al., 1997). Therefore, the delay of cell death observed for necrotic 
phenotypes in our experiments fits with death by Parthanatos, because at this later time point 
ATP could be sufficiently depleted to shift the cell fate away from apoptosis. Furthermore, the 
occurrence of MOMP in all dying cells regardless of the phenotype argues for Parthanatos 
since the presence of MOMP distinguishes it from other necrotic cell deaths (Fatokun et al., 
2014). However, one key feature of Parthanatos is not observed in our work, which is that its 
induction is considered independent of caspase activity. When using a pan-caspase inhibitor 
we observed that ~90% of the cells survived, and, of the ones that still died in the absence of 
caspase activation, none showed a necrotic phenotype, arguing that the necrotic phenotype 
we observed is caspase-dependent (Fig. 3.18). It should be noted, that in this experiment we 
analysed only 45 cells in total, therefore requiring repetition to further strengthen this 
conclusion.  
In summary, necrotic cells observed here in response to Cisplatin show some key features of 
Parthanatos, but direct experimental validation is required to confirm this association. One 
approach could be to measure ATP levels in cells treated with Cisplatin using the available 
FRET-based biosensors (Imamura et al., 2009; Tantama et al., 2013) replacing one caspase 
sensor in our platform or extending it with additional FRET pairs currently under development. 
Measurement of PARP levels in single cells by labelling of the endogenous locus using gene 
editing is a further possibility to confirm Parthanatos as cell death mechanism.  
Connection of cell death phenotype with caspase dynamics  
In apoptotic cells, caspase-3 inhibits PARP by cleavage preventing further ATP depletion 
required for the execution of apoptosis (Galluzzi et al., 2012), and thus, mechanistically linking 
caspase activity with cellular energy levels and the propensity to die from a necrotic cell death.  
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The connection between the mode of cell death and caspase activity in response to Cisplatin 
has been studied by a number of groups which collectively converged on a model where the 
shift from apoptotic to necrotic cell death functions as a backup mechanism when apoptosis is 
not executed efficiently. Lacking or insufficient activation of caspases has been suggested as 
one reason for such a ‘defective apoptosis’ (Cepeda et al., 2007; Gonzalez et al., 2001; 
Lemaire et al., 1998; Segal-Bendirdjian and Jacquemin-Sablon, 1995; Vakifahmetoglu et al., 
2008). We, therefore, hypothesized that the disruption of the caspase network observed in the 
c2/c3 population of cells and in response to chemical perturbation is the cause for a shift from 
apoptotic to necrotic cell death. Indeed, we observed an increased lag time between caspase-3 
activation and the first occurrence of blebs (Fig. 3.19K), suggesting that in late-dying ‘bleb’ 
cells, cell death is indeed less efficiently activated, or ‘defective’ (Segal-Bendirdjian and 
Jacquemin-Sablon, 1995). We also observed a trend for necrotic cells to exhibit lower caspase-
9 activity (Fig. 3.20) 
Although the data is suggestive of a correlation between the late-dying c2/c3 and the necrotic 
phenotype, we could not establish an identity between c2/3 cells and c2/c3/c9 cell with necrotic 
and apoptotic cells, respectively (Fig. 3.19). However, we did observe an increased likelihood 
for c2/c3/c9 cells to die early, for c2/c3 cells to die later and—at the same time—for necrotic 
and apoptotic cells to die later and early, respectively. Analysis of caspase-9 activities in 
relation to the onset of caspase-3 activation demonstrates a strong anti-correlation (Spearman 
coefficient of -0.4, p<<0.001; data not shown) suggesting that not only we are observing a 
continuum of cell death phenotypes, but also a continuum of caspase network activation 
patterns.  
Therefore, we hypothesised that the role of different mechanisms for cell death is to ensure 
death in the presence of high acute levels of DNA damage. However, different mechanisms 
result in different timing of death onset, with longer lag-times before cell death more likely 
resulting in necrosis. We speculate that the mechanism underlying cell-to-cell variability relates 
to IAPs heterogeneity and that the shift of phenotype may relate to ATP depleting as in 
Parthanatos.  
 Targeted perturbation of caspase dynamics allows fine-tuning 
of cell fate 
In the attempt of falsifying the hypothesis that timing of cell death could be the link between 
the dynamics of caspase network and death phenotypes, we perturbed the caspase network 
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using caspase inhibitors (Fig. 3.22). We found that the decrease in c2/c3/c9 cells coincided 
with the increase of necrotic cell death for all caspase inhibitors. In contrast to Cisplatin 
treatment alone, cells not activating all three caspases were over-represented among cells 
undergoing a necrotic phenotype (Fig. 3.24). Contrary to our expectations, we did not observe 
a significant delay in cell death or caspase activation for any caspase inhibitor, suggesting that 
under these conditions the increase in necrotic cells is independent of the time of cell death 
with the caveat that the number of cells triggering a necrotic phenotypes is small (53 cells) and 
further data may be needed to confirm this observation. Together, the caspase inhibitor data 
suggest that a strong perturbation of the caspase network is sufficient to shift cells from 
apoptotic to necrotic cell death. 
With a more subtle perturbation of the caspase network using a low, non-toxic dose of the IAP 
inhibitor LCL161, the prevalence of the c2/c3-population increased and the onset of cell death 
occurred at a later time; at the same time, the frequency of necrosis increased significantly 
(Fig. 3.27). However, in contrast to the caspase inhibitor experiment, cells not activating all 
caspases were not overrepresented among necrotic cells compared to apoptotic cells. One 
possible reason for this result is that while still activating all caspases above the threshold, the 
rate of activation and maximum activity is also reduced in c2/c3/c9 cells which could explain 
the increase in necrotic cells across all populations. This supports the hypothesis that a 
perturbation of caspase signalling, which can manifest as an increase in the c2/c3 population 
as well as a subduction of activation in all caspases in c2/c3/c9, leads to increased necrotic 
cell death. 
Unleashing caspases by MEK and AKT inhibition accelerates cell death and may 
decrease the prevalence of necrotic cell death 
Finally, to test if a faster caspase activation would decrease the frequency of necrosis, we used 
inhibitors of the pro-survival kinases MEK and AKT. These inhibitors resulted in an increase of 
the activity of all caspases (Fig. 3.28). We could confirm a faster apoptotic process and no 
necrosis, opposite to the LCL161 experiments. We notice, however, that in the matched 
solvent-control we detected only 2 necrotic cells. Therefore, further data is currently acquired 
to confirm this observation. If confirmed, these results are of key importance, because they are 
not only confirming the link between caspase dynamics and cell fate but also suggest that by 
removing the inhibition on caspases cell fate can be shifted from necrosis to an early apoptotic 
cell death. Moreover, MEK and AKT seem to act in synergy. While low-dose single treatment 
is sufficient to alter network dynamics and prevent necrotic cell death, the acceleration of cell 
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death is only observed when cells are treated with both inhibitors. Considering translation into 
cancer treatment, such a synergistic effect and use of low non-toxic doses are key to minimize 
toxicity, and could even allow reducing the Cisplatin dose without losing efficacy in a 
combination treatment. 
In summary, we provided evidence to support the hypothesis that a ‘defective’ caspase 
signalling network, present in a population of cells both prior to chemical network perturbation 
and exacerbated by it, can lead to a continuum of necrotic and apoptotic cell death at the 
population level. While the absence of caspase-9 activation in c2/c3 cells alone is not sufficient 
to induce necrotic cell death, cells with a low caspase activity, including that of caspase-9, are 
more likely to die from a necrotic cell death, possibly because of a delay of cell death under 
certain conditions. In contrast, accelerating cell death and increasing caspase activity shifts 
cell fate towards apoptosis. 
Targeted perturbation of the caspase network could allow modulating cell death 
phenotype in vivo to balance pro- and anti-inflammatory response 
A key feature of necrotic cell death is the inflammation and immune response that it entails, in 
contrast to apoptosis which is considered to be anti-inflammatory (Berghe et al., 2014; Crusz 
and Balkwill, 2015). Conventionally, a reduction of inflammation by promoting apoptosis is 
considered ideal in tumour treatment, but with advances in the understanding of the tumour 
microenvironment and the role of adaptive immunity, it becomes clear that at least some local 
inflammation that promotes antitumour immunity can be beneficial. For example, LCL161, 
which increased necrosis in our assays, has both been shown to promote local anti-tumour 
immunity in melanoma (Chesi et al., 2016), while at the same time reducing viability in a mouse 
model of lymphoma by inducing a detrimental systemic inflammatory response (West et al., 
2016). This dual role strongly argues that pro-inflammatory necrosis and anti-inflammatory 
apoptosis need to be finely balanced to maximize the effectiveness of anti-tumour treatments. 
By investigating cell-to-cell variability that seems key in setting a balance between necrosis 
and apoptosis, we provided mechanistic insights into these cell death choices and underlying 
dynamics in the caspase network. Using this knowledge, we identified strategies to perturb 
network dynamics to shift phenotypes and, thus, demonstrate a powerful proof-of-concept on 
how to develop strategies to achieve the balance between phenotypes. 
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Concluding remarks 
Targeting of network dynamics to elicit specific responses is an emerging concept in 
pharmacology (Behar et al., 2013; Jørgensen and Linding, 2010; Pawson and Linding, 2008). 
Our novel multiplexing platform allowed us to identify heterogeneity in dynamics of multiple 
caspases at the single-cell-level and, thus, recommending this network as a valuable target to 
tune responses to Cisplatin and likely other chemotherapeutic drugs to increase their efficiency 
both by directly sensitizing cancer cells and harnessing anti-tumour immunity.  
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Chapter 4 Overall conclusion and outlook 
We set out to develop an imaging platform that would allow multiplexing of at least three FRET 
sensors in single living cells to measure dynamics of intricate signalling networks and 
connecting them with the cell fate that they encode. 
Going through an intensive phase of rationally designing and improving FRET pairs for three-
colour FLIM, we were successful in creating a suite of three spectrally separated pairs by 
combining bright blue, green and fluorescent donors excitable at a single two-photon excitation 
wavelength with non-fluorescent chromoproteins as acceptors. 
Next, we applied this sensor suite to study the activity of caspase-2, -3 and -9 in response to 
DNA damage. Unexpectedly, we did not only find broad heterogeneity in the timing of caspase 
activation, but we also identified a previously unnoticed heterogeneity in patterns of caspase 
activation with a cell population lacking a robust caspase-9 response and exhibiting delayed 
cell death. The concurrent analysis of signalling dynamics at a single-cell level and cell fate 
permitted to establish a connection between cells that exhibit reduced caspase dynamics and 
those that are more likely to die from a necrotic form of cell death. Our results further suggested 
that cell-to-cell variation of the levels of IAP family proteins could be the underlying cause for 
differences in network topology and dynamics. These novel insights into caspase dynamics 
permitted us to design and test targeted perturbation strategies using clinically relevant 
inhibitors against IAPs as well as pro-survival kinases MEK and AKT to fine-tune caspase 
dynamics and with it delaying cell death and shifting the fate from apoptotic to necrotic cell 
death. In light of the emerging role of inflammation as pro- as well as antitumour mechanism, 
the ability to control the prevalence of pro-inflammatory necrotic cell death could be key to 
maximize treatment efficiency and overcome resistance.  
To further increase the capabilities of the multiplexing platform presented in this dissertation, 
several avenues for future development could be considered. While the simultaneous imaging 
of three-nodes of a network has yielded important insights into its dynamics and heterogeneity, 
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the platform has been designed to be amenable to extension, for example by adding additional 
FRET sensors or complementing it with non-FRET based fluorescent sensors. Moreover, work 
is ongoing to develop light-controlled, optogenetic tools to be able to perform targeted and 
quantitative network perturbation on a subcellular level. The combination of biochemical 
multiplexing and optogenetics will permit us to perform all-optical analysis of biochemical 
networks at the single-cell level. This could enable the generation of mathematical models 
describing biochemical networks at a single-cell level with dynamic information, creating the 
foundations for single-cell systems biology of cell fate.  
Furthermore, the multiplexing platform developed in this work could be used to study a wide-
range of different signalling pathways exploiting the plethora of FRET sensors available to 
date. Indeed, we are currently adapting the sensors to study dynamics of RAS-dependent 
signal transduction pathways. Moreover, while two-dimensional cultures used in this and many 
other studies have given valuable insight into biological questions, three-dimensional cultures 
are emerging as a better model for the situation in vivo. Thus, the increased penetration depth 
of two-photon microscopy could be harnessed to perform multiplexed imaging in three 
dimensions, for example by using tumour spheroids or whole tissues either with a system as 
described in this work or through adaptation of light sheet microscopy. For instance, Baek et 
al. recently showed intra- and inter-cell line heterogeneity of 3D spheroids in response to 
Cisplatin (Baek et al., 2016). We have started to grow spheroid from HeLa-BAK cells and will 
continue to move the multiplexing platform to 3D. 
In summary, the successful development and application of three-colour FRET imaging have 
permitted us to study network dynamics at an unprecedented detail uncovering pronounced 
non-genetic heterogeneity, which we exploited to design novel strategies for modulating cell 
fate in response to DNA damage. As the multiplexing platform is easily adaptable to study a 
wide-range of biological networks, this work could represent the start of a number of in-depth 
investigations into key biological questions whose answers have so far been in hidden in 
inaccessible heterogeneous cell populations.  
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All videos are supplied on a CD attached to this work.  
 
Video S1 - HeLa-BAK cells undergoing Cisplatin induced cell death 
Representative videos of cells treated with 100 µM Cisplatin (right) or 0.9% NaCl (left) as 
control and imaged every 15 min for 16 hours on the multiplexing platform. Composite image 
of maximum projections from mTagBFP and mAmetrine channels are shown. 
 
Video S2 - Dynamics for caspase-2, -3 and-9 activation in HeLa-BAK cells 
Representative animations of cells treated with 100 µM Cisplatin and imaged every 15 min for 
16 hours. Shown are REA of caspase-2 (blue), -3 (green) and -9 (magenta) in a 3D blot relative 
to the uncleavable (unc) controls (upper left) and as trajectory over time (lower left). The 
fractional contribution of cleaved (solid lines) and uncleaved (dashed lines) forms of sensors 
used to calculate REA are shown as a function of time (upper right). Maximum projections of 
images from the three channels are depicted (lower right). 
A: Cell from the c2/c3/c9 population that exhibits a ‘shrunk’ death phenotype. 
B: Cell from the c2/c3 population that exhibits a ‘bleb’ death phenotype. 
 
Video S3 - HeLa parental stained with TMRM undergoing Cisplatin-induced cell death 
Representative field of view of HeLa Parental cells stained with 20 nM TMRM for 15 min and 
treated with 100 µM Cisplatin imaged every 15 min for 16 hours on a Nikon Ti Widefield 
microscope. Shown are DIC (grey) and TRITC (red) channels 
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Video S4 - HeLa-BAK cells stained with TMRM undergoing Cisplatin-induced cell death 
Representative field of view of HeLa Parental cells stained with 20 nM TMRM for 15 min and 
treated with 100 µM Cisplatin imaged every 15min for 16 hours on Leica SP5 confocal laser 
scanning microscope using a 594 nm Argon for excitation of TMRM. Shown are bright field 
(left) and TMRM (right) channels. 
 
Video S5 - HeLa-BAK cells show a continuum of death phenotypes in response to 
Cisplatin 
Representative movies of HeLa-BAK cells undergoing different death phenotypes (as defined 
in Figure 3.17) in response to 100 µM Cisplatin. Left: ‘shrunk’, middle: ‘shrunk-bleb’, right: 
‘bleb’. Not that the middle image also contains a ‘shrunk’ cells (lower cell). Imaging was 
performed on the multiplexing platform. Composite image of maximum projections from 
mTagBFP and mAmetrine channels are shown. 
 
Video S6 - Parental HeLa cells co-stained with TMRM, Annexin-V and 7-AAD undergoing 
Cisplatin-induced cell death 
Representative field of view of parental HeLa cells that were stained with TMRM (top right), 
FITC Annexin-V (lower left) and 7-AAD lower right prior to being treated with 100 µM Cisplatin. 
Imaging was performed on a Nikon Ti wide field microscope every 15 min for 16 hours.   
 
Video S7 - U2OS cells expressing the BAK caspase-2/-3/-9 sensor suite undergoing 
Cisplatin induced cell death 
U2OS cells transiently transfected with the BAK sensor for caspase-2, -3 and -9 were treated 
with 100 µM Cisplatin and imaged every 15 min for 16 hours on the multiplexing platform. 
Composite image of maximum projections from mTagBFP and mAmetrine channels are 
shown. 
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Table S1 – Oligonucleotides used in this study. All oligonucleotides were obtained from 
Sigma Aldrich. Sequences are shown in 5’ to 3’ direction. Sorted by the date of purchase. 
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Table S2 – Origin of cDNA templates for molecular cloning 
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Table S3 – Antibodies used in this study.  
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Table S4 – Reagents used for multiplexed caspase imaging and related assays. All 
reagents were filtered sterile or kept sterile if received as solution. 
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